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Summary
A plethora of studies have suggested that copy number variation in the human 
genome is extensive and may play an important role in susceptibility to disease, 
including neuropsychiatric disorders such as schizophrenia and autism. The possible 
involvement of copy number variants (CNVs) in bipolar disorder has received little 
attention to date.
This PhD thesis describes work that sought to determine whether large 
100 kb) and rare (with frequency £ 1%) CNVs are associated with susceptibility to 
bipolar disorder and to make comparisons with previous findings in schizophrenia.
In order to do that, a genome-wide survey of large and rare CNVs in a case- 
control sample using a high-density microarray was performed. 1697 cases of bipolar 
disorder and 2806 non-psychiatric controls were genotyped using Affymetrix 500K 
array set. Subsequently, the copy number data were inferred and analysed.
The burden of CNVs in bipolar disorder was not increased compared with 
controls. Furthermore, CNVs > 1 Mb were found with statistically significant lower 
rate in bipolar disorder as compared to schizophrenia. In addition, CNV loci 
previously implicated in the aetiology of schizophrenia were not more common in 
cases with bipolar disorder.
The main observation was that large and rare CNVs do not have a major effect 
in the susceptibility to bipolar disorder. In addition, it was noted that bipolar disorder 
and schizophrenia differ with respect to CNV burden in general and specific CNVs in 
particular. As the same CNVs implicated in schizophrenia, have been observed in 
autism and mental retardation, and not in bipolar disorder, it is reasonable to postulate 
that CNVs could be a specific genetic factor for a predisposition to disorders with 
stronger neurodevelopmental component than bipolar disorder.
This study has provided one of the first glimpses of the possible involvement 
of copy number variation in the susceptibility to bipolar disorder.
1
General structure of the PhD thesis
This PhD thesis comprises four main chapters. The first one will provide a 
general review of bipolar disorder and the putative genetic factors involved in the 
susceptibility. I will also provide evidence of the involvement of copy number 
variation in the predisposition to neuropsychiatric disorders. Then, I will list the aims 
and the objectives of the PhD project. Chapter three, the materials and methods 
section, provides a detailed description of the cases and the controls analysed in the 
thesis and the laboratory, statistical and bioinformatical methods applied in the copy 
number variation analyses. Then, I will move on to present the results from the 
performed analyses of copy number variation in bipolar disorder. In the last chapter 
(i.e. the discussion) I will discuss the main findings and will put them into perspective 
of what is known in the field of neuropsychiatric genetics in general with respect to 
copy number variation. Finally, given the new work reported here, I will bring to a 
close with general conclusions and possible future avenues for research.
2
1. Introduction
In the introduction section of the PhD I will summarise what is known about 
bipolar disorder in terms of classification, diagnostic criteria, mode of inheritance and 
aetiology. Then I will move on to discuss why it is important to study genetic factors 
and what is known with respect to the involvement of such genetic variants in the 
susceptibility to the disorder. I will then move on to consider the contribution of a 
relatively recently discovered type of variation in the human genome, namely copy 
number variation. I will briefly review the mechanisms for copy number variation 
occurrence, how CNVs could influence the phenotype and the current methods for 
their detection. Given the existing evidence for the involvement in susceptibility to 
conditions such as mental retardation, autism and schizophrenia, I will consider the 
potential involvement of copy number variation in liability to bipolar disorder.
1.1. Bipolar disorder
Bipolar disorder causes unusual intense emotional states with extreme changes 
in mood, energy levels, activity and the ability to carry out day-to-day tasks. The 
symptoms are severe and cannot be compared with the normal ups and downs that 
everyone experiences once in a while.
Bipolar disorder is not a disorder that has been recognized recently. The 
ancient Greeks and Romans were the first to describe conditions related to mood. At 
that time the terms melancholia and mania were coined.
Aretaeus of Cappadocia (ca.150) is credited to be the first who made the 
connection between melancholia and mania (Akiskal 2009). His description of mania 
closely corresponds to the contemporary one:
“There are infinite forms o f mania, but the disease is one o f them. I f  mania is 
associated with joy, the patient may laugh, play, dance all night and day, and 
go to the market crowned as i f  a victor in some contest o f skill. The ideas the 
patients have are infinite. They believe they are experts in astronomy, 
philosophy, or poetry. ”
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Nowadays it is recognized that bipolar disorder is a chronic disease with 
periods of remission and subsequent relapse. It is a disabling condition, which in 
tragic cases can lead to suicide.
Bipolar disorder is a condition which along with unipolar depression is 
referred to with the umbrella term o f’’Mood disorder” or “Major affective disorder”. 
The subdivision to bipolar and unipolar disorder is based on the course of illness. 
Major affective disorder may have manic-depressive (bipolar) or exclusively 
depressive course of illness (American Psychiatric Association 1994).
Bipolar affective disorder is characterised by episodes of mania (bipolar I 
disorder) or hypomania (bipolar II disorder) interspersed with episodes of depression 
(American Psychiatric Association 1994). According to the World Health 
Organisation (WHO), 29.5 million people were affected by bipolar affective disorder 
in 2004. In addition it was estimated that bipolar disorder is among the top 20 leading 
causes of disability, with around seven years of healthy life lost through time spent in 
states of less than full health (World Health Organisation 2008). Moreover, now it is 
thought that mood disorders are among the most frequent psychiatric illnesses in 
community (Rihmer and Angst 2009).
These figures and the severity of the disease warrant further investigation of 
the symptoms, causes, effective treatment and prevention of bipolar disorder.
Emil Kraepelin established the manic-depressive illness as a nosological entity 
and differentiated it from dementia praecox (which came to be known as 
schizophrenia). Kraepelin’s work was based on extensive clinical observation (i.e. 
longitudinal study of 1000 cases); he described the episodic course and the different 
family history, which separate manic-depressive “insanity” from dementia praecox. 
Kraepelin noted that the melancholic and manic states are recurrent, whereas 
dementia praecox leads to degeneration of cognition and the personality of the 
affected individuals (reviewed in (Kendler 1986)). This delineation is still prevalent 
nowadays. However, observations of overlapping boundaries between bipolar 
disorder and schizophrenia put this division to the test.
Kraepelin did not distinguish between what nowadays is termed as unipolar 
disorder and manic-depressive illness. In his work, people suffering from depression 
were still classified as manic-depressives (reviewed in (Kendler 1986)).
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After Kraepelin’s work, the classification of manic-depression was still 
evolving. Based on clinical observation and the different family history data in 
patients with depression, Leonhard proposed to distinguish between bipolar and 
unipolar disorders (Goodwin and Jamison 2007). The face validity of the separation 
of unipolar disorder from bipolar disorder was later supported by independent 
research carried out by Angst, Perris and others (reviewed in (McGuffin and Katz 
1986)).
In contrast to bipolar disorder, unipolar disorder is markedly more common in 
terms of frequency of occurrence. The lifetime prevalence estimates substantially vary 
from 4.4% to 17.1% according to the applied diagnostic criteria, methodology and 
sample (Jones et al. 2002). In addition, it has been observed that the two disorders 
differ with respect to greater familial burden in bipolar disorder as compared to 
unipolar disorder (Kelsoe 2009). The separation between the two types of affective 
disorders was later implemented in the World Health Organisation International 
Classification of Diseases and in the American Psychiatric Association Diagnostic 
and Statistical Manual of Mental disorders (American Psychiatric Association 1994; 
World Health Organisation 1992).
1.1.1. Classification and diagnostic criteria
Bipolar disorder cannot be detected with a laboratory test, which makes 
diagnosing challenging. Great efforts have been undertaken in the psychiatric field to 
establish diagnostic criteria. One of the most important tasks was to introduce 
diagnostic criteria which are “reliable”, i.e. two independent investigators will agree if 
a certain diagnostic label applies to a certain patient (Strachan and Read 2004). To 
standardise the diagnosis, classification systems like the Diagnostic and Statistical 
Manual of Mental Disorders, 4th edition (DSM-IV) (American Psychiatric Association
1994) and International Statistical Classification of Diseases and Related Health 
Problems, 10th revision (ICD-10) have been introduced (World Health Organisation 
1992).
The DSM-IV criteria for manic and major depressive episodes are summarised 
in Table 1.
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Table 1 DSM-IV diagnostic criteria for major depressive episode and manic 
episode
Major depressive episode Manic episode
A. Five or more of the following symptoms 
present during the same two week period 
and represent a change from normal 
functioning
1. Depressed mood
2. Loss of interest or pleasure
3. Change in appetite and weight
4. Sleep change
5. Psychomotor agitation or retardation
6. Loss of energy
7. Feeling of worthlessness or excessive or 
inappropriate guilt
8. Diminished concentration
9. Recurrent thoughts of death/suicidal 
ideation
B. The symptoms do not meet the criteria for a 
mixed episode
C. The symptoms cause clinically significant 
distress or impairment in social, 
occupational or other important areas of 
functioning
D. The symptoms are not due to direct 
physiological effects of a substance or a 
general medical condition
E. The symptoms are not better accounted for 
by bereavement
A. Abnormally and persistently elevated, 
expansive or irritable mood lasting at least 
one week (if hospitalised- any duration)
B. Three or more of the following symptoms 
(four if mood is only irritable) present to a 
significant degree
1. Increased self-esteem or grandiosity
2. Decreased need for sleep
3. More talkative than usual or 
pressure to keep talking
4. Flight of ideas or racing thoughts
5. Distractibility
6. Increase in goal oriented activity or 
psychomotor agitation
7. Excessive involvement in 
pleasurable activities that have a 
high potential for painful 
consequences
C. The symptoms do not meet the criteria for a 
mixed episode
D. The mood disturbance is sufficiently severe 
to cause impairment in occupational 
functioning or in usual social activities or 
relationship with others or to necessitate 
hospitalisation, or there are psychotic 
features
E. The symptoms are not due to direct 
physiological effects of a substance or a 
general medical condition
Hypomanic episode; milder form of a manic 
episode with less duration.
A distinct period of persistently elevated, expansive 
or irritable mood, lasting at least four days. Like a 
manic episode, pathological change in functioning is 
observed, but the episode is not severe enough to 
cause marked impairment in functioning or to 
necessitate hospitalisation and there are no 
psychotic features
Mixed episode
The criteria are met for both manic and for a depressive episode except the duration. It is still 
sufficiently severe to cause significant impairment in functioning.
An example could be the following: May feel sad and hopeless while feeling energised
The presence of all of A, B, C, D and E is required to diagnose illness. Modified from 
Psychiatric Genetics & Genomics (Jones et al. 2002)
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According to DSM-IV, bipolar disorder spectrum is further subclassified into 
bipolar I disorder (BDI), bipolar II disorder (BDII), cyclothymia and bipolar disorder 
not otherwise specified (BD NOS) (American Psychiatric Association 1994).
BDI is diagnosed if one or more manic episodes or mixed episodes are present 
while BDII is diagnosed if the individual experiences milder forms of mania (termed 
hypomania) (Jones et al. 2002). Cyclothymia is a mild form of bipolar disorder, 
characterised with episodes of hypomania that interchange with mild depression for at 
least two years. When the symptoms of the illness do not meet the criteria for BDI 
and BDII (e.g. the symptoms do not last long enough or not all the required symptoms 
are present), BD NOS is diagnosed. Even though the BDII, cyclothymia and BD NOS 
are characterised with somewhat milder presentation of the disease, they are still out 
of the normal range of behaviour.
Due to the fact that the current diagnostic criteria are not based on evidence 
coming from the biology of psychiatric diseases, the most appropriate boundaries 
between the bipolar spectrum subphenotypes and the other psychiatric illnesses are 
still unclear. At the severe psychotic end of the spectrum, some patients exhibit 
features which do not belong strictly to bipolar I disorder or schizophrenia but belong 
to both of the disorders (Jones et al. 2002). More about the overlap between bipolar 
disorder and schizophrenia will be discussed further in section 1.1.6 (page 27).
1.1.2. Epidemiology
The lifetime rates of developing bipolar disorder are comparable between the 
different human populations and range between 0.8 and 1% (American Psychiatric 
Association 1994; Weissman et al. 1996). This figure has been challenged and there 
are now convincing data that bipolar disorder may affect -5% of the population. This 
is largely due to the better detection of bipolar II disorder. Results from the National 
Comorbidity Survey Replication Study showed a lifetime prevalence of 1% for 
Bipolar I disorder, 1.1 % for bipolar II disorder and 2.5% for clinically manifested 
subtreshold bipolar disorder (Rihmer and Angst 2009). The lifetime prevalence rates 
for the separate disorders comprising the bipolar spectrum disorders are presented in 
Table 2.
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Table 2 Lifetime prevalence rates of bipolar I disorder, bipolar II disorder,
cyclothymia and hypomania
Lifetime Prevalence [%1
Bipolar I disorder 0.0-2.4
Bipolar II disorder 0.3-4.8
Cyclothymia 0.5-6.3
Hypomania8 2.6-7.8
Full bipolar spectrum 2.6-7.8
a Including recurrent brief hypomania (lasting one to three days, not fulfilling the DSM-IV 
criteria for hypomania) (adapted from (Rihmer and Angst 2009))
When the gender distribution is studied across cases, it has been observed that 
both genders are equally distributed (Weissman et al. 1996). The most frequent age of 
onset of bipolar disorder is ~ 20 years of age. Earlier onset in men has been noted, 
four to five years earlier than women (Rihmer and Angst 2009). It has also been 
observed that individuals may develop the first episode of bipolar disorder at any time 
of their life (Jones et al. 2002). When rates of bipolar I disorder have been compared 
in Caucasians, African American and Hispanic individuals, it has been observed that 
the prevalence is not different across the different race groups (Rihmer and Angst 
2009). It has been suggested that some seasonality is associated with the illness, with 
depressive episodes found to be more frequent in spring and autumn, whereas mania 
has been found more frequently in summer (Goodwin and Jamison 2007).
It has been noted that bipolar disorder is most frequent among divorced, 
separated or widowed individuals and that the rate of family breakdown is increased. 
Bipolar I disorder can lead to unemployment and low income resulting in regression 
in the socioeconomic status. On the other hand, a lack of significant downward social 
drift has also been noted. This has been attributed to the natural history of the illness, 
i.e. frequently the onset is after university, the prognosis of the illness is good and in 
addition, individuals often have compensatory energy, ambition and cognitive 
changes (Goodwin and Jamison 2007). For example, bipolar II individuals tend to 
belong to higher social classes, are educated above average and are relatively 
overrepresented among creative people (Rihmer and Angst 2009).
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1.1.3. Aetiology
1.1.3.1. Genetic factors
To determine if a non-Mendelian disorder like bipolar disorder is caused by 
genetic factors, family, twin and adoption studies have been performed. Such studies, 
conducted in the last 30-40 years provided consistent body of evidence supporting the 
hypothesis that bipolar disorder is indeed a genetic disorder (Craddock and Sklar 
2009; Kelsoe 2009).
1.1.3.1.1. Family studies
Family studies have clearly shown that there is a reduction of the risk to 
develop bipolar disorder when the genetic relatedness to the affected proband 
diminishes (Craddock and Jones 1999). This has been shown by measuring a genetic 
parameter called relative risk, which is generally used to answer the question if a 
given illness runs in families. The relative risk is defined as the ratio of the rates of 
developing bipolar disorder in 1st degree relatives of bipolar disorder probands 
compared to the rates of illness observed in the 1st degree relatives of healthy controls, 
or where control subjects are not available, to an assumed risk in the general 
population of 1% (Kelsoe 2009). Figure 1 shows the relative risk of bipolar I disorder 
in 1st degree relatives of bipolar disorder cases as a function of the number of 
analysed samples in the relevant data that the graph has been based on. The graphical 
summary has been based on family studies published up to 1999, which have met the 
following criteria: the probands suffer from bipolar I disorder, the lifetime risk of 
bipolar disorder has been measured in 1st degree relatives and at least some of the 
relatives have been interviewed directly. The data for producing the graph come from 
21 studies, eight of which included control sample set. All of the studies have 
observed a relative risk of > 1, which reflects an increased risk of developing bipolar 
disorder in relatives of a bipolar proband compared with the risk in the general 
population (Craddock and Jones 1999). Based on the eight studies that included then- 
own control subjects, an overall relative risk has been measured in 1st degree relatives
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of bipolar I cases- seven, indicating strong familial risk of developing bipolar disorder 
(reviewed in (Jones et al. 2002)).
Figure 1 Family studies of bipolar disorder
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(Craddock and Jones 1999)
A recent study based on a large sample set of bipolar disorder affected 
individuals (n=40,487) along with their families has provided support of the 
hypothesis that 1st degree relatives of individuals with bipolar disorder exhibit an 
elevated risk for developing the condition than the populational risk. Having a mother 
or a father with bipolar disorder inreases the risk of an offspring for developing the 
illness 6.4 times (95%C7:5.9 -  7.1), compared with a person whose mother or father 
do not have bipolar disorder (Lichtenstein et al. 2009).
In conclusion, the family studies support the familial nature of bipolar 
disorder. It is of note, that not only bipolar disorder is observed in the families of 
bipolar probands. Other psychiatric illnesses, namely unipolar depression, bipolar II
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disorder, schizoaffective disorder and schizophrenia, have been also detected 
suggesting some degree of common genetic underpinnings between the separate 
disorders (Jones et al. 2002; Kelsoe 2009; Lichtenstein et al. 2009).
I.I.3.I.2. Twin and adoption studies
Data from family studies have indicated that bipolar disorder tends to run in 
families. As individuals in families share both genetic and environmental factors, 
family studies are unable to show whether a disease is due to inheritance of specific 
genetic factors or to shared environment. To this end, twin and adoption studies 
provide a relatively more powerful approach to separate genetic from environmental 
factors, than family studies (Hayden and Numberger 2006; Kelsoe 2009).
The most common way of performing twin studies is to identify monozygotic 
(MZ) and same-sex dizygotic (DZ) twin pairs where one of the twins has bipolar 
disorder. Subsequently, the other twin from the pair is examined to determine the 
proportion of twin pairs both affected with bipolar disorder (concordance rate)
(Kelsoe 2009).
The basic principle of the twin studies is that monozygotic (identical) and 
dizygotic (fraternal) twins share common environment, whereas only the monozygotic 
pairs share -100% genetic factors (DZ twins share on average 50% common genetic 
factors). Any greater similarity in MZ as compared to DZ twins should be attributable 
to heritable genetic factors (McGuffin et al. 1994).
Table 3 (page 12) summarises several twin studies (reviewed in (Jones et al.
2002)).
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Table 3 Lifetime rates of affective disorder in co-twins of bipolar twin probands
Reference
Sample
Lifetime rates of illness in co­
twin of bipolar twin probands 
(proband-wise concordance 
rate) [ % ] Comment
Source N MZ pairs
N DZ 
pairs
MZ DZ
(Kringlen 1967) Norway twin and psychosis register 6 0 BD-BD 67 ~ small sample size
(Allen et al. 
1974)
USA Veteran twin 
register (15,909 
twin pairs in 
register)
5 15 BD-BD 20 0
~ low rate o f  BD detected in 
the twin sample-0.07%
(Bertelsen et al. 
1977)
Denmark twin and 
psychiatry registers 34 37
BD-BD
BD-BD/UP
62
79
8
19
(Torgersen
1986)
Norway twin 
register 4 37
BD-BD
BD-BD/UZ
75
100
0
0
~ small sample which may 
overlap partially with that of 
Kringlen
(Kendler et al. 
1993)
Sweden twin and 
psychiatric registers 13 22
BD-BD
BD-BD/UZ
39
62
5
14
~  large sample, used 
questionnaire assessment, 
likely to have underestimated 
concordance
(Cardno et al. 
1999)
UK psychiatric 
hospital twin 
register
22 27 BD-BD 36 7
Diagnoses based on hospital 
notes, likely to have 
underestimated concordance
Based on Jones et al. (Jones et al. 2002); BD-BD- refers to twin pairs in which both have 
BDI; BD-BD/UP- refers to twin pairs where one twin have BDI and the other has broadly 
defined BD phenotype (including unipolar depression)
Overall, an increase in the concordance rate is observed for bipolar disorder in 
the MZ twins compared to those in the DZ twins. Pooling the data together from these 
studies provides an estimate of MZ concordance for bipolar I disorder of 50% 
(95%C7:40 -  60 ) (Jones et al. 2002).
It is of note, that the concordance rate associated with monozygotic twins is 
not 100%. This suggests that factors which are not heritable (i.e. environmental 
factors) could also play part in developing bipolar disorder (Kelsoe 2009).
A genetic parameter called heritabilitv provides an estimate of the proportion 
of causation of a specific character that is due to genetic causes (Strachan and Read 
2004). Based on twin studies, the heritability for bipolar disorder has been estimated 
to be 93% (95%C7:0.69 -1.00) (Kieseppa et al. 2004). A similar heritability 
estimate has been calculated by McGuffin et al.- 89% (McGuffin et al. 2003). A lower 
figure than these previous observations has been estimated by Lichtenstein et al.- 59% 
(Lichtenstein et al. 2009).
Another approach to separate genetic from environmental factors is using 
adoption studies. The most common approach is to study probands who have bipolar
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disorder and who have been adopted at birth. Subsequently, the rates of psychiatric 
illness are determined in the biological and the adoptive parents (Kelsoe 2009).
Due to the inherent difficulties in making such observations, there are a 
limited number of studies. The results from the adoption studies have been insofar 
inconsistent. A study by Knorring et al. investigated the biological and adoptive 
parents of probands with affective disorder and the biological and adoptive parents of 
healthy controls. No statistically significant differences between the groups were 
observed. In contrast, a study by Mendlewicz and Rainer based on 29 bipolar and 22 
control adoptees found almost a 3-fold increase in the rate of bipolar disorder in the 
biological parents of bipolar probands as compared to the adoptive parents (18% risk 
versus 7% risk respectively). Furthermore, in a Danish sample, a 3-fold increase in the 
rate of unipolar illness and a 6-fold increase in the rate of suicide in the biological 
relatives of probands with affective disorders have been noted as compared to the 
adoptive parents and the biological/adoptive parents of healthy probands (reviewed in 
(Jones et al. 2002)).
Adoption studies are characterised with difficulties in obtaining large number 
of subjects. Therefore the examined sample sets are quite small, which could be the 
reason why these data are less consistent than the data obtained using twin studies 
(Kelsoe 2009).
The recent large epidemiological study by Lichtenstein at al. screened adopted 
children whose biological parents had bipolar disorder. The results unequivocally 
supported the role of genetic variants in the susceptibility to bipolar disorder. Adopted 
children with an affected biological parent were > 4 times more likely to develop the 
disorder than the general population (Lichtenstein et al. 2009).
In conclusion, data from family, twin and adoption studies provide compelling 
evidence of the involvement of genes in developing bipolar disorder. In addition, 
these studies also show a gradation of the risk for developing bipolar disorder 
between the various classes of relatives with monozygotic co-twin showing the 
highest risk, when the lowest risk is observed in an unrelated person from the general 
population. The approximate risk for developing bipolar disorder in the lifetime of 
relatives of a bipolar proband is presented in Table 4.
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Table 4 Approximate lifetime rates for developing bipolar disorder in various 
classes of relative to individual affected with bipolar disorder
Degree of relation to affected 
individual Risk of bipolar disorder [%]
Identical co-twin 40-70
First degree relative 5-10
Unrelated individual from the general 
population 0.5-1.5
Adapted from (Jones et al. 2002)
1.1.3.2. Environmental factors
As noted previously, the concordance between monozygotic twins is not 
100%. This suggests that other than genetic factors also play an essential role in the 
susceptibility to bipolar disorder.
The data with respect to the possible involvement of environmental factors are 
not conclusive. Sleep deprivation, drug abuse, hormonal alterations, pregnancy, 
childbirth, winter-spring birth, traumatic brain injuries, stressful life events have been 
found to be involved in bipolar disorder (Goodwin and Jamison 2007; Tsuchiya et al.
2003). Stressful life events do appear to trigger episodes of bipolar depression, while 
life events involving goal attainment appear to elicit manic symptoms (Johnson 2005).
1.1.4. Mode of inheritance
Despite the consistent body of data that bipolar disorder is a genetic disorder, 
the mode of inheritance is still not clear. This is likely due to the fact that no gene 
involved in the susceptibility to the disorder causes a 100% of the people who have 
the genotype to develop the disorder. In addition, there is a decrease in the observed 
rate of illness when the genetic distance from the affected proband increases (Table 
4), which is not consistent with a single gene disorder (Craddock and Jones 1999). 
Therefore, bipolar disorder is not recognised as a disorder which is inherited in a 
Mendelian manner (that is, one to one relationship between genes and trait). However, 
there are families with multiple affected individuals, where the inheritance is likely to 
be in agreement with Mendel’s laws (Blackwood et al. 1996; Freimer et al. 1996). 
Segregation analyses on large pedigrees have generated mixed results, with some 
studies showing consistency with a single gene model (Pauls et al. 1992; Spence et al.
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1995), while others have not observed a transmission of a major locus (Bucher et al. 
1981; Goldin et al. 1983). X-linked causation has been also suggested (Hayden and 
Numberger 2006). Nevertheless, the involvement of genes with major effect in certain 
families does not explain the majority of bipolar cases.
Based on these data, it has been suggested that bipolar disorder is a complex 
disorder, involving more than one locus (Jones et al. 2002). Complex non-Mendelian 
conditions like bipolar disorder are suggested to depend on two, three or many genetic 
loci, with contribution from environmental factors. Such conditions have been 
combined under the umbrella term- multifactorial disorders. The genetic 
determination could involve a small number of loci (oligogenic modeB or many loci, 
each with a weak effect (polygenic modeB (Strachan and Read 2004).
It has been suggested that the liability to develop bipolar disorder is a 
continuous trait and the disorder is expressed when a certain threshold along this 
continuum has been reached. Based on this hypothesis, when describing factors which 
determine developing conditions like bipolar disorder, often the term susceptibility is 
used. The reason stems from the hypothesis that such disorders are caused by a 
combination of many different genetic and environmental factors. Adding or 
removing one additional factor, could potentially determine disease or healthy status, 
without this specific factor being the cause of the disorder. In addition, Falconer and 
Mackay have also proposed the existence of a critical threshold for the underlying 
factors; the threshold can be regarded as the neutral point of the balance between the 
factors, and altering the balance of the factors can move the phenotype either way- 
disease or health (Falconer and Mackay 1996).
This model also provides explanation of the observed rate of illness in 
different classes of relatives, which exponentially declines as the genetic distance 
from the affected proband increases (presented in Table 4, page 14). Affected people 
have an unfortunate constellation of factors exceeding a certain threshold with each 
gene contributing a small amount towards the overall genetic effect. As probands’s 
relatives share genes with them, they will also possess some of these factors and will 
have an increased susceptibility to the condition without surpassing the critical 
threshold. The liability to the disorder is defined by multiple genes acting together to 
determine a quantitative trait and follows a normal distribution in the population. 
People whose liability is above a certain threshold are affected. The distribution of 
liability in the relatives of affected people also follows a Gaussian distribution, but is
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characterised with mean shifted to the right as on average they will have more 
susceptibility factors than the people sampled from the general population. Therefore 
a greater proportion of the relatives will have a liability over and above the critical 
threshold (Figure 2) (Falconer and Mackay 1996).
Figure 2 Falconer’s threshold model for non-Mendelian characters
Distribution of liability in
the general population Threshold
Distribution of liability in 
the sibs of affected people unaffected affected
Low
liability
Average liability 
in general
Average liability 
among sibs of
High
liability
population affected people
Adapted from (Strachan and Read 2004)
As previously suggested, multiple genes are likely to be involved in the 
susceptibility to bipolar disorder which leads to the following question: How do these 
genes interact to produce the phenotype? Several genetic mechanisms of how the 
underlying factors interact have been suggested in bipolar disorder. The proposed 
mechanisms are presented in Table 5, page 17.
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Table 5 Genetic mechanisms suggested in bipolar disorder
Genetic mechanism Description based on (Strachan and Read 2004) Reference
Allelic heterogeneity
many different mutations 
within a given gene are causing 
the specific condition in 
different patients
(Sandkuyl and Ott 1989)
Locus heterogeneity
the clinical phenotype results 
from mutations at any one of 
several loci
(Hodgkinson et al. 1987)
Epistasis
multiple disease genes interact 
together to determine disease 
susceptibility
(Craddock and Jones 
1999)
Dynamic mutation
unstable portions of DNA that 
expand when they are passed 
from parent to the child
(Mclnnis et al. 1993)
Imprinting
the expression of a gene 
depends upon its parental 
origin
(McMahon et al. 1995)
Mitochondrial inheritance
the disease mutation lies in the 
mitochondrial genome leading 
to a maternal pattern of 
inheritance
(McMahon et al. 1995)
adapted from (Jones et al. 2002)
Overall, even though there are many mechanisms proposed to explain the 
possible relations between the contributory factors, none of them have been 
unambiguously shown to be associated with bipolar disorder (Kelsoe 2009).
With a prevalence of 1% bipolar disorder is regarded as a common disorder in 
comparison to Mendelian monogenic diseases, which are very rare and relatively 
uncommon (Antonarakis and Beckmann 2006). Two hypotheses have been proposed 
about the genetic background of common disorders. Namely these are the common 
disease/common variant (CD/CV) and common disease/rare variant (CD/RV. multiple 
rare variant hypothesis) hypotheses (Alaerts and Del-Favero 2009). Pritchard and Cox 
suggested that less penetrant susceptibility variants (that is, variants that not always 
manifest themselves in a given phenotype), involved in complex diseases could be 
subject to less strong natural selection and therefore able to reach intermediate 
frequencies in the population (Pritchard and Cox 2002). According to the CD/CV 
hypothesis, the genetic risk is dependent on a few, common disease predisposing 
factors (present in > 1% in the general population) with a small predisposing effect 
(odds ratio < 2), such as the effect of several genes would be combined together to
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produce the observed frequency of the disorder in the population (Alaerts and Del- 
Favero 2009; Bodmer and Bonilla 2008; Chakravarti 1999; Gershon 2000; Yang et al.
2005).
Although persistence in the population at this rate (i.e. 1%) is explicable by a 
polygenic model comprising many weak effects (that is, CD/CV model), it is also 
reasonable to postulate that variants of large effect may be replenished by new 
mutations. In addition, the involvement of common single nucleotide polymorphisms 
(SNP, any variation at a single nucleotide with a frequency >1% in a population) has 
not yet explained a significant proportion of the genetic risk for developing common 
disorder like bipolar disorder (Cichon et al. 2009). Therefore, it has been suggested 
that a large number of rare variants (possibly hundreds of different genes) with 
relatively large effects (odds ratio >2), linked with locus and allelic heterogeneity, 
could explain a substantial proportion of the susceptibility to neuropsychiatric 
disorders (Alaerts and Del-Favero 2009; Bodmer and Bonilla 2008; Gorlov et al.
2008; McClellan et al. 2007; Smith and Lusis 2002). The common disease-rare 
variant model allows for a heterogeneous collection of rare recent mutations that 
could account for some of the susceptibility to bipolar disorder (similar to Mendelian 
diseases) (Pritchard 2001; Reich and Lander 2001). With respect to CD/RV 
hypothesis, it has been argued that causal alleles will not reach common frequencies 
due to reduced fecundity, which will lead to negative natural selection. If “slightly 
deleterious” alleles account for modest changes in gene function; and if the combined 
action of several alleles result in an increased risk, then the selection may not be 
strong enough to purify new mutations, but will keep them at low frequencies (Alaerts 
and Del-Favero 2009).
In summary, it has been previously shown that genes influence the 
susceptibility to bipolar disorder. However, not 100% of the variance is explained by 
genetic factors. This suggests that other factors such as environmental factors, 
unknown genetic factors, gene-gene and gene-environment interactions, epigenetic 
effects and some factors with purely stochastic origin may influence the development 
of disease (Cichon et al. 2009). It is also important to acknowledge that the genetic 
complexity has to be fully appreciated when searching for the genetic factors 
predisposing to common disorders. Genetic mechanisms like dynamic mutations (e.g. 
expanding trinucleotide repeats), imprinting (e.g. Prader-Willi syndrome), copy 
number variation and mitochondrial inheritance may also influence and contribute to
18
the risk of developing neuropsychiatric illness. To add to the complexity that stems 
from gene-environment interplay, different genes and different genetic mechanisms 
may be involved in different pedigrees (that is genetic heterogeneity) with one or 
more affected individuals.
1.1.5. Identifying complex disease genes: linkage and candidate genes 
studies
Since it has been established that episodes of severe mood tend to run in 
families, the genetic factors influencing the susceptibility ought to be studied. Recent 
advances in molecular genetics provide the tools needed to identify such susceptibility 
variants. Strategies for disentangling the genetic component to bipolar disorder 
susceptibility comprise of linkage and association methods (Hayden and Numberger
2006).
1.1.5.1. Linkage analyses
In essence, linkage analysis involves genotyping several hundred markers that 
cover the human genome in families segregating the disease of interest. Markers 
inherited along with the disease are indicative of the chromosomal regions that could 
harbour disease genes (Kelsoe 2009).
Linkage analysis could be hypothesis driven (testing particular candidate 
genes) or genome-wide analysis without the requirement of a prior biologically driven 
hypothesis. It is applied in order to identify broad genomic regions on which the 
disease gene may reside. Linkage analysis makes use of the following characteristic 
of the genetic loci- if two loci are linked they will be transmitted together from a 
parent to the offspring more often than expected under independent inheritance. More 
specifically, two loci are linked if during meiosis, recombination between them occurs 
with < 50% probability. Linkage analysis is based on studying the chromosomal 
segments that are inherited together in a family, relying on the fact that the likelihood 
of sharing of chromosomal segments by the affected individuals is relatively high 
(Teare and Barrett 2005). Linkage is usually reported as a logarithm of the odds that 
loci are linked (LOD scores). Higher LOD scores are sign of a greater probability of 
linkage between the studied and disease variants (Hayden and Numberger 2006).
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Linkage analysis has proved a very successful method for mapping loci 
causing rare Mendelian conditions. Unlike Mendelian disorders, complex diseases 
proved to be much more difficult with respect to using linkage as a method for 
identifying contributory variants (Jones et al. 2002). The difficulties arise as complex 
diseases pose some inherent challenges: the exact mode of inheritance is difficult to 
establish as incomplete penetrance, gene and locus heterogeneity have been observed. 
In addition, several/many genes and environmental factors may contribute to 
developing the disease. Therefore, for studying multifactorial disorders like bipolar 
disorder, model-free (non-parametric) linkage analysis is used. The basic principle is 
that, between affected relatives an excess sharing of alleles or chromosomal segments 
identical by descent (IBD) would be observed in the region of a disease-causing gene 
irrespective of the mode of inheritance. Several methods are applied to test if the IBD 
sharing at a locus is greater than expected under the null hypothesis of no linkage. The 
methods include testing sibling pairs, both of whom are affected with the disease and 
testing families with larger numbers of affected individuals of different relationship 
(Teare and Barrett 2005).
To date, a large number of linkage studies in bipolar disorder have been 
conducted. A large meta-analysis of 18 data sets was performed in an attempt to 
identify susceptibility regions for bipolar disorder in the combined data. No region 
reached genome-wide statistical significance. It was concluded that larger data sets 
are required (especially of cases with bipolar I disorder and schizoaffective disorder, 
bipolar type). It is of interest that no correspondence was observed between the 
highest ranked regions from linkage studies in bipolar disorder and schizophrenia 
(Segurado et al. 2003).
Hayden and Numberger have reviewed linkage studies after 1999, taking into 
account only linkage studies passing the Lander and Krugly ak’s cut off for significant 
linkage result (i.e. LOD score of 3.3 when studying pedigrees and 3.6 when studying 
affected sibling pairs) (Lander and Kruglyak 1995) and instances where a region has 
been implicated by independent studies (Hayden and Numberger 2006). Based on 
these stringent criteria Hayden and Numberger concluded that the following loci are 
the most supported: 2p, 4p, 4q, 6q, 8q, lip , 12q, 13q, 16p, 16q, 18p, 18q, 21q, 22q 
and Xq (Hayden and Numberger 2006).
In summary, the application of linkage analysis to complex conditions like 
psychiatric disorders has not been as successful as with rare Mendelian disorders. It
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has been largely marred by unreplicated findings (Burmeister et al. 2008; Risch and 
Botstein 1996). In addition, the genes driving these statistically significant linkage 
results have not been clearly identified due to the relatively large size of the 
implicated regions. Such regions could comprise hundreds of genes, some of which 
may be biologically relevant candidates (Barnett and Smoller 2009; Teare and Barrett 
2005).
A reason why the linkage studies in neuropsychiatric conditions were not as 
successful as in discovering genes for monogenic diseases, perhaps in part is because 
when genes of small effect are sought, the required sample sizes become very large. 
Based on power calculations, it has been shown that linkage analysis can provide 
evidence for the location of a disease locus with high genotype relative risk (s: 4) and 
intermediate allele frequencies between 5 and 50%. The sample size of detecting 
linkage to genes with a genotype relative risk of < 2 (which is typical for genes with 
a small overall effect), could be prohibitively large (Risch and Merikangas 1996; 
Risch 2000).
Based on the results from linkage studies, one could conclude that no gene of 
major effect underlies susceptibility in most of the affected individuals. Furthermore 
as linkage studies have not been able to accurately and reproducibly identify loci 
involved in bipolar disorder, it has become clear that there are no common loci of 
large effect involved in developing the disease (Craddock and Sklar 2009). However, 
genes with large effect could still exist; they may be specific to particular families 
which could explain the large extent of non-replicated linkage studies. The results 
from linkage studies have generated evidence that bipolar disorder is a genetically 
complex disorder. In order to allow for this intrinsic complexity, the focus of the 
genetic research in bipolar disorder has shifted towards association studies. Such 
studies are more suitable for the inherent challenges in detecting susceptibility 
variants which could be relatively common in the population and comprise a modest 
increase in the risk for developing bipolar disorder (Barnett and Smoller 2009).
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1.1.5.2. Association studies
In a seminal work published in 1996, Risch and Merikangas suggested that 
association studies are better equipped than linkage studies when genetic variants 
have weak effect on risk for developing of disease (Risch and Merikangas 1996). 
Furthermore, association studies are relatively easier to conduct as it is difficult to 
recruit extended families. Association studies are based on testing the association 
between a disease and a genetic locus using either family-based or case-control design 
(Burmeister et al. 2008). Initially, the design of the studies was based on a candidate 
gene approach, although these were surpassed by genome-wide based search.
I.I.5.2.I. Candidate genes approach
Before the advent of whole-genome arrays, earlier association studies of 
bipolar disorder have used relatively small sample sizes and tested polymorphisms in 
functional candidate genes, or genes suggested by linkage and cytogenetic studies. 
Some of the obvious candidate genes have been the ones involved in neurotransmitter 
systems targeted by medication. Namely, the antidepressant drugs block the re-uptake 
of serotonin and noradrenaline, when antipsychotic block the dopamine receptors. 
Such systems have been the “usual suspects”- dopamine, serotonin, glutamate and the 
noradrenalin systems. Genes from these systems which have received a lot of 
attention over the years include the genes encoding monoamine oxidase A (MAOA), 
catechol-O-methyltransferase (COMT), the serotonin transporter (5-HTT) and the 
NMDA glutamate receptor, subunit 2 B (GRIN2B) (Barnett and Smoller 2009; 
Craddock et al. 2001; Jones and Craddock 2001). In addition, genetic variants in 
biological candidate genes in a metabolic pathway that is either known or 
hypothesised to be associated with bipolar disorder have also been investigated 
(Burmeister et al. 2008). One such pathway has been the circadian system given the 
episodic nature of bipolar disorder (Craddock and Sklar 2009). It is of note, that 
lithium and valproate, used for treatment of bipolar disorder, have an effect on the 
circadian rhythm. Association studies have found some evidence for correlation 
between SNPs in genes that control circadian rhythms and predisposition to bipolar 
disorder- CLOCK and BMAL1 genes (reviewed in (Barnett and Smoller 2009)).
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Other genes investigated in bipolar disorder have been suggested on the basis 
that statistically significant associations have been observed in schizophrenia. To date, 
a number of genes already implicated in schizophrenia have been investigated in 
bipolar disorder. Namely, these are: disrupted in schizophrenia 1 (DISCI), G72/G30 
locus, neuregulin 1 (.NRG1), brain-derived neurotrophic factor (BDNF), dystrobrevin 
binding protein 1 (DTNBP1), tryptophan hydroxilase 2 (TPH2), dopamine receptor 
D4 (DRD4) and solute carrier family 6 (neurotransmitter transporter, dopamine), 
member 3 (DAT1) (Craddock and Sklar 2009; Serretti and Mandelli 2008).
For all of the aforementioned genes, studied for association with bipolar 
disorder, some statistically significant and some non-significant findings have been 
observed. The replication of association signals is essential for association studies, but 
as yet, no unequivocal support of the above-mentioned genes in developing bipolar 
disorder has been shown. One reason for this could be the inherent limitation of the 
candidate genes approach. It relies heavily on our current understanding of the disease 
pathology and hence depends on our prior knowledge. Studies which are not based on 
a certain biologically driven hypothesis and therefore explore new unbiased avenues 
of research are the genome-wide association studies.
1.1.5.2.2. Genome-wide association (GWA) studies
GWA studies have become possible due to the recent advances in methods for 
genotyping, statistical analysis tools and cost. They are based on the advent of high- 
throughput genotyping arrays and the extensive SNP information, provided by the 
HapMap Consortium (http://hapmap.ncbi.nlm.nih.gov/) (Burmeister et al. 2008; The 
International Hapmap Project 2003; Wollstein et al. 2007). These recent advances 
permit peppering the whole human genome with a dense collection of markers 
(hundreds of thousands, even millions). These SNPs are then genotyped 
simultaneously and rapidly in large sample sets and subsequently the data are 
interrogated for possible associations with disease without the need for a biologically- 
driven prior hypothesis about the studied variants (Alaerts and Del-Favero 2009; 
Barrett and Cardon 2006; Hirschhom and Daly 2005).
Several genome-wide surveys in bipolar disorder have been published, with 
the first being the Wellcome Trust Case-Control Consortium study (WTCCC) on
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1868 cases and 2938 controls (Wellcome Trust Case Control Consortium 2007). In 
Table 6 are summarised the recent whole-genome studies in bipolar disorder along 
with the main findings.
Table 6 Whole-genome association studies in bipolar disorder
Study (reference)
Sample
Method Top hit (SNP, nearest gene, chromosome, significance)N
cases
N
controls
WTCCC
(Wellcome Trust Case 
Control Consortium 
2007)
1868 2938
Affymetrix 500K 
array, individual 
genotyping
rs420259, PALB2, chr 16, 
p  = 6.3 xlO-8
STEP-UCL
(Sklar et al. 2008) 1461 2008
Affymetrix 
500K/5.0 array, 
individual 
genotyping
rs4939921, MY05B, chr 18, 
p  = 1.7 xlO-7
ED-DUB-STEP2
(Ferreira et al. 2008) 1098 1267
Affymetrix 
5.0/6.0 array, 
individual 
genotyping
rs7221510, SKAP1, chr 17, 
p  = 1.4xl0-6
NIMH/Bonn
(Baum et al. 2008a) 1233 1439
Illumina 550 
array, pooled and 
individual 
genotyping
rsl012053, DGKH, chr 13, 
p  = 1.5xl0~8
WTCCC, STEP- 
UCL and ED-DUB- 
STEP2
(Ferreira et al. 2008)
4387 6209 Meta-analysis
rsl0994336, ANK3, chr 10, 
p  = 9.1xl0~9; 
rsl006737, CACNA1C, 
chrl2, p  = 7.0xlO"8
NIMH/Bonn and 
WTCCC
(Baum et al. 2008b)
3101 4377 Meta-analysis
rs 10791345, JAM3, chr 11, 
random effect p  = lx lO -6; 
rs4806874, SLC39A3IZIP3, 
chr 19, p  = 5 x l0 '6
EA/AA study
(Smith et al. 2009)
1000 EA 
345 AA
1033 EA 
670 AA
Affymetrix 6.0 
array, individual 
genotyping
EA: rs5907577, chr X, 
p  = 1.6xlO-6; rslOl93871, 
NAP5, chr 2,p  = 9.8xlO '6; 
AA: rs2111504, DPY19L3, 
chr 19 p  = 1.5xlO-6; 
rs2769605, NTRK2, chr 9 
p  = 4.5 xlO-5
EA=European ancestry; AA=African ancestry
Most of the GWA studies in bipolar disorder did not reach the generally 
accepted genome-wide statistical significance evidence level for association for GWA 
studies, i.e. applying a Bonferroni correction for 1 million independent tests (a
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threshold of p  < 5.0x10 8). A better approach, which has been proven successful in 
another complex disorder, type 2 diabetes, is pooling raw genotypes together (Zeggini 
et al. 2008). Such meta-analysis combining the WTCCC study and the NIMH/Bonn, 
suggested the involvement of additional two genes in the predisposition to bipolar 
disorder- JAM3 and SLC39A3/ZIP (Baum et al. 2008a; Baum et al. 2008b; Wellcome 
Trust Case Control Consortium 2007). In addition, the most robust statistical evidence 
has come from a meta-analysis of WTCCC, STEP-UCL and ED-DUB-STEP2 
(Ferreira et al. 2008). Two signals met the genome-wide statistical significance 
threshold of p  < 5.0 x 10~8 in the large sample set comprising 4387 cases and 6209 
controls- CACNA1C zxuXANK3. CACNA1C encodes an alpha-1 subunit of a voltage- 
dependent calcium channel (http://www.ncbi.nlm.nih.gov/gene). The ANK3 gene is a 
member of a family of proteins that link the integral membrane proteins to the 
underlying spectrin-actin cytoskeleton and have key roles in activities such as cell 
movement, activation, contact, and maintenance of specialized membrane domains 
(http://www.ncbi.nlm.nih.gov/gene). Additionally, ANK3 is known to modulate the 
activity of neuronal sodium channels. Interestingly, both genes implicated by the 
meta-analysis, code for proteins that are known to influence neuronal excitability 
through ion channel function. Markedly, dysfunctions in ion channel function have 
been implicated in diseases with episodic course like epilepsy, ataxia and migraine. 
The findings from the Ferreira et al. study have provided compelling evidence that ion 
channelopaties may also be associated with bipolar disorder (Craddock and Sklar
2009). Even though further evidence is emerging for the involvement of 
polymorphisms in CACNA1C and ANK3 in the liability to bipolar disorder (Bigos et 
al. 2010; Erk et al. 2010; Schulze et al. 2009), additional work is required to build up 
the knowledge of the exact function and ultimately potentially targeting these genes 
by drugs.
Genome-wide association studies in bipolar disorder revealed several novel 
loci which have not been implicated before. Interestingly, evidence has not been 
observed for any of the previously associated candidate genes. This finding is in 
contrast to findings in type 2 diabetes, where the most significant GWA studies 
replicated previous findings (Scott et al. 2007). It has to be noted that the study on 
type 2 diabetes has been based on > 38,000 cases and controls, whereas the studies on 
bipolar disorder have examined fewer individuals. A reason for the little agreement of
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association studies pre-WGA studies advent and since could be the inherent 
complexity of bipolar disorder. In addition, there is little correspondence between the 
most significant results coming from separate whole-genome studies in bipolar 
disorder. Possible explanations for such non-replications are that GWA studies are 
characterised with some inherent limitations which could result in detecting false- 
positive findings (type I errors). This could be caused by population stratification or 
lack of suitable multiple hypothesis testing. Another limitation of GWA studies is due 
to genotyping error, a true susceptibility variant could have been missed (that is, type 
II errors, ). Alternatively, the lack of replicated associations in bipolar disorder 
could be due to a non-sufficient number of studied individuals, i.e. genuine positive 
results are detected in one study but not replicated in another similarly sized sample 
set. A solution would be to analyse much larger sample group, i.e. increase in power 
to detect certain effect size (1-/3).
In summary, WGA studies performed in bipolar disorder have resulted in 
mixed success. They have not been as successful as WGA studies in non-psychiatric 
common diseases, including diabetes, cardiovascular disease, Crohn’s disease, etc. 
Nevertheless, new candidate genes have been suggested (i.e ANK3, MY05B, 
CACNA1C, DGKH and others).
GWA studies are equipped to detect particular type of genetic variation (i.e. 
common SNPs) and a particular type of genetic effect (i.e. weak effect) (Newton- 
Cheh and Hirschhom 2005). The detected polymorphisms explain a small proportion 
of the genetic variance and the majority of the genetic risk for developing bipolar 
disorder remains to be elucidated. There is a possibility that other types of genetic 
variation may account for some of the susceptibility to bipolar disorder.
In conclusion, the phenotype and genetics of psychiatric disorders including 
bipolar disorder have proved to be complex. As a result, most genetic risk alleles have 
not been found, despite the high heritability observed in bipolar disorder. Potential 
reasons could be the involvement in the susceptibility of multiple genes, allelic 
heterogeneity, epistatic gene interactions and non-analysed environmental factors 
among other factors. In addition, genetic factors like de novo mutations, copy number 
variation, epigenetic changes, gene-gene interactions or a complex combination of all 
the factors have not received much attention as factors potentially accounting for 
liability to developing bipolar disorder.
26
1.1.6. Overlap between bipolar disorder and schizophrenia
It has to be noted that a psychiatric diagnosis is made on the basis of 
diagnostic criteria through clinical examination. Thus, one potential problem could be 
a partial overlap in the separate psychiatric categories. For example, psychosis (e.g. 
hallucinations or delusions) can be part of schizophrenia, bipolar disorder and 
psychotic depression. Furthermore, mood disturbances are common in schizophrenia 
(Craddock et al. 2009). Also the “intermediate” phenotype of schizoaffective disorder 
could suggest the existence of clinical continuum rather than a distinct separation 
between bipolar disorder and schizophrenia (Alaerts and Del-Favero 2009).
Therefore, one could speculate that patients do not cluster neatly into separate 
diagnostic groups but rather intermediate forms are seen frequently.
In addition, if  symptoms are not distinct, the boundaries between the separate 
diagnoses could be somewhat arbitrary (Figure 3, page 27) (Burmeister et al. 2008).
Figure 3 Graphical representation of the “boundaries” between the separate 
diagnoses
Cognitive processing
Mood
Depression
Volition
Anxiety
disorders
Anxiety
Nature Reviews | Genetics
(Burmeister et al. 2008)
Therefore, Burmeister et al. concluded that due to the somewhat “blurred” 
boundaries between the separate diagnoses, it is possible that these diagnostic
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categories are quite heterogeneous and that the diagnoses may not reflect the true 
genetic aetiology (Burmeister et al. 2008).
It has been observed that relatives of bipolar probands are at an increased risk 
of developing other psychiatric phenotypes, viz. unipolar depression, schizoaffective 
disorder and schizophrenia (Craddock et al. 2005; Mortensen et al. 2003; Valles et al. 
2000). This suggests that certain, currently unknown genetic factors could be shared 
between bipolar disorder and schizophrenia. Rzhetsky et al. analysed 1.5 million 
patient records from a clinical database at the Colombia University Medical Center 
and 161 disorders to examine if there was a correlation between some of the 
disorders. Based on these extensive data, it was suggested that autism, schizophrenia 
and bipolar disorder share significant genetic component (Rzhetsky et al. 2007).
There is accumulating body of experimental evidence that bipolar disorder and 
schizophrenia could share some of the genetic susceptibility factors (Bramon and 
Sham 2001; Craddock et al. 2005). A balanced translocation between chromosomes 1 
and 11 ((I;ll)(q42;ql4.3)), involving DISCI (disrupted in schizophrenia 1) and 
DISC2 (disrupted in schizophrenia 2) genes has been observed in both schizophrenia 
and bipolar disorder probands in the same Scottish pedigree (Blackwood et al. 2001). 
It has been shown that bipolar disorder and schizophrenia have shared linkage signals 
at identical loci in the human genome, i.e. 6q21-25,10pl4, 13q32-34,18pl 1 and 
22ql 1-13 (Barnett and Smoller 2009; Berrettini 2000; Bramon and Sham 2001; 
Smoller and Gardner-Schuster 2007). In addition, some genetic loci have been 
proposed to be susceptibility factors for both schizophrenia and bipolar disorder: 
BDNF, COMT, NRG1, G72/G30 (DAOA) and DISCI (Kelsoe 2009). Furthermore, 
Moskvina et al. analysed genome-wide association data from schizophrenia and 
bipolar disorder and observed an excess of genes showing evidence for association for 
both of the disorders (Moskvina et al. 2009). Based on these data, one could speculate 
that the genetic associations are not unique to one of the traditional diagnostic 
categories of schizophrenia and bipolar disorder.
Lichtenstein et al. studied a population-based group of more than two million 
families. In this group, large sample sets of patients suffering from bipolar disorder 
(~40,000 cases) and schizophrenia (~35,000 cases) were screened. When relatives of 
bipolar disorder probands were analysed, an increased risk not only for developing 
bipolar disorder, but also for developing schizophrenia were found to be elevated 
(Table 7).
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Table 7 Relative risk for schizophrenia and bipolar disorder
Relation to proband
Risk for SZ when 
proband has BD
Risk for BD when 
proband has SZ
RR 95%C7 RR 95%C7
Biological relationship
Parent Offspring 2.4 2.1-2.6 5.2 4.4-6.2
Sibling Sibling 3.9 3.4-4.4 3.7 3.2-4.2
Sibling Maternal half-sibling 1.4 0.7-2.6 1.2 0.6-2.4
Sibling Paternal half-sibling 1.6 1.0-2.7 2.2 1.3-3.8
Adoptive relationships*
Biological
parent
Adopted away 
offspring 4.5 1.8-10.9 6.0 2.3-15.2
* the biological parent in the adoptions was the one with the illness, not the proband 
(Lichtenstein et al. 2009)
The increased risks for schizophrenia existed for all relationships, including 
adopted children to biological parents with bipolar disorder. Furthermore, the 
comorbidity between the two disorders was found to be mainly ascribable (63%) to 
additive genetic effects common to both of the disorders thus providing evidence that 
bipolar disorder and schizophrenia partly share common genetic cause. In addition, it 
has been also observed that a proportion of the genetic variance is not attributable to 
common genetic factors shared between the disorders suggesting that some genes may 
be associated with risk for both of the conditions while some- with the risk for one of 
the disorders (Lichtenstein et al. 2009). The study of Lichtenstein et al. is of great 
importance in the elucidation of a possible common genetic cause between bipolar 
disorder and schizophrenia, as it makes use of extremely large meticulously analysed 
sample and is likely to yield robust results. Another large cohort of 2.6 million 
persons and their biological parents from Denmark have provided evidence for a 
possible overlap in the determinants between the two disorders (Gottesman et al.
2010). In couples where both individuals have been diagnosed with schizophrenia, the 
incidence of the offspring to have bipolar disorder was ~ 10 times higher than in the 
general population (10.8%; 95%CI: 2.6 -19.0).
The separation between schizophrenia and bipolar disorder initially originated 
from Emil Kraepelin (reviewed in (Kendler 1986)). However, the recent evidence 
challenges the Kraepelinian dichotomy of dementia praecox and manic-depressive 
illness. The hypothesis of a continuum between the disorders, rather than separate 
conditions, has been supported by a large body of data (Craddock and Owen 2005).
29
In summary, it has been shown that there is an overlap in the risk across 
bipolar disorder and schizophrenia. This suggests that some of the susceptibility 
factors could be shared between the disorders. Therefore it is hoped that the research 
coming from genetic studies will elucidate the relationship between these diagnostic 
entities which were initially thought to be separate disorders.
1.2. Copy number variation
1.2.1. Description
Large duplications and deletions have been detected in the human genome for 
quite some time (Miller and Therman 2001). Until recently, their frequency was 
presumed to be low and directly related to a specific rare genetic disorder (Freeman et 
al. 2006). However, in recent years, it has become clear that deletions and 
duplications are widely-spread in the human genome and that this type of variation 
does not always lead to a disease (Iafrate et al. 2004; Redon et al. 2006; Sebat et al.
2004). Apart from being part of the normal genetic variation, structural changes in the 
human genome like deletions and duplications are being recognised as a cause for 
developing diseases, which have been termed genomic disorders (Lupski 2009).
Historically, the first differences observed between the genomes of two 
individuals, have been mainly rare changes in the quantity and structure of the 
chromosomes. Namely, these have been aneuploidies, structural rearrangements, 
heteromorphisms and fragile sites (Miller and Therman 2001). Detecting these 
changes is facilitated by their large size ( 2= 3 Mb) as they are visible with a 
microscope (Feuk et al. 2006a).
Consequently with the development of new molecular biology methods, the 
detection of smaller (^ 3 Mb) variations has become possible (Figure 4, page 32). 
These include single nucleotide polymorphisms (SNPs), repetitive elements that 
comprise short DNA sequences (i.e. microsatellites, minisatellites, small ( < 1 kb) 
insertions, deletions, duplications, inversions and frameshift mutations) (Feuk et al. 
2006a). These 1 -1000bp variants were thought to be the most widely-spread type of 
genetic variation in the human genome, with SNPs being the most abundant, 
numbering at least 10 million (Kruglyak and Nickerson 2001). The variation at single 
nucleotide level has been studied extensively (Frazer et al. 2007; International
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HapMap Consortium 2005; The International Hapmap Project 2003). The analysis of 
the human genome has suggested that single nucleotide polymorphisms are the main 
source for genetic and phenotypic variation (Feuk et al. 2006a; Freeman et al. 2006; 
Scherer et al. 2007; Sharp et al. 2006a). In addition, the microscopic variation (that is 
^ 3 Mb) in the human genome has been examined comprehensively too (Jacobs et al. 
1992; Warburton 1991). Until recently, the variation between these two categories 
(i.e. lkb < variation < 3 Mb) has been largely unknown.
However, due to the discovery of new methods and tools for genotyping, 
knowledge with regards to DNA variation involving segments > 1 kb and < 3 Mb, has 
started to emerge (Iafrate et al. 2004; Redon et al. 2006; Sebat et al. 2004; Tuzun et al.
2005).
Variants within this range and present at a variable copy number in 
comparison with a reference genome, are defined as submicroscopic structural 
variants and are referred to as copy number variants (CNV) (Feuk et al. 2006a).
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Figure 4 Types of genomic variation
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adapted from (Scherer et al. 2007); Inv-inversion; Dupl-duplication; Insert-insertion; Del- 
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Iafrate et al. and Sebat et al. were the initial two studies that pointed to the 
intrinsic dynamic structure of the human genome (Iafrate et al. 2004; Sebat et al. 
2004). Furthermore, these two breakthrough studies demonstrated that copy number 
variants are widely distributed throughout the human genome and could underlie 
normal human phenotypic variation and susceptibility to disease (Iafrate et al. 2004; 
Sebat et al. 2004).
1.2.2. M echanism s for the occurrence of copy n um ber v a rian ts
Three mechanisms have been proposed for the occurrence of copy number 
variants in the human genome (Lupski and Stankiewicz 2005). Specifically, these 
comprise non-allelic homologous recombination (NAHR), non-homologous end- 
joining (NHEJ) and fork stalling and template switching (FoSTeS) (Lee et al. 2007; 
Lupski and Stankiewicz 2005). These mechanisms could arise in both germ and
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somatic cells. If  they occur in germ cells, the genomic rearrangements could lead to a 
genomic disorder, and if they occur in somatic cells, the rearrangements can cause 
disorders like cancer (Gu et al. 2008). If the disease-causing genomic rearrangements 
share a common size and fixed breakpoints, they are said to be recurrent and they 
could share similar clinical manifestations in multiple affected individuals. Non­
recurrent rearrangements are of different sizes in affected individuals. Even though, 
the rearrangements do not affect exactly the same genetic region, they could share a 
region of overlap, which could explain shared clinical features in different patients 
(Figure 5, page 33) (Gu et al. 2008).
Figure 5 Recurrent and non-recurrent genomic rearrangements associated with 
genomic disorders
A recurrent (common) B non-recurrent C non-recurrent
(with breakpoint grouping)
i ... i i
i1 I i
1[ ii 1
1 +1
i j\ * i
S-»
Breakpoint clustering SRO
|-gene
I- low-copy repeat (LCR)
i- complex genomic architectural elements (e.g. palindromes) 
H I  - duplicated/deleted rearrangement with the corresponding 
H H  - duplicated/deleted rearrangement with the corresponding
SRO - smallest region of overlap
Breakpoint grouping
adapted from (Gu et al. 2008)
A. Recurrent copy number variants, sharing a common size and common breakpoints in 
different patients;
B. Non-recurrent rearrangements. They do not involve the same breakpoints, but they share a 
region of overlap, which could explain common phenotypic features in different patients;
C. Non-recurrent rearrangements with grouping of one breakpoint. The grouping of the 
breakpoint is dissimilar to the one observed in breakpoint clustering as these non-recurrent 
rearrangements have one of their breakpoints localized in one small genetic region. Like 
clustering where low copy repeats are responsible for the genetic rearrangements, here the 
underlying genetic culprit for the rearrangement could be a DNA palindrome
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I.2.2.I. Non-allelic homologous recombination (NAHR)
Non-allelic homologous recombination has been proposed to be the major 
mechanism for occurrence of recurrent rearrangements in the human genome (Lupski 
and Stankiewicz 2005).
Most recurrent genomic rearrangements originate by NAHR between two low 
copy repeats (LCR, also called segmental duplications, SD) (Stankiewicz and Lupski 
2002). Low copy repeats are chromosome-specific DNA sequences, normally with 
size variation between 10 and 300 kb and of > 95% similarity to each other 
(Stankiewicz and Lupski 2002). As a result of the high degree of sequence similarity, 
in meiosis and mitosis, non-allelic copies of LCRs can be aligned, as a substitute of 
the normal allelic positions. The outcome of this “misalignment” between non-allelic 
sequences and the following crossover between them could lead to a genomic 
rearrangement in the daughter cells (Gu et al. 2008). Thus, the non-allelic LCRs play 
a role of “mediators” for the homologous recombination. In addition, they are the 
cause for the observed breakpoint clustering between different individuals (Figure 5, 
page 33) (Gu et al. 2008).
A plethora of data has shown that segmental duplications are associated with 
NAHR (Redon et al. 2006; Sebat et al. 2004; Sharp et al. 2005). Itsara et al. replicated 
this finding and demonstrated that NAHR is a major contributor to copy number 
variation. Specifically, a 25-fold enrichment of CNVs between pairs of homologous 
LCRs was observed (Itsara et al. 2009).
Depending on the location of the NAHR, there are different classes (Figure 6, 
page 35) (Lupski 1998). Recombination between low copy repeats can occur in one of 
three ways: between paralogs on the same chromatid (i.e. intrachromatid), between 
LCRs on sister chromatids (i.e. interchromatid or intrachromosomal) and between 
those on homologous chromosomes (i.e. interchromosomal) (Lupski 1998; 
Stankiewicz and Lupski 2002; Turner et al. 2008).
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Figure 6 Different classes of NAHR
B. Intermolecular NAHR 
(interchromatid, interchromosomal)
A. Intramolecular NAHR 
(intrachromatid)
x x
adapted from (Stankiewicz and Lupski 2002; Turner et al. 2008)
A. Intrachromatid NAHR generates a deletion and a circular DNA molecule;
B. Interchromatid and interchromosomal NAHR generates deletion and reciprocal 
duplication;
— * Low copy repeat 
The thin line represents the genomic region affected by NAHR
Examples of genomic diseases caused by NAHR include Charcot-Marie-Tooth 
disease type 1, Hereditary Neuropathy with Liability to Pressure Palsies, Potocki- 
Lupski syndrome, Smith-Magenis syndrome, DiGeorge/Velocardiofacial syndrome 
and inter alia many cancers are also thought to originate from somatic NAHR (Gu et 
al. 2008).
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I.2.2.2. Non-homologous end-joining (NHEJ)
Non-homologous end-joining has been proposed to be a cause for many of the 
non-recurrent rearrangements in the human genome (Lupski and Stankiewicz 2005).
NHEJ is one of the mechanisms used in eukaryotic organisms to repair double 
strand breaks (DSB), caused by ionizing radiation or reactive oxygen (Lieber et al. 
2003; Weterings and van Gent 2004).
NHEJ is executed in four steps (Figure 7, page 36):
1. Detection of the double strand break;
2. Bridging of the broken strands;
3. Modification of the ends to make them compatible and “sticky”;
4. Final ligation step (Gu et al. 2008; Weterings and van Gent 2004).
Figure 7 Schematic representation of NHEJ 
DSB
1. Detection I
2. Bridging 
 \
I
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3. Modification
f
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I
adapted from (Gu et al. 2008) 
DSB- double strand break
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When compared with NAHR it is obvious that low copy repeats are not 
required for the occurrence of NHEJ. A characteristic of the NHEJ mechanism is that 
it leaves an “information scar” at the rejoining site as the pre- joining editing of the 
ends (during step 3) involves cutting out or adding nucleotides from the ends or to the 
ends. This potentially could lead to a deletion of some genetic material (Gu et al. 
2008).
The proposed mechanism by which the non-homologous end-joining could 
cause the occurrence of duplication is the following: if a strand break has occurred on 
one of the DNA strands, one of the broken ends could potentially invade and copy 
using the sister chromatid as a template. After DNA synthesis, the chromosome is 
repaired by rejoining of ends by the NHEJ mechanism (Lee et al. 2006a).
As yet, the extent of the involvement of non-homologous end-joining as a 
mechanism for occurrence of copy number variation has not been fully characterised 
(Lupski and Stankiewicz 2005).
I.2.2.3. Fork stalling and template switching (FoSTeS)
FoSTeS can lead to non-recurrent rearrangements and is a replication-based 
mechanism (Lee et 2d. 2007).
During DNA replication, the active replication fork can stall and pause near 
DNA lesions or near low copy repeats. The lagging strand disengages from the 
original chain and due to sequence similarity can switch to another replication fork 
and start DNA replication. Some unusual genetic architecture such as microhomology 
due to LCR, palindromes, cruciforms or non-B DNA structure could facilitate this 
faulty replication. The fork may be in physical proximity, but separated by some 
distance. The result of this switch could be joining of different sequences from 
separate genomic positions. If the switching was to a downstream fork, the end result 
would be a deletion, whereas if the switching was to a fork located upstream, the 
result would be a duplication (Gu et al. 2008; Lee et al. 2007). Schematic 
representation of the FoSTeS mechanism is given in Figure 8.
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Figure 8 Schematic representation of FoSTeS mechanism
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Lee at al. hypothesised that this could be the mechanism by which complex 
genomic rearrangements associated with a dysmelinating central nervous system 
disorder occurs (Pelizaeus-Merzbacher disease) (Lee et al. 2007). It has also been 
suggested that duplications at amyloid precursor protein gene (APP), which have 
been found to be associated with Alzheimer’s disease, could have occurred by this 
mechanism (Lee et al. 2007). Furthermore, it has been hypothesised that FoSTeS is 
potentially the main mechanism for the origin of duplications and the occurrence of 
LCRs in the human genome (Gu et al. 2008).
1.2.3. Frequency of copy num ber varian ts in the general population
“Each human’s genome is distinguished by extra, and sometimes missing, 
DNA that can powerfully impact everything from development to disease” (Cohen
2007).
The advent of the genome-scanning technology has revealed an unexpected 
magnitude of deletions and duplications in the human genome. Therefore, the extent 
of copy number variation in healthy populations and disease had to be determined.
In 2004, two papers presented analysis of CNVs in healthy human 
populations. The main observation was that on average each person has ~ 12 CNVs 
across the genome (Iafrate et al. 2004; Sebat et al. 2004). When the total number of 
nucleotides affected by these CNVs was taken into account, it was hypothesised that 
CNVs contribute to the overall variation between two people at the same rate as SNP, 
Another study suggested that 12% (~  360 Mb) of the human genome is covered by 
CNVs and that they are affecting many genes and functional elements (Redon et al.
2006).
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Evidence from sequencing of the genome of one individual has revealed that 
insertions and deletions comprise a minority of the observed variations (22% ), while 
they account for ~ 74% of the affected nucleotides (Levy et al. 2007). Taking CNVs 
into account has showed that two haploid genomes differ by 0.5% which was a 
substantial increase over the previously estimated difference of 0.1% (Levy et al. 
2007; Venter 2010). It was later discovered that the genomes of different individuals 
may differ by between 1% and 3% (Venter 2010).
Itsara et al. studied 2500 individuals for CNV by mining data from an Illumina 
array and observed that 65% to 80% of the individuals have a CNV >100 kb,
5 -10% of the individuals have CNVs > 500 kb, while 1 -  2% have CNVs > 1 Mb. 
The average amount of CNVs per person is estimated to be between three and seven 
variants (Itsara et al. 2009). Another important observation has been that the majority 
of the genomic variations are present at ~ 0.02 to 1% frequency and spanning 6% of 
the human genome, whereas polymorphic CNVs encompass 0.09% of the genome. 
Another study also reported that large CNVs affect much less of the genome than 
previously thought (i.e. the estimation by Redon et al. of 12% ). Furthermore, the 
detected CNVs were smaller than the ones found by Redon et al., with which a direct 
comparison was performed (McCarroll et al. 2008). This overestimation has been 
explained by the usage of large insert BAC clones, which are characterised by 
decreased sensitivity. In conclusion, these data have not replicated the initial 
estimation of 12% of the genome is encompassed by CNVs, but suggested rates closer 
to 5%. This rate was also further supported by Pinto et al. who studied healthy 
control population and observed that 160 Mb of the genome (~  5%) is covered by 
CNVs. Of these CNVs, 96% are rare with frequency of < 2%, and the rest are 
common (Pinto et al. 2007).
Currently, it is recognised that CNVs are surprisingly omnipresent in the 
human genome. They can be common (frequency > 1%) or rare (frequency < 1% ), 
inherited or de novo, biallelic or multiallelic (Alaerts and Del-Favero 2009). With 
respect to their size, a negative correlation has been observed, i.e. decrease in size 
results in increase in frequency (Estivill and Armengol 2007).
Like other mutations, it is thought that copy number variation is a mechanism 
that contributes to the plasticity of the human genome and ultimately to evolution. To 
this end, it is not surprising that CNVs often affect genes that are involved in sensory
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perception and immune response functions (Alaerts and Del-Favero 2009; Cooper et 
al. 2007). It has been suggested that the observed enrichment of CNVs in genes 
associated with olfaction and immunity is a sign of adaptive benefit of an increased 
gene dosage (Nguyen et al. 2006). An example is the observed copy number variation 
that affects the CCL3L1 gene (human immunodeficiency virus-1-supressive 
chemokine and ligand for the HIV coreceptor CCR5). Interestingly, a lower CCL3L1 
copy number than the populationai average, is associated with susceptibility to HIV 
(Gonzalez et al. 2005). The more copies are carried of the CCL3L1 gene, the less 
likely is a person susceptible to HIV. The gene codes for a protein which binds to a 
receptor, used by the virus to penetrate the white blood cells; hence the more protein 
produced, the fewer receptors are available for annealing of HIV.
Another example suggesting that copy number variation could be a substrate 
for natural selection, resulting in differences between individuals and populations, is a 
duplication affecting the salivary amylase (AMY1) gene. AMY1 gene participates in 
the digestion of starch in food. Individuals can have between 1 and 10 copies of this 
gene with a corresponding level of amylase in the saliva (Perry et al. 2007). There is a 
clear difference between the populations in the number of copies depending on the 
amount of starch consumed, with the higher number of copies observed in populations 
with a high-starch diet (Perry et al. 2007). It has been argued that this example of 
positive selection may improve the digestion of starchy food and possibly prevent 
intestinal disease (Perry et al. 2007).
In conclusion, there is evidence that copy number variation is one of the 
factors accounting for normal genetic differences between people. In addition, it is 
reasonable to speculate that if a disorder has a large genetic component accounting for 
the susceptibility, copy number variation can be involved in the aetiology (based on 
the fact that CNVs are genetic variants). CNVs can influence the expressed phenotype 
by several mechanisms which are discussed in the next paragraph.
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1.2.4. Influence of copy number variants on phenotype
It is logical to hypothesise that changes in copy number may exert an effect on 
the phenotype by changes in gene expression levels (Henrichsen et al. 2009a). 
Schematic representation of the manner by which the phenotype could be influenced 
by changes in copy number is presented in Figure 9.
Figure 9 Schematic presentation of the influence of copy number variation on 
phenotype
Copy number change of 
dosage-sensitive gene
Gene disruption Position effect
Unmasking a recessive allele Gene fusion
recessive mutation
deletion or duplication
gene
regulatory element i.e. promoter, enhancer etc.
Adapted from Feuk et al. and Lupski and Stankiewicz (Feuk et al. 2006a; Lupski and
Stankiewicz 2005)
Rearrangements could influence the phenotype by the following mechanisms:
A. Gene dosage: altering the copy number of a gene sensitive to dosage 
effects, may lead to a change in the amount of mRNA leading to a change in the 
amount of the affected protein. For certain genes and pathways for which the amount 
of the product is crucial, this could lead to a disease (Shianna and Willard 2006). An 
example of such mechanism is the duplication of the gene encoding peripheral myelin 
protein-22 (PMP22),  which leads to an extra dose of the gene, causing the sheaths that 
protect nerve cells to disintegrate and thus obstructing the signal between brain and 
hands and feet (Cohen 2007). The resulting disease is called Charcot-Marie-Tooth 
disease type 1 A. It is of note that a deletion at the same locus causes another 
neuropathy- hereditary neuropathy with liability to pressure palsies;
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B. Gene disruption: genes that partially overlap with a copy number 
variant will be directly disrupted. This could lead to reduced expression of dosage- 
sensitive genes (Feuk et al. 2006a);
C. Position effect: could be manifested due to either deletion or 
duplication (Kleinjan and van Heyningen 2005; Lee et al. 2006b). There is evidence 
that regulatory elements can be a million base pairs away from a gene, hence even if 
the CNV does not directly affect a gene, it can still affect it in an indirect manner by 
affecting the regulatory elements (e.g. enhancer, repressor elements, etc.) (Feuk et al. 
2006b). Merla et al. studied a deletion associated with Williams-Beuren syndrome 
and observed that not only is the deletion correlated with low relative levels of 
expression of genes within the deletion, but also with a decreased expression of genes 
up to several megabases from the copy number rearrangement (Merla et al. 2006);
D. Unmasking of recessive mutation bv deletion: in dosage-sensitive 
genes a deletion could also lead to disease if it reveals a recessive mutation on the 
homologous chromosome (Feuk et al. 2006a);
E. Fusion genes at the breakpoint generating gain-of-function mutation: 
copy number variants in which breakpoints coincide with a gene, could also lead to 
formation of new transcripts through gene fusion or exon shuffling (Feuk et al. 
2006a).
Stranger et al. ascertained the relative contribution of CNVs to phenotypic 
variation. They analysed the gene expression levels of ~ 14,000 genes in individuals 
that participated in the HapMap project and estimated the association of the 
expression levels with CNVs. The main observation was that CNVs account for 
~ 20% of the detected genetic variation; the rest was explained by SNPs (Stranger et 
al. 2007).
Evidence that CNVs have a phenotypic effect also comes from studies in mice 
and rats. Henrichsen et al. studied whole genome expression data from six major 
organs in mice. Their primary finding was that not only the expression of genes that 
map within CNVs was associated with changes in copy number, but CNVs were also 
found to influence the expression of genes which were not directly affected by CNVs, 
but were up to 500 kb away from the copy number change (Henrichsen et al. 2009b). 
This study was one of the first to demonstrate that CNVs have direct influence on
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tissue transcriptomes and the findings are consistent with Merla et al. study presented 
above.
As yet, not many studies have investigated the functional impact of CNVs at 
the cellular and organism level, further studies are warranted to assess the global 
influence of CNVs on the gene expression, phenotypic variation and the correlation 
with disease.
1.2.5. Methods for copy number detection
The methods for copy number detection are constantly evolving with a 
continuing improvement in resolution. The whole genome or a specific sequence 
could be targeted. The whole-genome scans include karyotyping, SNP arrays used to 
identify CNV structure, array-based comparative genome hybridisation and 
computational approaches based on sequence-assembly comparison. Targeted scans 
include multiplex amplification and probe hybridisation, quantitative PCR, 
fluorescence in situ hybridisation and multiplex ligation-dependent probe 
amplification. The list presented above does not intend to be fully comprehensive.
The method for inferring copy number variants used in this PhD work was 
based on whole-genome SNP array data. The details will be presented further in the 
Methods section of the thesis.
Usually, when reporting genomic imbalances observed with one of the above- 
mentioned methods, the detected variants are subsequently confirmed using an 
alternative method for detection. Compared to SNPs which can be detected with high 
confidence, CNVs are much more difficult to identify. With respect to SNPs the 
identification involves identifying which nucleotide is present at a certain locus, 
whereas CNVs involve deletion/duplication of a certain sequence which is more 
challenging to infer. Therefore, a validation with a different than the initial discovery 
method is required in order to ensure that the observed results are robust.
With the improvement of methods for CNV detection, studies of the possible 
involvement of this type of variation in various disorders are beginning to emerge. In 
the next section I will present evidence with respect to the potential association 
between copy number variation and susceptibility to psychiatric disorders.
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1.2.6. CNV involvement in neuropsychiatric disorders
Structural variation was found to be a potentially important factor for 
developing neuropsychiatric conditions such as mental retardation, autism and 
schizophrenia.
Herein I will predominantly focus on studies published before 2008 as this 
was the start of the work described in this PhD thesis. In this way I will provide a 
snapshot of the field as it was at the beginning of my PhD. More recent findings are 
discussed along with the main findings from this study in the Discussion chapter 
(page 132).
1.2.6.1. Mental retardation
The cause of mental retardation (MR) is currently unknown in 1/3 to 1/2 of the 
cases. It is largely assumed that chromosomal abnormalities (visible with microscope) 
are the most frequent cause and may account for up to 10% of cases (Friedman et al.
2006).
The development of methods for CNV detection has prompted the discovery 
of chromosomal imbalances which are smaller than the ones, detected using light 
microscopy karyotyping (Friedman et al. 2006; Vissers et al. 2003). Table 8 (page 45) 
summarises the main findings (until 2008) with respect to the involvement of 
structural variants in developing mental retardation.
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Table 8 Pathogenic CNV in mental retardation
Reference Diagnosis N cases Locus %  of cases with CNV
(de Vries et 
al. 2005) MR 100 10 {de novo)
(Friedman 
et al. 2006) Idiopathic MR 100 11 {de novo)
(Shevell et 
al. 2008)
Global developmental 
delay 94 6.4
(Shaffer et 
al. 2006)
Variety of developmental 
problems 1500 5.6
(Sharp et al. 
2006b) MR 290
17q21.31,1 q2 l.l,15ql3, 
15q24, 17ql2 5.5
(Koolen et 
al. 2006)
MR, dysmorphic 
features 1200 17q21.31 0.3
(Koolen et 
al. 2008)
Development delay, 
dysmorphic features 22 17q21.31
(Shaw- 
Smith et al. 
2006)
Learning disability 3 17q21.31 de novo
(Ullmann et 
al. 2007)
Autism 182 16p 13.1 (duplication)
MR 95 16p 13.1 (deletion)
(Sharp et al. 
2008) MR, epilepsy 2082 15ql3.3 (deletion)
(Brunetti- 
Pierri et al. 
2008)
Autism, MR and/or 
congenital anomalies and 
dysmorphic features
16,557 1q21.1 (deletion/duplications)
(Mefford et 
al. 2008)
MR, autism, 
congenital anomalies 5218
1q21.1 
(deletion/duplications)
del-0.5
dup-0.2
literature review until 2008
The pathogenicity of these CNVs has been suggested on the basis of the 
following criteria: not observed in control populations, de novo events or phenotypic 
similarities between carriers which could eventually be classified as syndromes.
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It has been observed that submicroscopic chromosomal abnormalities are a 
frequent cause for developing idiopathic mental retardation. It is thought that ~I0% of 
cases with MR/intellectual disability carry a pathogenic copy number variant and this 
observation has been independently confirmed in a number of studies. Some specific 
variants have been found to be involved in liability to mental retardation. It is of note 
that the evidence for the involvement for some of the implicated variants comes from 
multiple studies and these independently replicate the original findings. Many 
different variants have been observed associated with the disorder, suggesting that 
brain dysfunction could be a consequence of disruption of many different genes. With 
respect to some of the observed variants (i.e. 16pl3.1, lq21.1), incomplete penetrance 
has been noted. This suggests that these variants are predisposing factors and not 
sufficient for developing of the disorder.
I.2.6.2. Autism
Autism spectrum disorders are neuropsychiatric disorders where genetic 
factors are known to play a role in the susceptibility. Cytogenetic evidence suggests 
that 3 to 5% of autism cases could be due to chromosomal abnormalities (Freitag
2007). In addition, several loci of potentially pathogenic CNVs have been also 
detected (Abrahams and Geschwind 2008).
Sebat et al. assessed the possible involvement of de novo events in developing 
autism, by screening 188 simplex families, 77 multiplex families and 196 control 
subjects. De novo events were found to be correlated with autism (p  = 0.0005 ) and 
were present with a frequency of 10% in simplex families, 3% of patients in families 
with another affected first-degree family member, whereas amongst controls the 
frequency was 1% (Sebat et al. 2007). Similarly to this finding, Christian et al. 
observed that ~ 11% of the screened autism cases could be due to CNVs (Christian et 
al. 2008).
Some of the submicroscopic variants implicated in the causality of ASD are 
presented in Table 9.
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Table 9 CNV studies in autism
Reference Diagnosis N cases Locus % of cases with the CNV
(Brunetti-Pierri et al. 
2008)
Autism, MR and/or congenital 
abnormalities and dysmorphic 
features
16,557 1q21.1 
(deletion/duplication)
Deletion-0.16 
Duplication-0.1
(Mefford et al. 2008) MR, autism or congenital abnormalities 5218
Deletion-0.5
Duplication-0.2
(Kim et al. 2008; 
Szatmari et al. 2007) autism NRXN1
(Falk and Casas 2007) MR, autism 2q37
(Miller et al. 2009) Autism, MR 2886
15ql3.3
Deletion -0.17 
Duplication-0.17
(Pagnamenta et al. 2008) Autism
(Christian et al. 2008) Autism 372
15qll-15ql3
(maternal
duplication)
0.8
(Kumar et al. 2008; 
Marshall et al. 2008; 
Weiss et al. 2008)
Autism
16pll.2
(duplication/deletion) 1
(Ullmann et al. 2007)
Autism 182 16p 13.1 (duplication) 1.6
MR 95 16p 13.1 (deletion) 2
(Durand et al. 2007) Autism 324 22ql3 /SHANK3 0.9
iterature review until 200i
A region, subject to genomic imprinting, at 15qll-13 has been observed to be 
associated with autism spectrum disorders (Hogart et al. 2008). It has been shown that 
duplications at this region account for ~1% of autism cases and that these duplications 
are predominantly of maternal origin (Freitag 2007).
The deletion at 16pll.2 locus has been investigated in a large sample 
consisting of a plethora of phenotypes including schizophrenia, bipolar disorder, 
attention deficit hyperactivity disorder, panic disorder, language disorder and a vast 
sample set of controls (n=l 8,834). The observed frequencies were: 1% in autism,
0.1% in the other psychiatric phenotypes and 0.01% in general population (Weiss et 
al. 2008). The reciprocal duplication has been detected in schizophrenia and bipolar
47
disorder cases (Walsh et al. 2008; Weiss et al. 2008). This locus will be discussed in 
more detail in the Discussion section (5.10.2, page 153) and in order to avoid 
reiteration, here only data, published until 2008 have been referred to.
Like 16pl 1.2 locus, copy number variants at lq21.1 locus have been observed 
to be associated with autism, MR and schizophrenia, thus suggesting that it could 
potentially be important in all of these disorders. The manifestation of this CNV 
cannot be assigned to one phenotype, but could be considered in a broader context of 
development, as it has been found associated with a wide range of paediatric and 
developmental abnormalities. The deletion has been detected in some unaffected 
family members and based on this evidence, it has been proposed that CNV at this 
locus could produce subtle phenotype features, which could become evident after 
further clinical assessment (Mefford et al. 2008).
It has been shown that rare copy number variants are a significant factor for 
developing autism. Similar to MR, in autism spectrum disorder several variants have 
been replicated in a number of studies which provide evidence that these findings are 
robust. Furthermore, some of these variants have been implicated as predisposing 
factors in MR and schizophrenia suggesting that at least partially, similar underlying 
mechanisms may be relevant to these disorders. It could be speculated that the 
observed copy number variants act together with genes, other contributing CNVs and 
environmental factors, which could influence development of MR in some 
individuals, and autism or schizophrenia in others.
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1.2.6.3. Schizophrenia
There is compelling evidence that CNVs play a role in the susceptibility to 
schizophrenia. Early evidence for structural abnormalities in schizophrenia comprises 
the following two classical examples: a translocation of the gene disrupted in 
schizophrenia (DISCI) and a deletion at the 22ql 1.2 locus. In addition, new evidence 
has started accumulating since the beginning of 2008 with a flurry of reports. Unlike 
previous experience with lack of replication of statistically significant findings with 
respect to association with SNPs, the findings from CNVs have shown strong 
independent replication across different populations.
In a large Scottish pedigree it was observed that schizophrenia and affective 
disorder cosegragate with a balanced reciprocal translocation between chromosomes 1 
and 11 (t( 1; 11)(q42.1;ql4.3)) (Blackwood et al. 2001; St Clair et al. 1990). In the 
family, the performed linkage analysis showed highly statistically significant 
association with psychotic illness- LOD score of > 7. Two genes have been identified 
at this locus- DISCI and DISC2, and interestingly, both are brain-expressed (Millar et 
al. 2000). DISCI gene has been prioritised as the more probable candidate gene of the 
two as it is directly disrupted by the translocation. Since discovery, the DISC locus 
has been studied extensively. The findings have been independently replicated in a 
number of genetic linkage and association studies (reviewed in (Chubb et al. 2008)). 
The locus has been implicated to be associated with a number of phenotypes- 
schizophrenia, bipolar disorder, unipolar and schizoaffective disorder.
The other locus, a deletion at 22qll.2, has also been studied extensively for 
association with neuropsychiatric conditions as it confers a substantial risk for 
developing schizophrenia and is the underlying cause for velo-cardio-facial syndrome 
(VCFS) (Bassett and Chow 2008). A deletion at 22ql 1.2 causes DiGeorge (MIM 
#188400)/velocardiofacial syndrome (VCFS) (MIM#192430). It is commonly 
referred to as 22ql 1.2 deletion syndrome (22ql 1.2 DS). The 22ql 1.2 deletion 
syndrome is the most common microdeletion syndrome occurring in ~1 of every 4000 
live births (Oskarsdottir et al. 2004). 22ql 1.2 DS is characterised with developmental 
delay and wide range of cognitive and neurological deficits, including speech, 
language, memory and attention (Bearden et al. 2001). Interestingly, it has been found 
that deletions at this locus are one of the highest known genetic factors for
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development of schizophrenia (Murphy and Owen 2001). This suggests that there 
could be a possible link between genes in this region and susceptibility to 
schizophrenia. Ivanov et al. estimated the frequency of the deletion to be -0.6% in 
schizophrenia cases from early studies (Ivanov et al. 2003). More recent data based on 
Stefansson et al. and the International Schizophrenia Consortium studies provided 
evidence for a lower rate of 0.2% to 0.4% (International Schizophrenia Consortium 
2008; Stefansson et al. 2008). Nevertheless, it has been shown that the deletion carries 
the highest odds ratios (OR) for development of psychosis. Murphy et al. found a rate 
o f-  30% of adult carriers developing a psychotic illness (Murphy et al. 1999). It is of 
note, that the deletion has not been observed in healthy controls from the general 
population even though the number of the screened control individuals has been 
extremely large especially in the Stefansson et al. study (n=39,299 healthy controls) 
(Stefansson et al. 2008).
Since, with the help of the development in the methods for detection, evidence 
for the involvement in schizophrenia of microdeletions and microduplications has 
become apparent.
Kirov et al. presented one of the first studies of copy number variation in 
schizophrenia. In the screened 93 cases, 13 CNVs not present in controls were 
detected. The main findings have been a deletion disrupting NRXN1 gene (neurexin 1) 
at locus 2pl6.3 (present in two affected siblings) and a de novo duplication affecting 
APBA2 gene (amyloid beta (A4) precursor protein-binding, family A, member 2) at 
15ql3.1 locus (Kirov et al. 2008). Deletions in NRXN1 have been also detected in 
autism cases (Szatmari et al. 2007). In addition, a duplication affecting APBA2 has 
been reported in a patient with autism (Christian et al. 2008).
Schizophrenia is characterised by reduced fecundity and yet the lifetime risk 
has been stable at around 1% . Although persistence in the population at this rate is 
explicable by a polygenic model comprising many weak effects (International 
Schizophrenia Consortium et al. 2009), it is also reasonable to postulate that variants 
of large effect may be replenished by new mutations implicating de novo CNVs in the 
susceptibility. It has been suggested that a new mutation in an affected individual 
could be potentially relevant to the pathogenesis of schizophrenia. As a reduction in 
fecundity has been observed (that is also the case with other neurodevelopmental 
disorders), due to negative selection, variants of large effect will be found with low
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frequencies in the population. Such rare events could arise in multiple unrelated 
individuals by de novo occurrence (Stefansson et al. 2008). Therefore, CNVs with 
large effect could be enriched in such de novo events. To evaluate the potential 
involvement of rare de novo CNVs in schizophrenia, parent-offspring transmissions 
have been studied (Xu et al. 2008). This team observed that de novo CNVs contribute 
to susceptibility to schizophrenia (p  = 0.00078). CNVs were observed eight times 
more frequently in sporadic cases (frequency of 10%) when compared with familial 
cases and control population (1.3% ) (Xu et al. 2008). This provided evidence of the 
involvement of rare events of large effect size in the liability to schizophrenia.
Furthermore, Walsh et al. observed that rare CNVs were more frequent in 
cases (15% in cases with adult onset), when compared with healthy controls (5%) 
( p -  0.0008). This effect was more pronounced for cases with childhood onset-20% 
of them were found to harbour a CNV (p  = 0.0001) (Walsh et al. 2008). The 
overrepresentation was replicated in a sample of 83 trios, where a 2.6-fold enrichment 
of rare structural variants was observed in cases compared with the untransmitted 
parental chromosomes (p  = 0.03 ). Walsh et al. also found that genes affected by the 
CNVs were statistically significantly overrepresented in neurodevelopment pathways 
including neuregulin and glutamate pathways (Walsh et al. 2008).
In 2008, two seminal papers investigating the possible involvement of copy 
number variation in schizophrenia were published in Nature- the International 
Schizophrenia Consortium and the Stefansson et al. studies (International 
Schizophrenia Consortium 2008; Stefansson et al. 2008).
Stefansson et al. identified 66 de novo CNVs in a population-based sample by 
analysing 9878 transmissions from parents to offspring. Three CNVs exhibited an 
association with schizophrenia in a subsequent study of patients with schizophrenia 
and controls-1 q21.1,15ql 1.2 and 15ql3.3. These variants were rare with high OR of 
14.83 (95%C7:3.55 -  60.40; p  = 2.9x 10"5), 2.73 (95%C7:1.50-4.89; 
p  = 6 x 10-4) and 11.54 (95% CI: 2.53 -  49.58; p  -  5.3 x 10^ ) respectively for the 
three deletions. The 22ql 1.2 deletion was observed with a frequency of 0.2% in the 
cases and 0% in the controls (3838 cases and 39,299 controls) (p  = 4.2 x 10-5,
OR = oo) (Stefansson et al. 2008).
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Noteworthy correspondence was observed between the Stefansson et al. study 
and the International Schizophrenia Consortium (ISC) study (International 
Schizophrenia Consortium 2008; Stefansson et al. 2008). ISC analysed large sample 
set of 3391 patients with schizophrenia and 3181 healthy controls, using high-density 
microarrays. Similar to the Stefansson et al. study, rare deletions at 22ql 1.2, lq21.1 
and 15ql3.3 were detected in cases with high OR (21.6, 6.6 and 17.9 respectively). In 
addition, when CNVs with frequency of < 1% and with size >100 kb were analysed, 
it was found that schizophrenia cases have 1.15 higher rate of CNVs when compared 
with controls. This effect was more pronounced for rarer, single-occurrence CNVs 
and CNVs affecting genes in patients (International Schizophrenia Consortium 2008). 
Our department was involved in this study, and the findings in schizophrenia 
prompted my research interest in the area, which subsequently led to the design of this 
PhD study.
In conclusion, an increased frequency of rare CNVs in schizophrenia has been 
observed, suggesting that such structural variants could be important for the liability 
to the disorder. In addition, some specific CNVs have been found to be involved in 
susceptibility. It is of note that some of the observed CNV have been independently 
supported in several studies. Moreover, it has been shown that all of the associated 
structural variants confer a substantial risk for developing schizophrenia. Some of the 
implicated variants, viz. 1 q21.1, NRXN1 deletion and 15ql3.3 have also been 
observed to increase the risk for developing other neurodevelopmental disorders, such 
as mental retardation, autism spectrum disorder and/or variable paediatric phenotypes. 
Similarly, deletions at 22ql 1.2 have been implicated in other phenotypes- attention- 
deficit hyperactivity disorder (ADHD) and bipolar disorder.
The findings of these specific loci account only for a fraction of the 
schizophrenia cases. There is an increased burden of CNVs in schizophrenia, although 
these specific loci do not provide explanation for most of this specific burden. 
Therefore, it could be speculated that other loci remain to be found that could explain 
the rest of the increased burden. Discovering these variants could be of great benefit, 
as these CNVs could point to identification of additional risk variants in genes and 
pathways involved in schizophrenia.
Since these early studies on the whole-genome CNV structure in 
schizophrenia, a lot more research has been performed. The more recent findings will 
be considered in the Discussion section (page 153) in order to avoid repetition.
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I.2.6.4. Bipolar disorder
Unlike schizophrenia, the copy number variation has been largely unexplored 
in the susceptibility to bipolar disorder. There had been only one systematic study of 
CNVs in bipolar disorder, published when the work towards this PhD was underway. 
The involvement of rare and large CNVs (> 100 kb) in developing BD was assessed 
in 1001 cases and 1034 controls (Zhang et al. 2008). The copy number variation was 
inferred using data from Affymetrix 6.0 arrays. No increased burden was observed in 
cases when compared with controls. However, single-occurrence deletions were 
found more frequently in cases (16.2% ) than in controls (12.3% ), with a 
corresponding significance level of p  -  0.007. The number of genes affected by 
singleton deletions did not show a statistically significant difference when the cases 
were compared with controls (p  = 0.21). No statistically significant difference was 
noted between cases and controls with respect to singleton duplications (p  = 0.054). 
Nevertheless, when only cases with early disease onset ( < 18 years) were investigated, 
the effect of singleton deletions was found to be more pronounced. A comparison of 
early onset versus late onset cases revealed a marginally higher frequency of singleton 
deletions in early onset cases (p  = 0.05). In addition, Zhang et al. performed pathway 
analysis which revealed that genes affected by CNVs were overrepresented in 
pathways involved in psychological disorders and learning behaviours 
(p  = 6.30 xlO-6 and p  = 8.29 xlO-3 respectively).
Based on these findings, it was concluded that developing bipolar disorder 
could be a result of joint function of multiple rare structural variants (Zhang et al.
2008).
Prior to the publication of the above-mentioned report, studies investigating 
the possible involvement of copy number structural variation in bipolar disorder were 
anecdotal. The majority of studies analysed limited number of samples.
Namely the studies providing data, based on analysing copy number variation 
in bipolar disorder were the following:
A balanced chromosomal translocation t( l : 11) (q43,q21) affecting the DISCI 
gene observed in a Scottish pedigree, segregated with disease. In this family, both 
schizophrenia and mood disorders have been detected (St Clair et al. 1990).
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A duplication at 3ql3.3 affecting GSK3fi gene (glycogen synthase kinase 3 
beta) and two other genes has been found associated with bipolar disorder (Lachman 
et al. 2007).
The 22qll.2 locus has also been associated with developing bipolar disorder. 
This locus has been extensively studied in the neuropsychiatric field as it has been 
observed that schizophrenia and bipolar disorder are present in some of the affected 
individuals with VCFS, amongst other symptoms (facial, immunological and 
cardiovascular) (Carlson et al. 1997; Murphy et al. 1999; Papolos et al. 1996). A more 
detailed description of the data with respect to 22ql 1.2 was already presented in 
section 1.2.6.3 (page 49).
Wilson et al. studied brains from bipolar disorder cases, schizophrenia cases 
and controls for copy number variation. Ip34.3,14q23.3 and 22ql2.3 affecting the 
GLUR7, AKAP5 and CACNG2 genes were found to be associated with disease 
(Wilson et al. 2006).
In conclusion, it has been shown that copy number variation accounts for 
some of the susceptibility to neuropsychiatric conditions, such as mental retardation, 
autism and schizophrenia. The amount of accumulated evidence with respect to some 
specific CNVs has been large and even more, some of the evidence has been 
replicated in independent studies.
In addition, previously it has been shown that bipolar disorder and 
schizophrenia may share some of the underlying genetic factors for the predisposition 
to disease. Thus, to ask the question of the possible involvement of copy number 
variation in liability to bipolar disorder is in order. The knowledge with respect to 
CNVs in the predisposition to developing bipolar disorder has been very limited, with 
the predominant number of studies focusing on specific candidate genes or has been 
based on a limited number of samples. There was only one study based on whole- 
genome CNV investigation in a large sample of bipolar cases and controls at the time 
when the work towards this PhD was already underway. Therefore, further studies 
were warranted to elucidate if structural variation is a predisposing factor for the 
susceptibility to bipolar disorder.
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1.3. Summary
Bipolar disorder is a severe neuropsychiatric condition affecting ~1% of the 
human population worldwide. A strong genetic component has been implicated in its 
causality. Thus far, a number of genetic variants have been shown to increase the 
susceptibility (i.e. variants in the ANK3, CACNA1, DGKH, MY05B and other genes), 
although conclusive evidence has proved elusive. Recent developments in the 
neuropsychiatric field have found support for the possible involvement of rare 
structural variants in human disorders including autism spectrum disorders, mental 
retardation and schizophrenia. At the start of this PhD work, the possible involvement 
of copy number variation in the causality of bipolar disorder was understudied and 
largely unknown. This stimulated my interest in this area and led to the work 
described in this thesis.
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2. Aims and objectives
The primary aim of this PhD research project was to investigate the possible 
involvement of copy number variation in the susceptibility to bipolar disorder.
In order to achieve this, I aimed to:
1. Analyse the CNV structure in a large cohort of bipolar cases (n=l 868) 
and healthy controls (n=2938) using SNP genotyping data from Affymetrix 500K 
arrays. In addition, I wanted to compare bipolar cases with a large number of non­
psychiatric controls (-10,000), with respect to their copy number variation structure;
2. Determine whether large ( > 100 kb) and rare (frequency- < 1% ) copy 
number variants were associated with susceptibility to bipolar disorder;
3. Determine whether some specific deletions or duplications were 
involved in developing bipolar disorder;
4. Compare bipolar disorder and schizophrenia with respect to their CNV 
burden and the possible involvement of some specific deletions/duplications.
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3. Material and Methods
In this chapter I will provide a description of the methodology used in the PhD 
work. Here, I will therefore cover: case and control sample description, laboratory 
methods, CNV calling procedure, bioinformatical and statistical methodology.
Unless otherwise stated, all work and analyses have been performed by me.
3.1. DNA samples
3.1.1. Cases
3.1.1.1. Bipolar disorder
The collection of the bipolar samples involved in this work, including the 
diagnosis of patients, was performed by Professor Nick Craddock, Dr George Kirov, 
Dr Ian Jones and other members of the Department of Psychological Medicine, 
Cardiff University and the Department of Psychiatry, Birmingham University. The 
total number of the analysed bipolar cases was 1868. The majority of the sample was 
recruited by the Department of Psychological Medicine, Cardiff University and the 
Department of Psychiatry, Birmingham University as shown in Figure 10.
The recruitment of the rest of the sample was undertaken throughout the UK 
by teams based in Aberdeen (Institute of Medical Sciences, University of Aberdeen), 
London (the Institute of Psychiatry, King's College London) and Newcastle 
(Neurobiology and Psychiatry, Royal Victoria Infirmary).
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Figure 10 Proportion of the sample set recruited in the four different sites 
throughout the UK
8°/o
15%
□ Cardiff/Birmingham
□ London
□ Aberdeen 
■ Newcastle
All participants were Caucasian and of UK origin. 37% of the sample were 
male cases; mean age 47 (SD 13) years and mean age of onset 26 (SD 11) years. All 
participants have provided written informed consent to take part in genetic studies. 
Protocols and procedures were approved by relevant ethical review panels.
Individuals who had been in contact with mental health services were 
recruited if they suffered with major mood disorder characterised with significant 
episodes of elevated mood. This was defined as a lifetime diagnosis of bipolar mood 
disorder according to Research Diagnostic Criteria (Spitzer et al. 1978) and included 
the bipolar subtypes that have been previously shown in family studies to co- 
segregate (Rice et al. 1987): bipolar I disorder, schizoaffective disorder bipolar type, 
bipolar II disorder and manic disorder (Figure 11).
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Figure 11 Proportion of the sample diagnosed with disorders from the bipolar 
spectrum
□ bipolar I disorder
□ schizoaffective disordei 
bipolar type
□ bipolar IT disorder 
■ manic disorder
Lifetime best-estimate method was used to make the diagnoses (Leckman et 
al. 1982) by a trained psychologist or psychiatrist. All diagnoses were confirmed by a 
consensus of two people. The diagnoses were based on data from semi-structured 
interview- Schedules for Clinical Assessment in Neuropsychiatry (SCAN) (Wing et 
al. 1990), information obtained from psychiatric case records and an OPCRIT 
checklist (McGuffin et al. 1991). The Bipolar Affective Disorder Dimension Scale 
(BADDS) was used to rate key clinical variables relating to psychosis (Craddock et al. 
2004).
The 1868 bipolar cases were exactly the same cases that took part in a large 
collaborative project to perform genome-wide single nucleotide polymorphism 
association study of 14,000 cases of seven common diseases and 3000 shared controls 
(that is the Wellcome Trust case control consortium study, WTCCC). The studied 
common diseases comprised: bipolar disorder, Crohn’s disease, rheumatoid arthritis, 
type 1 diabetes, type 2 diabetes, hypertension and coronary artery disease (Wellcome 
Trust Case Control Consortium 2007).
70%
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3.1.1.2. Schizophrenia
Along with the bipolar cases, 520 unrelated schizophrenia/ schizoaffective 
disorder cases were also studied in this PhD work. All were white and bom in the UK. 
The mean age at first psychiatric contact was 23.8 (SD 7.9) years and the mean at 
ascertainment was 44.8 (SD 13.1) years. Of those 520,471 survived copy number 
detection filtering and 440 of them were further analysed for this PhD. The rest were 
excluded as they had diagnoses of schizoaffective disorder.
All patients were interviewed by trained psychiatrists or psychologists using 
Present State Examination (Wing 1974) or SCAN interview (Wing et al. 1990).
Based on the interview information, along with review of case notes, 
consensus diagnoses of schizophrenia were made according to DSM-IV criteria 
(American Psychiatric Association 1994), by two independent raters. Cases were 
screened to exclude substance-induced psychotic disorder or psychosis due to a 
general medical condition. Ethics committee approval was obtained from all regions 
where patients were recruited.
These schizophrenia cases were genotyped in the same pipeline as the 
WTCCC study and were processed at the same time and with the same methods along 
with the bipolar cases and the controls (O'Donovan et al. 2008).
3.1.2. Controls
Control subjects were derived from two sources: half from 1958 Birth Cohort 
and the remainder from a new UK Blood Service sample (National blood service, 
NBS). The DNA preparation, DNA extraction, quality control and normalization of 
the control DNAs were performed at the Wellcome Trust Laboratories at Sanger, 
Cambridge. These controls were part of the WTCCC study (Wellcome Trust Case 
Control Consortium 2007).
60
3.I.2.1.1958 Birth Cohort
The 1958 Birth Cohort (also known as the National Child Development Study) 
comprised all births in Scotland, England and Wales during one week in March, 1958. 
From the original sample of ~ 17,500 births, the survivors were followed up at 7,11, 
16, 23, 33 and 42 years of age
(http://www.cls.ioe.ac.uk/studies.asp?section=000100020003) (Power and Elliott 
2006). At the age of 44-45 years, biomedical examination along with blood sample 
collection were carried out (http://www.b58cgene.sgul.ac.uk/collection.php) (Strachan 
et al. 2007). From the blood samples of the consenting 7692 individuals, Epstein-Barr 
virus-transformed cell lines were prepared.
For the purposes of the WTCCC study, DNA samples were extracted from 
1504 cell-lines of self-reported white ethnicity and representative of gender and each 
geographical region in agreement with the gender and geographical region 
distribution of the 14,000 cases that took part in the WTCCC study (Wellcome Trust 
Case Control Consortium 2007).
3.1.2.2. National blood service (NBS)
WTCCC in collaboration with the UK Blood Services set up a national 
repository of anonymized samples of DNA from 3622 consenting blood donors, aged 
18-69 years. A set of 1500 samples was selected from the total number. The selection 
was based on the sex and geographical region in order to reproduce the distribution of 
the samples in the 1958 Birth Cohort control group. The subjects were of self-reported 
European Caucasian ancestry. The DNA was extracted from blood (Wellcome Trust 
Case Control Consortium 2007).
3.2. DNA preparation of the bipolar DNA samples
The DNA preparation involved DNA extraction, assessment of the quality of 
the extracted DNA samples and DNA preparation for the WTCCC study.
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3.2.1. DNA extraction
From the 1868 analysed bipolar cases, ~ 23% were extracted by me. The rest 
were extracted by members of staff from the Department of Psychological Medicine, 
the Department of Psychiatry, Birmingham University or other centres in UK who 
took part in the bipolar WTCCC study (Institute of Medical Sciences, University of 
Aberdeen and the Institute of Psychiatry, London).
High molecular weight genomic DNA (gDNA) was obtained from 
lymphocytes from venous whole blood. Each sample was prepared via standard 
phenol-chloroform DNA extraction followed by ethanol precipitation. The DNA was 
subsequently diluted in TE buffer. The short term storage of the DNA samples was at 
4° C and at -  20° C for a long period of time.
3.2.2. DNA quality control using degradation test
A proportion of the extracted DNA samples was tested to determine if DNA 
degradation, smearing or low genomic product were present. DNA samples were run 
on a gel, able to detect samples with high molecular mass (AquaPor™ with DNA 
resolution between 1 and 50 kb). The gel was stained with ethidium bromide and 
DNA fragments with bound ethidium bromide were visualised using ultraviolet light. 
Since the DNA samples predominantly consist of fragments > 20 kb in length, the 
DNA forms one slow moving band on the gel. Any smearing is indicative of DNA 
with low molecular weight suggesting that DNA has degraded. An example of high 
molecular DNA samples and degraded DNA samples is presented in Figure 12.
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Figure 12 Example of a degradation test
3.2.3. DNA PCR check
A proportion o f the extracted DNAs was tested using a known, previously 
optimised PCR and the products were then visualised (using ethidium bromide to 
stain the PCR product and subsequent exposure to ultraviolet light) on a gel to 
examine if the DNA samples are in a viable condition.
3.2.4. DNA quantification
The PicoGreen® dsDNA Quantitation Reagent was used for DNA 
quantification. The PicoGreen dye is highly sensitive fluorescent nucleic acid stain for 
quantifying double-stranded DNA (dsDNA). It possesses strong affinity for binding to 
dsDNA and it undergoes fluorescent excitement upon binding to it. The fluorescence 
is measured using a microplate fluorometer.
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The assay was performed as outlined in a standard operating procedure used in 
the department. The DNA samples were diluted 200 times and pipetted in 96 well 
plates. Subsequently, the fluorescent intensity of the PicoGreen dye incorporated in 
the dsDNA was measured at excitation wavelength of 485 nm and recording the 
emission wavelength at 535 nm . A standard curve prepared by me was then used to 
calculate the concentration of DNA for each sample.
3.2.5. Preparation of case DNA samples for WTCCC
Unique sample identifiers were issued by WTCCC for all the samples that 
were sent for genotyping. In an Excel spreadsheet, provided by WTCCC, the 
following information was logged: unique WTCCC identifier, our laboratory sample 
ID, position in the shallow 96-well box, barcode of the box, case/control status, DNA 
concentration, DNA extraction method, DNA source, gender and geographical region. 
The WTCCC project included sending DNA samples to the Wellcome Trust 
Laboratories at Sanger Institute, Cambridge in two waves in 2005 and 2006.
In 2005,1229 DNA samples were sent, and in 2006- another 1055 samples. 
From these samples, 1868 were selected for genotyping by WTCCC and were further 
analysed. Half of the samples sent in the first wave were prepared by Mrs. Rachel 
Raybould and the other half by me. All the DNA preparation for the second wave in 
2006, was done by me.
The DNA preparation involved measuring all DNA samples with PicoGreen® 
quantitation assay, then selecting the DNA samples which had sufficient DNA 
concentration (DNA concentration > 10ng/ fjJ ) and sufficient DNA quantity 
(> 100jU/). The selected DNA samples were diluted or concentrated to ~ 100ngl \ d . 
The preparation of the DNA samples also involved performing a degradation test for a 
proportion of the samples.
After adjusting the concentration of the samples to ~ 100 ngl f i l , they were 
aliquoted into 96-wells Abgene® plates and barcoded accordingly to the file that was 
prepared with the required information by the Wellcome Trust Laboratories.
Many people from the Department of Psychological Medicine were involved 
in the recruitment, the selection process of the cases and file preparation of the 
required information for the project: Prof. Nick Craddock, Dr. George Kirov, Dr.
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Elaine Green, Dr. Liz Forty, Dr. Elen Russell, Mr. John Tredget, Mrs. Christine 
Fraser, Mrs. Rachel Raybould, and myself. At the Department of Psychiatry, 
Birmingham University, Mrs. Sian Caesar and Dr. Katherine Gordon-Smith, were 
also involved in the project. As the WTCCC project involved collaborators from the 
Institute of Medical Sciences (University of Aberdeen), the Institute of Psychiatry 
(King's College London) and the department of Neurobiology and Psychiatry (Royal 
Victoria Infirmary, Newcastle), I coordinated the DNA samples and case information 
receipt at our department. Subsequently, the DNA samples received from our 
collaborators throughout the UK were prepared by Mrs. Rachel Raybould or me, in 
exactly the same manner as our samples: normalised to the required DNA 
concentration, aliquoted in 96-wells Abgene® plates, barcoded and the file with the 
required information was prepared.
In addition, in exactly the same manner the schizophrenia cases were prepared 
by Dr. Hywel Williams, Mrs. Sarah Dwyer, Dr. Liam Carroll, Dr. Nadine Norton, Dr. 
Lyudmila Georgieva and Dr. Tim Peirce.
3.3. Wellcome Trust Case Control Consortium quality control 
measures and selection of samples for genotyping
The quality of all case and control DNA samples was assessed at the 
Wellcome Trust Laboratories, Sanger Institute, Cambridge (Wellcome Trust Case 
Control Consortium 2007).
On receipt at the Sanger Institute, the samples had DNA concentration 
measured by PicoGreen®, then were checked for DNA degradation on a 0.75% 
agarose gel, and subsequently genotyped with up to 38 SNPs arranged in two 
multiplex reactions using the MassExtend® (hME) and/or iPLEX® assay Sequenom® 
assays. The above SNPs were used to obtain concordance rate between Sequenom® 
and Affymetrix® assays (25 of the 38 SNPs were present on the Affymetrix 
GeneChip® 500K arrays) and experimentally confirming the gender of each sample. 
Samples with concentrations ^ 50ng/ fjd, showing limited or no degradation, having 
minimum of seven SNPs successfully genotyped out of the 10-plex (hME® reaction) 
and/or 14 SNPs successfully genotyped out of the 23-plex (iPLEX® reaction) SNPs, 
and having the sex markers in agreement with the supplied information from us, were
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deemed fit for whole-genome genotyping. The SNPs in the hME multiplex assay were 
replaced with a second iPLEX® reaction in the course of the project to increase 
marker density. 1868 samples were selected from the bipolar cases collection and 
~ 1500 samples from the two control collections- 1958 cohort and NBS. The selected 
samples were normalized to 50ng! fd and re-arrayed robotically into 96-well plates, 
so that each plate comprised 94 samples representing at least two different collections 
(that is, samples from the seven separate disorders that took part in WTCCC) at a ratio 
of 1:1.
3.4. Genotyping with Affymetrix platform
DNA from all cases (bipolar and schizophrenia) and controls was genotyped 
with the Affymetrix GeneChip® 500K Mapping Array Set at the Affymetrix Services 
Lab in California. The GeneChip® 500K Array Set comprises two arrays: NspI and 
Styl. NspI array comprises 262,000 SNPs and Styl -238,000 SNPs respectively. The 
SNPs chosen by Affymetrix to be present on the arrays, have been selected, based on 
genotyping accuracy, call rate and linkage disequilibrium analysis across the genome. 
The SNPs present on the 500K Mapping array, have been selected in a way that 
85% of the human genome is within 10 kb of a SNP (http://www.affymetrix.com).
The genotyping procedure is as follows (Figure 13, page 67): two aliquots of 
250wg of genomic DNA are digested with restriction NspI and Styl enzymes. 
Subsequently, an adaptor is ligated. The adaptor recognises the “sticky” four base-pair 
ends that are produced after the digestion with the enzymes. A generic primer that 
recognises the adaptor sequence is used to amplify the adaptor-ligated fragments. 
Preferentially only fragments with size range between 200 and 1100 bp are amplified 
due to the selected PCR conditions. The amplified DNA is fragmented, labelled and 
hybridised to the corresponding GeneChip® 250K array (NspI or Styl). Each array in 
the GeneChip® Mapping set, comprises more than 6.5 million features, each 
consisting of more than one million copies of a 25-bp oligonucleotide probe of a 
defined sequence. Each SNP is interrogated by 6- or 10-probe quartets, where each 
probe quartet comprises perfect match and a mismatch probe for each allele. Each 
enzyme preparation is hybridised to the corresponding SNP array- NspI or Styl.
Up to the hybridisation step, samples were processed in batches of 96-well 
plate format. The processing of the samples in batches proved to have a profound
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effect on the copy number variation identification and is further discussed in detail in 
section 4.1.3 (page 92V
Each 96-well plate carried a positive and negative control. CEL files contained 
the row hybridisation signal intensity data of the various probes on each array.
Figure 13 Affymetrix GeneChip® 500K Mapping overview
Genomic DNA (250 ng) RE Digestion ■
Adaptor
LigationPCR: One Primer 
Amplification
Complexity
Reduction
Hybridization 
& Wash
Fragmentation 
and End-Labeling
(http://www.affymetrix.com)
3.5. Quality control of Affymetrix genotyping
The quality control of the genotyping with the Affymetrix platform was 
performed by me. The bipolar case DNA samples were genotyped for 46 markers in 
two separate panels, using the iPLEX® Sequenom MassARRAY platform 
(http://www.sequenom.com). The first panel comprised markers that were genotyped 
by Sanger institute for quality control of the DNA samples. In addition, these markers 
were also present on the Affymetrix GeneChip 500K array. The second iPLEX panel 
comprised markers that were present on the Affymetrix 500K platform.
The Sequenom MassARRAY genotyping system allows highly accurate 
genotyping of SNPs by combining iPLEX® GOLD primer extension chemistry with 
MALDI-ToF® (Matrix Assisted Laser Desorption Ionisation-Time of Flight) Mass 
Spectrometry (http://www.sequenom.com). IPLEX® GOLD involves single 
nucleotide primer extension over the polymorphism of interest and the examination of
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the mass of the extended product to discern the genotype of the sample. Results are 
stored and analysed using the Typer Analyzer software. The main advantage of this 
genotyping system is the high accuracy combined with high multiplexing level (up to 
a 40-plex) in a 384 microlitre plate.
It involves an initial PCR of all the SNPs in a 384 sample format. Should the 
1st step pass an initial quality control for contamination and PCR efficiency, the PCR 
reaction is cleaned up in order for the unincorporated dNTPs, primers, DNA 
polymerase and salts to be removed. The clean product is then subject to a primer 
extension reaction. It involves the addition of optimised concentrations of unextended 
primers, along with dideoxy nucleoside triphosphates.
After the extension reaction, desalting the solution with special resin, provided 
by Sequenom, is performed, in order to remove all ions that may alter the spectra of 
the sample and affect the subsequent analysis.
Samples are automatically spotted onto the Sequenom MassARRAY 
SpectroCHIP using a nanodispenser liquid handler. Each chip comprises 384 spots 
composed by a combustible matrix (3-hydroxypicolinic acid), which allows 
ioinisation of the product when excited by a laser (Buetow et al. 2001).
Each ioinised, extended and unextended MassEXTEND primer product differs 
in mass and is therefore amenable to MALDI-ToF mass spectrometry analysis using 
MassARRAY RT software (SpectroAcquire, Sequenom). The software estimates 
genotypes for each sample, based upon certain parameters such as peak height 
(intensity of mass signal) of each allele and also extension primer yield (successful 
extension of the unextended primer compared to the residual unextended primer). 
These genotypes can be then viewed and manually revised by the user using the Typer 
Analyzer software (Figure 14).
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Figure 14 Screenshot from Typer Analyzer software for one of the tested SNPs 
(rs4276227)
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3.6. Copy number variation detection
3.6.1. Affymetrix Genotyping console
Copy number variation was inferred from the raw intensity genotyping data 
(CEL files). The computer used for the analysis of the CNV data had the following 
specifications:
Operating System: Microsoft Windows XP Professional 
Processor: Intel ® Core ™ 2 Quad, 2.4 Giga Hertz 
Random Access Memory: 4 Giga Bytes 
Hard-Disk Drive: 500 Giga Bytes
Due to the large size of the raw intensity files (CEL), the amount of studied 
individuals and the size of some of the files generated by the Affymetrix Genotyping
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console, an external hard-drive was also required (Western Digital, dual drive storage 
system, 2 TB drive).
The CNV calling was carried out using stand-alone Windows-based 
application provided by Affymetrix, namely- Affymetrix® Genotyping console 2.1 
(Figure 15). The software was downloaded from the Affymetrix website 
(http://affymetrix.com).
Figure 15 Affymetrix® Genotyping console 2.1
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The software required intensity data files (CEL) for each individual. These 
data files have been generated by other Affymetrix software, when a microarray has 
been scanned. The CEL files comprise information about the intensity values of the 
individual probes present on the array. These files were provided by WTCCC. As the 
Affymetrix GeneChip® array set comprises two arrays- NspI and Styl, the CEL 
intensity files from one individual for the two arrays were analysed separately.
The workflow of the separate steps involved in the CNV detection analysis 
using the Affymetrix genotyping console is presented in Figure 16, page 71.
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Figure 16 Workflow of the Affymetrix genotyping console for CNV detection
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Review CEL data quality
The steps involved in inferring the CNV structure of the case and control 
samples using the Affymetrix genotyping console are presented in more detail below:
1. Quality control (QC) of the CEL intensity data- the default QC metrics 
of the program were used with a QC SNP call rate threshold ^ 93%. This QC 
measure provides an estimate of the overall quality of the samples. Samples with an 
average SNP call rate < 93% were excluded from further analysis. Gender analysis 
was also performed at this stage. It provided a gender call, which was used at a later 
step, when individuals were separated into two groups according to gender for the 
CNV calling step (as males and females were analysed separately). The QC step was 
performed for all individuals (i.e. all the cases for NspI or Styl arrays at once). It has 
been shown that removing poor quality CEL files at this stage could improve the 
quality of the genotypes of the remaining CEL files (Affymetrix Inc 2007);
2. Genotyping- at this stage, genotyping analysis of the intensity data that 
passed the initial quality control step was performed. The genotype calls (i.e. AA, AB, 
BB) were generated using a method that has been developed by Affymetrix (that is, 
Bayesian Robust Linear Model with Mahalanobis distance classifier algorithm) 
(http://www.affymetrix.com). Due to computational power limitation, the genotyping 
step was performed for groups of < 250 individuals at a given time;
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3. CNV analysis- the input for performing this step was the CEL and the 
genotyping files. Males and females were analysed separately. In addition, a set of 
reference samples was created at this stage. At this point of the analysis, a major batch 
effect in the data was noticed. A batch is a set of u p  to 96 samples processed at the 
same time in the laboratory. That is, the samples have been run in the Affymetrix 
service lab using the same reagents and as all of the samples have not been run at 
once, there is a possibility that systematic differences between the runs occur due to 
intrinsic variability of the starting material, hybridisation cocktail, the arrays or the 
scanning, etc. Therefore, to minimise artefacts due to batch effect, I suggested, to 
process the samples in the same batches for the CNV calling step as they have been 
processed up to the hybridisation step of the laboratory protocol. Around 100 
individuals were analysed against a reference set of ~ 100 individuals. From this 
comparison, the sample’s copy number data were inferred.
The copy number algorithms depend on comparing signal for each marker in 
each sample against a reference set formed from a group of samples 
(http://www.affymetrix.com). The assumption is that for each marker, the reference 
state in the group will be copy number = 2 (except for the Y chromosome, where the 
reference state is 1), and hence deviations from the reference can be detected by 
forming the log ratio of each marker’s signal compared to its reference value. For the 
autosomes, the reference value of a particular probe is estimated using the median 
signal of all samples in the reference for the specific probe. For the X chromosome, 
the reference value is estimated using the samples, determined to have two X 
chromosomes. Respectively, for the Y chromosome, the reference set is estimated by 
taking into account only the samples, having one Y chromosome. In the process of 
calculating the signal, various normalisation steps are made in order the signal from 
each sample to be compared with each other.
To assess the reliability of the copy number calls, the interquartile range 
( IQR) of the non-normalised log 2ratio was used. The IQR is a measure of
dispersion/spread of the data. It is the difference between the 75th percentile (named 
3rdquantile) and the 25thpercentile (named Istquantile). The formula for the IQR is 
as follows: 3rd quantile -  Ist quantile or alternatively 75* percentile -  25th percentile. 
The IQR is a robust measure for data spread as it represents the central 50% of the 
data and is relatively less affected by outliers.
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The default QC cut-off of the program for the IQR was < 0.4 and samples 
with IQR > 0.4, were not analysed further;
4. Segment report step- the segment reporting tool generated copy 
number segment report for each sample. The report file comprised all the segments 
that exhibited a copy number change. The filtering criteria used for this step were to 
take into account fragments comprising ^ 10 consecutive SNPs and segments that 
were >100 kb in length.
The file with the report comprised the genomic location, copy number state, 
size of the segment, number of markers and an overlap with known CNVs.
The CNV detection for the bipolar cases was carried out by me. The CNV 
calling of the controls and the schizophrenia cases was completed by Dr. George 
Kirov and me. The CNV identification step took approximately four months computer 
running time. Subsequently the data were manipulated in a number of different ways, 
which are described in detail in the next section.
3.6.2. Manipulation of data post-CNV detection
After the CNV detection, a quality control step was performed. This step 
comprised the following:
• Only deletions or duplications found independently on both arrays with 
overlap of the segments identified on the Styl and the NspI arrays of ^ 100 kb in 
length were taken into account. Matching of the segments of the two arrays was 
performed by using a standalone Windows-based program developed specifically for 
this analysis by Dr. Dobril Ivanov (Figure 17, page 74; available at 
http://x004.psycm.uwcm.ac.uk/~dobril/combine_cnvs_NSP_STY/);
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Figure 17 Program for matching fragments identified from the two Affymetrix 
arrays (that is NspI and Styl)
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The program worked with a file containing the identified segments obtained 
from the Affymetrix® Genotyping console. The minimum distance of overlap 
between the called segments per person between the NspI and Styl arrays was set to 
be 100 kb. The most conservative approach in reporting the CNVs that were observed 
on both arrays at a given genomic location was chosen- only the segments produced 
from the start and end position of the exact overlap between the two arrays were used 
for further analysis (Figure 18);
Figure 18 Schematic representation of the rationale for matching fragments 
identified from the two Affymetrix arrays (NspI and styl)
CNV observed on Styl array 
________ CNV observed on NspI array
• Samples with 2: 20 deletions and/or duplications were excluded from 
further analysis;
• CNVs with low SNP density ( < 3 SNPs per 100 kb) were also 
excluded.
Reported CNV
>100kb overlap!
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The post-CNV identification manipulation of the data was performed using 
SPSS® 16.
Common copy number variants (found in ^ 1% of the samples) were excluded 
from the subsequent analysis. CNVs that overlapped with > 50% of their length to 
common CNV regions were also excluded.
Using PLINK (Purcell et al. 2007) version 1.05, all rare deletions and 
duplications which remained after applying the above-mentioned criteria, were listed 
in a custom track for visualisation in USCS Genome Browser 
(http://genome.ucsc.edu/) and is also publicly available for download at 
http://x004.psycm.uwcm.ac.uk/~detelina/.
The genomic coordinates used in this PhD are based on March 2006 human 
genome sequence assembly (UCSC Hgl8, NCBI build 36).
3.6.3. Validation of large copy number variants (>1 Mb)
The validation of the large copy number variants was performed by me.
An oligo array Comparative Genomic hybridisation (aCGH) platforms- Agilent 
Human genome CGH 4x44K microarray, was the method of choice for validation of 
some of the CNVs inferred by the Affymetrix platform. Agilent oligo aCGH platform 
enables studying genome-wide copy number variations at a high resolution. The 
probes on the Agilent aCGH microarrays are 60-mer oligonucleotides synthesized in 
situ using Agilent’s inkjet SurePrint™ technology. On the 44K array that was used for 
validation, ~ 43,000 60-mer oligonucleotide probes are printed on a glass slide. It 
provides coverage with an average resolution of 30 -  35 kb. The probe selection was 
biased towards genes, with 84% of the probes being in intragenic regions. Well- 
characterised genes are represented by at least one probe 
(http://www.chem.agilent.com). The workflow of the experiment is presented in 
Figure 19 (page 76).
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Figure 19 Workflow of the Agilent microarray experiment
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24-hour hybridisation (65°C)
Microarray washing
adapted from http://www.chem.agilent.com
As presented in Figure 19, the preparation of the Agilent microarrays included 
the following: fragmentation of the DNA, chemical labelling, subsequent 
hybridisation onto the array and scanning of the glass slide. A detailed explanation of 
the steps is provided below:
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1. DNA preparation
The required quantity of the DNA for the Agilent experiment was 500ng , 
with minimum concentration of 62.5ngl fjJ. The DNA concentration was estimated 
using PicoGreen® dsDNA reagent in a Fluoroscan Ascent Fluoremeter as described 
in section 3.2.4 (page 63). The samples were diluted to a final concentration of 
10ng/ fjJ and subsequently aliquoted into 96-well Abgene skirted plates. Instead of 
using a healthy control with which to compare the DNA case sample, for cost- 
effective reasons, it was decided to use only DNA from cases. This was possible, as 
we were interested in testing only certain regions of the genomes of the studied 
individuals, and as long as we were comparing cases with different CNVs, we were 
confident that we were going to detect the CNVs of interest if they were genuine.
2. Heat Fragmentation
The DNA samples were incubated at 95° C in a PCR machine with heated lid 
for 10 minutes. The heat fragmented DNA was stored on ice until ready for chemical 
labelling;
3. Chemical Labelling
The Agilent labelling kit differentially and directly labels gDNA samples with 
fluorescent dyes in one step, using non-enzymatic procedure. Sample DNA from the 
test and the reference human genomes were labelled with different fluorescent dyes- 
Cyanine 3 (Cy3) and Cyanine 5 (Cy5) respectively. The fluorescent signal intensity at 
each spot of the array subsequently serves as a measure, indicative of the amount of 
the sample that has been bound to the DNA sequence of the particular probe. The 
ratio between the intensities of Cyanine 3 and 5 at each probe shows the relative 
quantities of the test and reference DNA. This ratio was used to detect copy number.
The Cy3 and Cy5 labelling master mixes were prepared by combining the 
components presented in Table 10:
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Table 10 Master mix for the labelling reaction
Reagents Per reaction ( y l ) Per slide ( yJ )
Nuclease-free water 0.5 2.5
Cy3 or Cy5 0.5 2.5
10 x labelling solution 1 5
Final volume of 
Labelling Master Mix 2 10
• The appropriate amount of Labelling Master Mix was added to each 
well containing the gDNA to make a total volume of 10 y l\
• The PCR tubes were incubated at 85°C for 30 minutes;
• 10 yJ of nuclease-free water was added to each PCR tube to make a 
total volume of 20/i/;
• The PCR tubes were stored on ice until dye removal with KREApure 
columns.
4. Removal of non-reacted fluorescent dyes:
Non-reacted Cy3 or Cy5 dyes could interfere with the subsequent microarray 
experiment and increase background noise, if they are not efficiently removed prior to 
hybridization. Agilent KREApure columns were used to remove non-reacted 
fluorescent dye. 20 yl of the labelled gDNA was put onto the Agilent KREApure 
column and subsequently centrifuged at speed of minimum 16,000g to collect the 
purified labelled gDNA in a collection tube.
Afterwards, the Cy3 and Cy5 labelled DNA samples were combined into 
eppendorf tubes to a total volume of 37 y l .
5. Preparation of labelled Genomic DNA for Hybridisation
The combined samples were concentrated to 22 yl using speed vacuum 
centrifuge. Subsequently, the samples were transferred to a skirted Abgene plate 
and the hybridisation master mix was added. The hybridisation master mix was 
prepared according to volumes given in Table 11.
78
Table 11 Hybridisation Master mix
Reagents Volume per 
Hybridization ( fjd )
Volume per slide 
(including excess) (fjJ)
Cot-1 DNA (1 mg /m l) 5 25
Agilent 100X CGH 
Blocking Agent 1 5
Agilent 2X CGH 
Hybridization Buffer 55 275
Final volume of 
hybridization master 
mix
61 305
• After adding the hybridisation master mix, the samples were put on 
PCR machine to incubate at 95° C for 3 min;
• The samples were transferred immediately to a heating block at 37°C 
and incubated for 30 minutes;
• The Agilent-CGH Block was added to each tube containing the 
labelled gDNA and Hybridisation Master mix to make the final volume of 
hybridisation sample mixture of llOjW/.
6. Microarray Hybridisation
Each microarray was printed on the side of the glass slide containing the 
“Agilent”-labelled barcode. This side is called the “active side”. The numeric barcode 
is on the “inactive side” of the glass slide. The hybridization sample mixture is 
applied directly to the gasket slide and not to the active side of the microarray slide. 
Then the active side of the microarray slide is placed on top of the gasket slide to 
form a “sandwich slide pair”. The hybridisation sample mixtures were dispensed onto 
the gasket. Eight samples (four labelled with red and four labelled with green dye) 
were placed onto one glass array. Hybridisation chamber was used to cover the 
sandwiched slides. The assembled slide chambers were put onto a rotator rack in a 
hybridisation oven set to 65 °C for a 24-hour hybridisation.
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The 24-hour hybridisation was carried out at the Department of Pathology 
using their Agilent Microarray Hybridization Chambers and Agilent Microarray 
Hybridization Oven. Dr. Yumin Teng from the Department of Pathology provided 
advice with regards to working with the hybridization chamber, oven and the 
subsequent washing steps.
7. Microarray Washing
The washing of the arrays was done following the conditions in Table 12:
Table 12 Microarray washing procedure
Step Dish Wash Buffer Temperature Time
Diassembly of the 
array-gasket 
sandwich
1
Oligo aCGH Wash 
Buffer 1
Room
temperature
1st wash of the 
array 2
Oligo aCGH Wash 
Buffer 1
Room
temperature 5 minutes
2nd wash of the 
array 3
Oligo aCGH Wash 
Buffer 2 37°C 1 minute
Acetonitrile wash 
of the array 4 Acetonitrile
Room
temperature 1 minute
3rd wash of the 
array 5
Stabilization and 
Drying Solution
Room
temperature 30 seconds
8. Microarray scanning using Agilent Scanner
The scanning of the arrays was performed at the Department of Medical 
Genetics by trained personnel. The data in TIFF format were transferred onto an 
external hard disk.
9. Data extraction using Feature Extraction Software
The Feature extraction software (downloaded from 
http://www.chem.agilent.com) was used for data extraction of microarray TIFF 
images of the scanned Agilent CGH microarrays. This software used the intensity 
data captured in the TIFF image at each probe spot to produce a file with the 
log 2ratio of the red and green intensities of each probe.
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Subsequently, the result files were analysed using SPSS® 16 and software 
developed by Agilent specifically for the analysis of microarray data- Agilent 
Genomic Workbench edition 6.0 (Figure 20, page 81).
Figure 20 Agilent Genomic Workbench edition 6.0
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3.6.4. Follow-up of 2 loci im plicated in schizophrenia in two fam ilies 
with a p roband  affected w ith b ipolar d isorder
Two families with a proband harbouring a specific CNV were genotyped 
using Human610-quad arrays (Illumina Inc, San Diego, California) in order for the 
results to be put through second platform for validation.
The DNA samples from the two families were normalised to the required 
concentration for performing the Illumina assay by me.
The Illumina assays were carried out by Dr. Masashi Ikeda and Dr. Irina 
Zaharieva following manufacturer’s protocols (http://www.illumina.com).
The used Human610-quad Illumina array provides comprehensive genomic 
coverage with access to more than 550,000 loci.
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The protocol features single-tube sample preparation and whole-genome 
amplification without PCR or ligation steps. After hybridizing an unlabelled DNA 
sample to the array, two-step allele detection provides high call rates and accuracy. 
Selectivity and specificity are accomplished in two steps. Target hybridization to 
bead-bound 50-mer oligonucleotides provides selectivity and enzymatic single-base 
extension provides specificity. The single base extension also incorporates a labelled 
nucleotide for assay readout. Then the signal intensities are detected using Illumina 
iScan System (http://www.illumina.com). The assay data were analysed using 
Illumina GenomeStudio Genotyping Module.
3.7. Bioinformatical and statistical methods
3.7.1. PLINK
CNV association analyses were performed using whole genome data analysis 
toolset- PLINK version 1.05, obtained from the following website- 
http://pngu.mgh.harvard.edu/~purcell/plink/ (Purcell et al. 2007). PLINK was run on a 
Linux-based multiprocessor server with the following specifications:
Operating System (OS): Fedora Core 12 Linux x86_64 
Processor: 4 Dual-Core AMD Opteron 8224 SE @ 3.2GHz 
Random Access Memory (RAM): 132 Giga Byte 
Hard-Disk Drive: 1.8 TB
As the CNV analyses performed with PLINK were not requiring large 
resources of computer power, the same analyses could be executed on a desktop 
computer as well.
PLINK is a genetic-analysis tool designed to handle large data sets of whole- 
genome data (Purcell et al. 2007). It provides an environment for a rapid manipulation 
and analyses of such data sets. PLINK includes data management, summary statistics, 
population stratification, association analysis and identity-by-descent estimation. In 
addition to whole-genome SNP analysis, PLINK offers functions for downstream 
analyses of CNV data. It is not a tool for CNV identification, but for CNV data 
management and statistical analyses.
There is a comprehensive web-based documentation 
http://pngu.mgh.harvard.edu/~purcell/plink/cnv.shtml with respect to CNV analyses.
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With the help of PLINK the following tasks were performed:
1. Basic support for CNV data and file types: The basic files that were 
required by PLINK were: CNV file, MAP file and FAM file.
The CNV file comprised the following information:
Family ID 
Individual ID 
Chromosome 
Start position (base-pair)
End position (base-pair)
Type of variant (l=deletion; 3=duplication)
Confidence score associated with the variant 
Number of probes in the variant
The confidence score and the number of sites values were not used in a direct way and 
did not impact the analysis performed with PLINK.
Prior to any analysis, PLINK required a MAP file. It was created using 
PLINK on the basis of the CNV file and the result MAP has entries corresponding to 
the start and end positions of all segments. This file was needed by PLINK for 
subsequent parsing and analysis of the CNV data.
The MAP file is created using the following command: 
plink — cnv-list BPCNV.cnv —cnv-make-map
The FAM file contained ID and phenotype information:
Family ID 
Individual ID
Paternal ID (used only when trio data were analysed, 0 was used for the 
purposes of the current study)
Maternal ID (used only when trio data were analysed, 0 was used for the 
purposes of the current study)
Gender (l=male; 2=female)
Phenotype (l=unaffected; 2=affected)
The basic commands for reading a list with CNV data were:
plink —cnv-list BDCNV.cnv —fam BDCNV.fam -map BDCNV.map
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plink -cfile BD_CNV
2. Filtering stens/PLINK commands:
A. CNV filtering based on frequency:
plink -cfile BPCNV -cnv-freq-exclude-above 45 -cnv-overlap 0.50 —cnv- 
write —BPCN V rare
B. Filtering based on size:
--cnv-kb 100 (minimum size in kb that PLINK will take into account when 
analysing CNV data, the number is put for illustration purposes)
—cnv-max-kb 500 (maximum size in kb that PLINK will take into account 
when analysing the CNV data, the number is put for illustration purposes)
C. Filtering based on CNV type:
-cnv-del (PLINK will take into account only deletions in the analysis) 
-cnv-dup (PLINK will take into account only duplications in the analysis)
If neither deletions nor duplications are specified, then the analysis includes all 
types of CNVs.
3. Association analysis:
A global test of CNV burden in cases versus controls was performed, based on 
permutations to generate empirical p  -values (10,000 permutations). All p  -values 
reported throughout the PhD are 2-sided, based on comparing the rate of CNVs in two 
independent samples (usually cases versus controls).
The following commands were used:
—cnv-indiv-perm 
—mperm 10000 
—cnv-2sided
4. Visualisation of data:
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PLINK was used to generate custom annotation track files (in BED format). In 
order to visualise the data, these custom-built annotation files were uploaded to UCSC 
Genome Browser (http://genome.ucsc.edu/cgi-bin/hgGateway ) (Figure 21).
Figure 21 Screenshot from the UCSC Genome Browser
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5. Miscellaneous PLINK commands:
--cnv-intersect regions.list/--cnv-disrupt- were used to extract a specific set of 
segments that overlap with one or more specified regions. This command was applied 
to test if segments intersect with genes. The file with the gene information and gene 
location was provided by PLINK (downloaded from 
http://pngu.mgh.harvard.edu/~purcelEplink/dist/glist-hg 18);
-segment-group- used in order to group and report sets of segments that span 
a particular position. More specifically, the command takes all segments in a given 
region (whole genome unless otherwise specified) and forms "pools" of overlapping 
segments. Several pools of overlapping segments will be created; these will be listed 
in order of decreasing size (number of segments). Using this command it was tested 
whether segments are observed more often in cases than controls. After “pooling” 
segments found in cases and controls for a specific region, a Fisher’s exact test (3.7.2, 
page 86) was applied, by using the number of segments in cases and controls;
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-cnv-write- given a set of filters is applied, a new CNV file can be generated 
comprising only samples/segments that satisfy the provided criteria.
3.7.2. Association analysis
To provide an estimation whether CNVs at a particular locus (i.e. 16pl 1.2, 
15ql3.3,17pl 1.2, etc.), is associated with disorder, a Pearson’s x 2 test with one 
degree of freedom ( df )  can be calculated (Altman 1991). The test compares the 
observed frequencies with the expected frequencies under the assumption of 
independence (i.e. CNVs are not associated with an increased frequency in cases and 
the rate is similar in cases and controls). The^2 test statistic is an appropriate 
statistical measure, when 80% of the cells in the contingency table (i.e. 2x2 table) 
have expected counts ^ 5, and all cells show expected counts > 1 (Altman 1991). The 
following website was used to calculate the significance level (p  -value):
http://www.graphpad.com/quickcalcs/contingencyl.cfm, 2-tailed x 2 with Yates’ 
correction.
In the case of small expected frequencies, two-tailed Fisher*s exact test was 
used. The significance level (p  -value) was then compared with a pre-specified 
a  = 0.05 value or Type I error. Results with a p  -value £ a  were deemed statically 
significant. Fisher’s exact test is a statistical significance test used in the analysis of 
contingency tables where sample sizes are small. The significance of the deviation 
from the null hypothesis is estimated exactly rather than relying on approximation 
(this is the case w ith^2) (Field 2009). An online Fisher’s exact test calculator was 
used (http://www.langsrud.com/fisher.htm).
3.7.3. Calculation of statistical power
The power of a statistical test represents the probability to detect an effect size 
of a particular magnitude with a specified Type I error rate ( a , or false positive rate) 
and a particular sample size, power = 1-/3  is Type II error rate, or false-negative 
rate). The analysis for power requires the assumption that genuine effect exists in the
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studied populations. The power calculations were performed using pwr.chisq.test 
package which is part of the R statistical language (http://cran.r-project.org/).
3.7.4. Pathway analysis
Genes, participating in the nervous system pathways (long-term potentiation, 
long-term depression and neurotrophin signalling pathway), development (axon 
guidance), and circadian rhythm (Homo sapiens) were downloaded from KEGG 
(Kyoto Encyclopedia of Genes and Genomes). More specifically, KEGG PATHWAY 
database was used (http://www.genome.jp/kegg/pathway.html).
KEGG is a database comprising 16 main databases, containing systems 
information, genomic information, and chemical information (Kanehisa and Goto 
2000; Kanehisa et al. 2006). One of these 16 databases, KEGG PATHWAY, is a 
collection of manually curated maps (based on published materials) for metabolism, 
other cellular processes, human diseases, organismal systems, etc.
In addition, the IDs of brain-expressed genes were obtained using Ensembl via 
BioMart Genome browser (http://www.ensembl.org, (Flicek et al. 2010)).
PLINK, version 1.07 was used to perform the pathway analysis (Raychaudhuri 
et al. 2010). The rates of CNVs affecting specific gene sets in cases versus controls 
were compared, i.e. case-control strategy is employed to test the above-mentioned 
pathways for association with bipolar disorder. 2-sided asymptotic p  -values are used 
to estimate the significance level of association.
The following PLINK commands were applied:
A. To test if genes from a certain pathway are enriched in the CNV data, 
relative to all observed CNVs
-cfile BD
-cnv-count glist-hgl8.dat
—cnv-subset pathway.txt
—cnv-enrichment-test
B. To test if genes from a certain pathway are enriched in the CNVs, 
relative to all CNVs affecting genes:
A list with CNVs affecting genes was generated using PLINK:
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—cfile BD
--cnv-intersect glist-hgl8.dat
—cnv-write
--out my_genic_CNV
Subsequently, the genes from the studied pathway were tested for enrichment 
in the CNV data, relative to all genic CNVs:
-cfile my_genic_CNV 
—cnv-count genes.dat 
-cnv-subset pathway.txt 
—cnv-enrichment-test
3.8. Comparison between bipolar cases and an extended control 
group
The CNV data from the whole WTCCC study that bipolar disorder took part 
in, became publicly available in 2010 (Wellcome Trust Case Control Consortium 
2007).
The studied sample comprised 11,909 UK Caucasian individuals. This sample 
set included 1650 bipolar cases and 10,259 individuals affected with several non­
psychiatric diseases (Table 13).
Table 13 Cohorts that participated in the WTCCC study
Sample set (abbreviation) Number of studied individuals
bipolar disorder (BD) 1650
controls (1958 cohort +NBS) 2777
coronary artery disease (CAD) 1855
Crohn’s disease (CD) 1450
hypertension (HT) 1864
rheumatoid arthritis (RA) 1374
type 1 diabetes (T1D) 1903
type 2 diabetes (T2D) 1813
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These individuals are of white European ancestry and live in the UK. All these 
subjects have been studied in the WTCCC study for associations of single nucleotide 
polymorphisms with the corresponding disorders (Wellcome Trust Case Control 
Consortium 2007). In addition, the WTCCC study also included 1434 controls bom in 
one week in 1958, and 1343 controls from the National Blood Transfusion Service 
(NBS). These controls have already been analysed in this PhD work and therefore 
were not used in this analysis.
The genotyping was performed using Affymetrix 500K arrays comprising the 
NspI and Styl arrays. Subsequently, using the intensities (log2ratio) at each SNP, 
copy number state was inferred. The CNV identification was performed by WTCCC 
and the results with the already called CNVs per individual were sent to us through a 
secure ftp server.
The procedure used to detect CNVs based on the raw intensity data involved 
normalisation of the data and subsequent CNV discovery (Barnes et al. 2008; Olshen 
et al. 2004; Price et al. 2005). Several quality control (QC) filter steps have been 
applied, i.e. removal of samples which failed SNP genotyping, removal of samples 
that had too many CNVs and samples producing outlier intensities (personal 
communication with WTCCC).
The CNV calling and the above-mentioned OC filtering measures were 
performed at the Sanger Centre and subsequently the data have been made publicly 
available. It is of note that the analysis of the CNVs in the bipolar cases involved 
exactly the same raw SNP genotyping intensity data that were analysed in this PhD 
work.
Subsequently, I applied additional QC filtering steps on the data received from 
WTCCC. Only CNVs surpassing the following thresholds were chosen for analysis:
• rare CNVs observed in £ 1% of the sample;
• CNVs *100 kb;
• CNVs with density of > 3 SNPs per 100 kb
• CNVs comprising * 10 consecutive SNPs per variant.
All chromosomal positions with respect to results obtained from WTCCC, 
were according to NCBI Build 35 (hgl7), May 2004 of the UCSC Genome Browser. 
To allow comparisons with the data generated in this PhD work (which are according
89
to NCBI Build 36 coordinates), the genome coordinates were converted to the 
appropriate versions of the genome browser, before examining the regions of interest.
PLINK and SPSS® 16 were applied to manipulate and analyse the CNV data 
obtained from WTCCC (Purcell et al. 2007).
For comparison purposes, schizophrenia samples, coming from two sources 
were also used:
• Part of publicly available International Schizophrenia 
Consortium (ISC) study (International Schizophrenia Consortium 2008). The sample 
set included 3391 cases and 3181 controls, genotyped with Affymetrix 6.0 or 5.0 
arrays. The ISC data were also according to NCBI Build 35 (hgl7);
• Schizophrenia cases (n=471) genotyped with the same array as 
WTCCC study (Affymetrix 500 K array) and analysed using the same pipeline as the 
samples in this PhD work (Kirov et al. 2009a). More information about this sample 
set has been already presented in section 3.1.1.2 (page 60).
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4. Results
4.1. Results from quality control
4.1.1. Wellcome Trust case-control consortium quality control
2284 bipolar DNA samples were prepared to 100 fig I ml dilution and -70 fd 
of each DNA sample was sent to the Wellcome Trust Sanger institute, Cambridge. 
Based on the quality control (QC) measures taken at the Sanger institute, 1997 DNA 
samples were approved for genotyping. The QC measures performed at the Sanger 
institute were based on: DNA quantification, test for degradation and PCR 
amplification (Wellcome Trust Case Control Consortium 2007).
1997 bipolar DNA samples were sent to Affymetrix Services laboratories in 
USA for genotyping. 3004 controls were selected using the same criteria and were 
sent along with the case’s DNA to be genotyped in the same pipeline.
After the genotyping with the Affymetrix GeneChip 500K array, more quality 
control steps were performed at the Sanger Institute. These included: sample call rate, 
duplication of samples, relatedness and evidence of non-European ancestry. Samples 
which did not pass the above-mentioned criteria were excluded from further analyses. 
129 bipolar individuals were excluded at this stage. 66 samples were excluded from 
the control set (24 from the 1958 cohort and 42 from the NBS). In Table 14 are 
presented the QC measures and the corresponding number of individuals not passing 
the QC criteria separately for the cases and controls (Wellcome Trust Case Control 
Consortium 2007).
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Table 14 Quality control measures, performed at Sanger Institute, after the 
genotyping with the Affymetrix 500K array
Number of individuals
Collection Initial Missingness
Discorda
nee
Non-
European
ancestry
Duplicate Relative Totalexcluded Accepted
1958
cohort 1504 9 4 6 4 1 24 1480
NBS 1500 8 5 14 0 15 42 1458
BD 1997 30 0 9 77 13 129 1868
These quality control steps resulted in a final dataset of 1868 bipolar 
individuals and 2938 controls.
4.1.2. Quality control of the Affymetrix genotyping
Markers already present on the 500K Affymetrix array, were chosen to be 
genotyped with a separate genotyping platform-Iplex® Sequenom MassARRAY 
platform. The reason for performing the genotyping was to estimate the concordance 
between the two platforms in an attempt to double check the genotyping accuracy of 
the Affymetrix array. Furthermore, this will also provide information for possible 
sample swaps.
All 1868 bipolar case DNAs that were already genotyped by Affymetrix, were 
genotyped with the Iplex chemistry for 46 SNPs by me. Overall, ~75,000 genotypes 
were analysed and > 99.5% agreement between the two genotyping platforms was 
observed.
The correspondence rate between the two platforms was very high, which 
indicated that the obtained results from the genotyping with the Affymetrix array are 
robust and trustworthy and that no sample swaps have occurred.
4.1.3. Quality control of the CNV detection algorithm
The Affymetrix ® Genotyping console ™ v2.1 software was used for inferring 
the CNV structure. The console utilises intensity raw data from the SNP genotyping.
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All intensity data (CEL files) from the WTCCC Sanger institute were put through the 
CNV calling software.
The numbers of individuals, mentioned in the ‘Initial’ column in Table 14 
(page 92) (i.e. 1997 BD individuals, 1504 from the 1958 cohort and 1500 from the 
National Blood Service sample set) were analysed for copy number variants. The 
reason for using all of the individuals was that these samples were genotyped by 
Affymetrix and at that point it was not known which individuals should be excluded 
from the analysis. Consequently, problems were observed with regard to duplicated 
samples, relatedness and non-Caucasian ancestry. At a later stage, the samples that 
showed any inconsistencies with regard to duplications, relatedness or non-Caucasian 
ancestry were excluded.
For quality control of the CNV calling, a number of filtering steps were 
applied during the CNV detection procedure. Namely these were:
A. The default parameters of the Affymetrix ® Genotyping console 
software were used for initial quality control filter (intensity quality control 
threshold < 93%). Intensity QC call rate of < 93% is indicative of a low sample 
quality. At this stage, 32 samples were excluded from the BD sample set and six and 
13 from 1958 cohort andNBS sample sets respectively;
B. The interquartile range (IQR) of the log 2 ratio was used to evaluate 
the quality of the arrays for the copy number analyses. Samples with IQR * 0.40
were excluded from the analyses. In total, 76 individuals were excluded due to 
IQR* 0.40 (47 from the bipolar sample, 11 and 18 from the 1958 cohort and NBS 
sample sets respectively);
When many samples produced high IQR measures ( * 0.40), this was 
indicative of presence of a batch effect. At first, at the CNV calling step, samples 
from one batch were analysed for copy number change using reference sets from a 
separate processing batch. Using this method, many samples were being filtered out 
due to IQR * 0.40. This effect was more pronounced for the Styl array.
Figure 22 and Figure 23 represent histograms with /^frequency  data for
NspI and Styl arrays for the 1958 cohort, showing the difference in the quality of the 
arrays.
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Figure 22 Histogram showing the frequency of distribution of IQR of 1958
cohort for the NspI array
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Figure 23 Histogram showing the frequency of distribution of IQR of 1958
cohort for the Styl array
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When the 7 0 ^ was s= 0.40, many copy number variants were observed, in the 
range of hundreds per person. This detected CNV rate per person, including the 
controls, was much higher than the average reported in the literature (Itsara et al.
2009; McCarroll and Altshuler 2007; Redon et al. 2006). In addition, it is highly 
unlikely that on one plate no individuals would have more than 20 CNVs per person, 
while on other plate most of the individuals would have copy number variants in the 
range of hundreds per person. Clearly, this was due to some technical issue. This 
pointed that these were spurious data due to systematic confounding effects. Figure 24 
presents an example of a number of segments and the corresponding IQR  for samples 
with high IQR  (the NBS control set genotyped with the Styl array). A strong positive 
correlation was observed between IQR and the corresponding number of segments, 
with many segments detected when the IQR  was elevated (Pearson’s correlation 
coefficient, p  = 0.948).
Figure 24 An example of the observed number of segments and the 
corresponding IQR  for samples with high IQR
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Therefore, the samples were analysed against samples coming from the same 
processing batches.
When samples were analysed using reference sets from the same processing 
batches, the number of individuals being filtered out due to IQ R  ;> 0.40, dropped 
dramatically. For comparison, Figure 25 and Figure 26 present NBS cohort CNV 
analyses before and after having the batch effect corrected.
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Figure 25 Frequency of IQR in the NBS sample, not taking the batch effect into 
account
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Figure 26 Frequency of IQR in the NBS sample after the batch effect was 
corrected
k
IQR=0.4
Tn-
Mean *0129 
Sid Dav *0 0551 
N «1.488
0 30  0 40
IQR STY
C. The following parameters of the Affymetrix software were used for 
CNV calling: only CNVs s  100 kb and only if they spanned 10 consecutive SNPs 
on each of the arrays were included;
D. Samples with 2* 20 segments were excluded from the analysis.
In total, 298 individuals were excluded (178 from the bipolar sample, 73 and 47 from 
the 1958 cohort and NBS sample sets respectively);
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Samples with & 20 segments were excluded even if the observed IQR was 
^ 0.4. Samples with IQR ^  0.4 produced with almost no exception > 20 deletions 
and/or duplications (and >100 CNVs when IQR was> 0.5), suggesting that 
observations corresponding to large number of CNVs per person were likely to be 
false-positive (Figure 24, page 96);
E. Deletions or duplications observed only on one of the arrays (i.e. only 
on NspI or Styl array) were excluded from the analysis. Effectively this meant that 
one array was validated with the other one:
F. Segments with very low SNP density ( < 3 SNPs per 100 kb) were also 
excluded. Such segments tend to intersect with low copy repeats or ‘difficult’ regions 
of the genome and have an increased probability of being false-positive.
After applying the above-mentioned criteria. 1697 cases and 2806 controls 
(1411 individuals from 1958 cohort and 1395 from NBS1 were further analysed.
4.1.4. Validation with Agilent array
Schizophrenia cases were also analysed in this PhD work. These cases were 
also part of the WTCCC study and were processed at the same time in the same 
pipeline as the bipolar cases and the controls. In addition, the CNV calling, QC and 
analysis were performed in exactly the same way as in bipolar cases and controls.
Validation of some relevant CNVs in schizophrenia samples was performed 
with Agilent Human Genome CGH 4x44K microarrays. The chosen CNVs (Table 15, 
page 99) for validation were deletions £ 1 Mb (as they provided the most statistically 
significant results in the schizophrenia study) and the CNVs that were regarded as 
being pathogenic in schizophrenia (that is, CNVs found to be associated with 
schizophrenia in a number of independent studies, e.g. 1 q21.1,15ql 1.2, etc.) (Kirov 
et al. 2009a). Each CNV was confirmed, reflecting the very stringent quality control 
criteria employed, including the fact that each call was made independently on both 
Styl and N spI arrays. Additional family members, where available, were also tested 
for these loci to examine the segregation with illness and possible de novo status.
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Table 15 Selected CNVs in schizophrenia cases for validation with an Agilent 
4x44K microarray
Sample ID Chromosome position Start position [Mb] End position [Mb]
19327C5 2pl6.3 (NRXN1) 50 51.2
19336A5 2q22.1 139.2 140.2
20577A5 3p24.3 17.2 20.6
19326C3 5pl5.33 0.2 1.2
19338E3 6pl2.3 48.1 49.3
19339E4 7q34 137.8 139.3
19328D4 7q36.3 157.7 158.8
19338A2 10pl3 12.7 14.6
19335B1 15ql 1.2 20.2 20.8
19335D1 15ql 1.2 20.2 20.8
19337A5 15ql 1.2 20.2 20.8
19337C5 15ql 1.2 20.2 20.8
19339G4 15q 11.2-q 13.1 21.2 26.2
19327C3 16p 13.11 14.9 16.4
19327F2 16p 13.11 14.9 16.4
20577B1 16pl3.11 14.9 16.4
19326A3 16pll.2 29.5 30.1
19328A3 16pll.2 29.5 30.1
19328G5 16pl 1.2 29.5 30.1
19325A4 17pl2 14 15.4
19338F6 17pl2 14 15.4
19338B6 22qll.2 (VCFS) 17.2 19.8
19326F4 22qll.2(VCFS) 17.2 19.8
20579B3 Xp22.33 0.3 2.7
19339D3 Xp22.31 6.5 8
Figure 27 (page 100) presents one of the confirmed copy number variations, 
namely the 22ql 1.2 deletion. The deletion exhibited an elevated log 2 ratio of the 
intensity of the region in question (marked with a red arrow). The deletion appears as 
duplication on the figure due to intricacy of the specific design of the experiment. In 
order to make the experiment as cost-efficient as possible, no control DNA was used 
as reference sample. Samples with different CNVs were analysed against each other 
which was possible as only specific regions were attempted to be validated and the 
experiment was not intended to serve as CNV discovery method. In this specific case,
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the sample with the 22ql 1.2 deletion was used as a “control” which will make the 
other sample appear to harbour duplication at this locus.
Figure 27 Example of 22qll.2 deletion successfully validated with an Agilent 
44K microarray in a schizophrenia sample
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As the schizophrenia samples, controls and bipolar cases were prepared, 
genotyped and analysed for copy number variants in the same pipeline, and all 
relevant (and large) CNVs in the schizophrenia sample validated successfully, it was 
concluded that there was no need to validate any of the CNVs in the bipolar cases. 
Furthermore, each CNV had already been called independently by two arrays (Styl 
and NspI). Nevertheless, two duplications observed in bipolar cases were confirmed 
because parental DNA was available and in this way the segregation with illness was 
also tested. This time Illumina arrays were used. These results are presented 
separately in section 4.2.7.1.1 (page 115).
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4.1.5. Comparison between the CNV analysis performed in this PhD 
work with an independently performed CNV analysis at WTCCC, 
Sanger Institute
Independently, the WTCCC group have analysed the copy number variation in 
the bipolar data set, the controls and six other diseases. The WTCCC group has 
studied the disorders that took part in the original WTCCC genome-wide association 
study (i.e. coronary artery disease, Crohn’s disease, hypertension, rheumatoid 
arthritis, type 1 diabetes and type 2 diabetes) (Wellcome Trust Case Control 
Consortium 2007). For inferring the CNV structure of the samples, other methods 
were used than the ones performed in this PhD work.
Data for the 125 CNVs ^ 1 Mb (Table 18, page 104) observed in the bipolar 
cases and controls were compared with the results from the CNV analysis of the 
WTCCC group.
From the compared 125 CNVs, 29 were not analysed by the WTCCC group as 
they were on the X-chromosome. From the remaining 96 variants, 89 (93%) were 
concordant and seven (7%) of these 96 were not called in the WTCCC data.
The data from WTCCC CNV calling, based on the Affymetrix 500 K 
genotyping, became publicly available in May 2010. This provided an opportunity to 
examine the frequency of some loci implicated in neuropsychiatric disorders in 
> 10,000 people from the general population in the UK, who were affected by non­
psychiatric disorders. Thus, it provided a chance to compare the observed CNVs in 
bipolar disorder cases with the ones observed in this large sample set. The results with 
respect to these analyses are presented in section 4.5 (page 126).
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4.2. CNVs in bipolar disorder
4.2.1. Global burden of CNVs
Initially all of the observed CNV were analysed. The results are presented in 
Table 16.
Table 16 Global burden analysis of all observed CNVs
CNV type Cases(n=1697)
Controls
(n=2806) CNV per case
CNV per 
control
case/control
ratio P
Del 912 1635 0.54 0.58 0.93 0.05
Dup 1838 3142 1.08 1.12 0.96 0.25
Total 2750 4777 1.62 1.70 0.95 0.03
The p  is empirical 2-sided based on 10,000 permutations; Del=deletions; dup=duplications
No statistically significant difference was observed between the mean number 
of duplications when the cases were compared with controls (p  = 0.25 ). When 
deletions were analysed, a trend for overrepresentation in controls was observed 
( p  = 0.05 ). When the total number of CNVs was compared between cases and 
controls, the controls exhibited an elevated number of CNVs-1.70 per control when 
compared with cases-1.62 per case (p  = 0.03). No correction for multiple testing was 
applied to these tests.
These observed CNVs were not analysed further as they were not going to 
lead to reliable results due to difficulties, inherent to the methodology of genotyping 
common CNVs (which are included in the above-mentioned results). Common CNVs 
tend to intersect with ‘problematic’ regions in the human genome and that was one of 
the main reasons why they were excluded from early Affymetrix arrays, similar to the 
one that is used in the present study. It has been shown that common CNVs 
correspond to ‘bald spots’ in the physical coverage of the early SNP arrays 
(McCarroll et al. 2008). Moreover, due to their frequency (i.e. being common, >1%), 
the reference set will undoubtedly contain a combination of 1, 2, 3, etc. copies of 
these CNVs which makes the detection unreliable. Furthermore, studies in 
schizophrenia have shown that the burden of rare ( £ 1%) CNVs is increased in cases 
when compared with controls (International Schizophrenia Consortium 2008; Walsh 
et al. 2008; Xu et al. 2008).
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Therefore, common CNV (>1% of the samples) were excluded. In addition, 
CNVs that overlapped with > 50% of their length to common CNVs were also 
excluded. Based on these criteria, a data set of rare CNVs was created and was used 
for all of the subsequent analyses.
4.2.2. Global burden of rare CNVs
The total number of rare CNVs (with frequency ^ 1% in the population) and 
the corresponding p  -value from the comparison between cases and controls are 
presented in Table 17. There was no statistically significant increase in the rate of 
CNVs between cases and controls, and there was a statistically significant association 
in the opposite direction (i.e. fewer CNVs in cases) when only deletions were 
analysed ( p  -  0.01). There was not a statistically significant difference between the 
cases and controls with regard to the number of duplications and the total number of
CNVs.
Table 17 Global burden of rare CNVs
CNV 
_ type
Cases
(n=1697)
Controls
(n=2806)
CNV per 
case CNV per control case/control ratio P
Del 324 632 0.191 0.225 0.85 0.01*
Dup 538 901 0.317 0.321 0.99 0.84
Total 862 1533 0.508 0.546 0.93 0.09
The p  is empirical 2-sided based on 10,000 permutations. Del=deletions; dup=duplications; 
*This significant result is for fewer CNVs in cases than controls
4.2.3. Global burden with respect to CNV size
As previous studies in schizophrenia have suggested that the CNV effect 
comes from CNVs larger than a certain size (International Schizophrenia Consortium 
2008; Kirov et al. 2009a), similar analysis was performed in the bipolar cases.
The observed CNVs were divided into size categories and were compared 
between cases and controls (presented in Table 18). Apart from a number of small 
deletions ( £ 200 kb) in cases and controls, statistically significant differences 
between cases and controls were not observed for any other size ranges. The 
statistically significant result with respect to deletions £ 200 kb is for fewer CNVs in 
cases than controls ( p  = 0.03). It is of note, that nearly all types of CNVs were 
observed at a lower frequency in cases as compared to controls.
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Table 18 Global burden with respect to CNV size
CNV type, size 
[kb]
Cases
(n=1697)
Controls
(n=2806) CNV per case
CNV per 
control
case/control
ratio P
Del<200 142 293 0.084 0.104 0.80 0.03
Dup<200 155 261 0.091 0.093 0.98 0.88
Total<200 297 554 0.175 0.197 0.89 0.09
Del 200-500 149 285 0.088 0.102 0.86 0.15
Dup 200-500 277 436 0.163 0.155 1.05 0.55
Total 200-500 426 721 0.251 0.257 0.98 0.72
Del 500-1000 26 34 0.015 0.012 1.26 0.42
Dup 500-1000 73 139 0.043 0.050 0.87 0.35
Total 500-1000 99 173 0.058 0.062 0.95 0.66
Del>1000 7 20 0.004 0.007 0.58 0.24
Dup>1000 33 65 0.019 0.023 0.84 0.47
Total>1000 40 85 0.024 0.030 0.78 0.20
The p  is empirical 2-sided based on 10,000 permutations. Del=deletions; dup=duplications;
4.2.4. Singleton CNVs
Zhang et al. studied the CNV structure in bipolar disorder cases and made 
comparisons with healthy controls (Zhang et al. 2008). An increased overall burden of 
rare structural genomic variants was not observed, although an increase was found 
with respect to deletions that appear only once in the dataset (16.2% of BD cases in 
contrast to 12.3% in controls,/? = 0.007).
In order to test if a similar effect was present in WTCCC BD data, the global 
burden of single-occurrence deletions and single-occurrence duplications was 
estimated. Deletions-only and duplications-only datasets were generated. In these 
datasets, a deletion was defined as a single-occurrence event, even if there was a 
duplication present in the same region. The same rule was applied to duplications. 
Thus, the number of single-occurrence deletions and single-occurrence duplications 
did not sum up to the total number of single-occurrence events.
No statistically significant difference was observed between the proportion of 
cases and controls with singleton CNVs when deletions and duplications were 
combined or when deletions and duplications were considered separately (Table 19, 
page 105).
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Table 19 Global burden with respect to singleton CNV events
Single CNV 
type
Cases
(n=1697)
Controls
(n=2806)
CNV per 
case
CNV per 
control
Case/control
ratio P
Del 104 179 0.06 0.06 0.96 0.77
Dup 130 251 0.08 0.09 0.86 0.17
Total 203 355 0.12 0.13 0.95 0.55
The p  is empirical 2-sided based on 10,000 permutations. Del=deletions; dup=duplications;
Zhang et al. reported that singleton deletions were particularly more common 
in cases with mania with an onset of illness £ 18 years of age (Zhang et al. 2008). In 
the 65 patients in the WTCCC BD sample with such an early age of onset, there was 
no statistically significant difference in the rate of singleton CNVs, compared with the 
controls (Table 20).
Table 20 Global burden with respect to singleton CNV events in bipolar cases 
with early onset
singleton/age 
onset mania
Cases
(n=65)
Controls
(n=2806) CNV per case
CNV per 
control
case/contr 
ol ratio P
Del 4 214 0.06 0.08 0.81 0.83
Dup 4 308 0.06 0.11 0.56 0.29
Total 7 446 0.11 0.16 0.68 0.36
The p  is empirical 2-sided 5ased on 10,000 permutations. Del=deletions; dup=duplications;
4.2.5. CNVs disrupting genes and analysis of pathways
Following previous studies in schizophrenia (International Schizophrenia 
Consortium 2008; Walsh et al. 2008), the burden of CNVs that delete, duplicate or 
disrupt genes was examined in the bipolar samples. This analysis was performed for 
all CNVs and for CNVs that occurred only once in the data (i.e. singleton events). 
Only CNVs that overlapped with at least one gene, based on the hgl8 genomic 
coordinates, were taken into account. Results for all CNVs and for singleton CNVs 
are presented in Table 21 and Table 22 respectively.
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Table 21 Copy number variants disrupting genes
Cases (n=1697) Controls (n=2806) CNV per case CNV per control P
Del 102 210 0.06 0.07 0.97
Dup 269 469 0.16 0.17 0.77
Total 371 679 0.22 0.24 0.94
Table 22 Single copy number variants disrupting genes
Cases (n=1697) Controls (n=2806) CNV per case CNV per control P
Del 44 87 0.03 0.03 0.86
Dup 85 187 0.05 0.07 0.99
Total 118 248 0.07 0.09 0.98
No statistically significant differences were observed in CNVs (single­
occurrence or not) that disrupt genes.
Genes affected by CNVs that were found only in cases but not in controls, 
were also studied. A list of all genes disrupted by CNVs in cases that were not 
disrupted in any of the controls is presented in Table 38 (page 177 in the Appendix). 
The list comprises not only singleton CNVs (those found once in the dataset), but also 
CNVs found in more than one case, but not in controls. Where several CNVs mapped 
to the same region, they did not always fully overlap. The start and end base pair 
positions in Table 38 refer to the total region covered by such a cluster of CNVs.
The results with respect to the pathway analysis are presented in Table 23.
Table 23 Pathway analysis
Brain-
expressed
genes
P
Circadian
rhythm
P
Neurotrophin
signalling
P
Axon
guidance
P
Long-term
potentiation
P
Long-term
depression
P
Enrichment of 
pathway genes, 
relative to the 
whole genome
0.03 1 0.98 0.6 0.03 0.99
Enrichment of 
pathway genes, 
relative to all 
genic CNVs
0.01 1 0.96 0.61 0.03 0.99
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The genes from the brain-expressed and long-term potentiation pathways 
exhibited an overrepresentation in the CNV bipolar data. As these statistically 
significant results were not corrected for multiple hypotheses testing, they should be 
treated with caution. After correcting for the 12 tests performed, no pathway showed 
enrichment in the CNV data.
4.2.6. Are there CNV loci occurring more often in bipolar cases than 
in controls?
CNVs occurring in cases were compared with those in controls. Although an 
overall increase of CNV burden in bipolar cases compared with controls was not 
observed, some individual CNVs were found more often in cases than in controls. 
Nevertheless, none were significantly associated after correcting for multiple 
hypothesis testing. Results of CNVs that exhibited an uncorrected for multiple testing 
nominal significance level ( a  ^ 0.05) are presented in Table 24.
Table 24 Regions showing more CNVs in cases than controls at nominal 
significance p  ^  0.05
Locus Start bp End bp Type BDcases Controls
Fisher’s 
exact test Gene
lq25.1 173,769,777 173,978,862 dup 5 1 0.03 TNR
9q31.1 104,826,097 104,885,068 del/dup 3 0 0.05 No genes
12pl 1.21 31,202,250 31,301,551 dup 19 16 0.03 OVOS2
18pl 1.21- 
11.1 14,694,694 15,092,421 dup 3 0 0.05 ANKRD30B
19pl2 20,001,614 20,177,979 del/dup 5 1 0.03
ZNF682,
ZNF90,
ZNF486
19pl2 24,013,968 24,295,825 dup 3 0 0.05 ZNF254
Locus refers to the chromosome band; Start bp and end bp provide the start base pair position 
and the end base pair position of the CNVs at the specified locus
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4.2.7. Follow up of previously implicated CNVs in psychiatric
disorders
4.2.7.I. CNVs implicated in autism spectrum disorders, mental 
retardation, epilepsy or schizophrenia
In Table 25 are summarised the main chromosomal regions reported to be 
associated with autism spectrum disorder, schizophrenia, mental retardation or 
epilepsy. The respective number of the observed CNVs in the bipolar disorder cases 
and in the controls is also included. Only loci reported in multiple studies or with 
strong statistical support from at least one large study are considered.
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Table 25 CNVs implicated in schizophrenia, autism spectrum disorders/mental 
retardation (MR)/epilepsy and the corresponding number of CNVs in the 
current study
Locus Position Type A rticle/ SZ Article autism/MR/ 
epilepsy
BD Cases 
(n=1697)
Controls
(n=2806)
1 q21 1 144.9- 146.3 deldup
(International 
Schizophrenia 
Consortium 2008; 
Stefansson et al. 2008; 
Walsh et al. 2008)
(Brunetti-Pierri et al. 
2008; Christiansen et al. 
2004; Mefford et al. 
2008)
1 dup 2 del; 2 dup
2pl6.3  
CN R X N 1 ) 50-51.3 del
(Guilmatre et al. 2009; 
Ikedaetal. 2010; 
Kirov et al. 2008; 
Kirov et al. 2009b; 
Need et al. 2009; 
Rujescu et al. 2009; 
Walsh et al. 2008)
(Glessner et al. 2009; 
Guilmatre et al. 2009;
Kim et al. 2008; 
Szatmari et al. 2007; 
Weiss et al. 2008)
0
4 del 
(various 
length)
7q34-
36.1 145.6-148.7 del (Friedman et al. 2008) 0 0
15q ll-
q i3
21.2-26.2 dup
(Ingason et al. 2010; 
Kirov et al. 2009a)
(Christian et al. 2008; 
Glessner et al. 2009; 
Jacquemont et al. 2006; 
Marshall et al. 2008; 
Sebat et al. 2007)
0 0
15q ll.2 20.2-20.8 del (Kirov et al. 2009a; Stefansson et al. 2008)
(de Kovel et al.; 
Doombos et al. 2009; 
Mefford et al. 2009)
3 del; 7 
dup
14 del; 
10 dup
15ql3.3 29-30.30 deldup
(International 
Schizophrenia 
Consortium 2008; 
Kirov et al. 2009a; 
Stefansson et al. 2008; 
van Bon et al. 2009)
(Dibbens et al. 2009; 
Helbig et al. 2009; 
Miller et al. 2009; 
Pagnamenta et al. 2008; 
Sharp et al. 2008; van 
Bon et al. 2009)
2 dup 0
16p 11.2 29.5-30.3
dup
del
(Guilmatre et al. 2009; 
McCarthy et al. 2009; 
Walsh et al. 2008)
(Bijlsma et al. 2009; 
Kumar et al. 2008; 
Marshall et al. 2008; 
McCarthy et al. 2009; 
Mefford et al. 2008; 
Sebat et al. 2007; Weiss 
et al. 2008)
3 dup 3 del; 1 dup
16pl3.1 15.0-16.2
dup
del
(Ikedaetal. 2010; 
Ingason et al. 2009; 
International 
Schizophrenia 
Consortium 2008)
(de Kovel et al.; Hannes 
et al. 2009; Mefford et 
al. 2009; Ullmann et al. 
2007)
2 dup 5 dup;1 del
17pl2 14.0-15.4 del (Kirov et al. 2009a) 1 dup 0
22q ll.2 17.4-19.8
del
dup
Multiple publications
(Christian et al. 2008; 
Guilmatre et al. 2009; 
Marshall et al. 2008; 
Szatmari et al. 2007)
0 8 dup
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The phenotypic data of the bipolar cases found to harbour schizophrenia 
implicated CNVs are presented below:
At locus lq21.1 (Figure 28), a duplication has been detected in one bipolar 
case (6014-1). 6014-1 suffers from bipolar I disorder with psychotic symptoms. The 
father of the patient also has bipolar I disorder. More information about the 
segregation of this CNV in the 6014 family is presented in section 4.2.7.1.1 (page 
115).
Figure 28 Locus lq21.1
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Three bipolar cases and 14 controls had deletions at 15qll.2 locus (Figure 
29). For two of the cases (10823-1 and 10720-1), phenotypic data were available. 
10823-1 had schizoaffective disorder, bipolar type with an age of onset of 14 years of 
age. In addition, the case manifested panic disorder, obsessive-compulsive disorder 
and had postnatal depression episode two week after childbirth. Furthermore, the 
patient also manifested psychotic symptoms during episodes of affective disturbance 
(i.e. auditory hallucinations, delusions of influence, persecutory delusions and 
perplexity). The second case (10720-1) with a deletion at 15ql 1.2 was diagnosed with 
BPNOS. Borderline personality disorder and eating disorder were diagnosed as well. 
Auditory hallucinations were also observed. Additionally, more than 100 suicide 
attempts have been noted. The age of onset was at 22 years o f age.
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Figure 29 Locus 15qll.2
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No deletions at locus 15ql3.3 (Figure 30) were observed in the sample, 
although two cases and no controls were found to harbour duplications in this region 
(Fisher’s Exact Test, p  = 0.14). Both of the bipolar cases with the duplication at this 
locus (10088-1 and 5344-1) were suffering from bipolar I disorder. No psychosis was 
observed. Interestingly, both had positive family history; 10088-1 had a daughter with 
bipolar I disorder, while 5344-1 had elder sister suffering from depression and a son 
suffering from manic depression.
I l l
Figure 30 Locus 15ql3.3
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A region on 16pll.2 has been implicated in a range of neuropsychiatric 
phenotypes. Duplications at 16pl 1.2 were found in three cases and one control, 
resulting in a 5-fold increase in the frequency, although the result did not reach 
statistical significance (0.2% vs. 0.04%, Fisher's Exact test,/? = 0.15). The deletion 
associated with this region was found in three controls and interestingly in none of the 
cases. It has to be noted that the 16pl 1.2 locus is covered by seven markers on the 
NspI array. Therefore it would have been filtered out by the applied quality control 
criterion of 2* 10 consecutive markers on each array. To target this region, every 
individual who showed a CNV in this region, detected by the SNPs on the Styl array, 
was individually inspected with the Affymetrix® Genotyping console™ v2.1 
software. Such a CNV was accepted if in addition to the SNPs on the Styl array, all 
markers on NspI array within this region also showed a deviation in the log2 ratios in 
the same direction. This region was then inspected in the CNV data that were received 
from the Wellcome Trust. It was reassuring that these duplications, detected with 
different methodology, were also observed by the Wellcome Trust.
The phenotypic information with respect to the three cases harbouring 
duplication at this locus is listed below:
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8026-1- suffered from bipolar I disorder, with an age of onset at 27 years. The 
onset was four days after she gave birth to a child; the illness was characterised by 
severe episodes with affective features and perplexity. Episodes of puerperal 
psychosis followed the births of her two children;
F400-4- bipolar I case with an age of onset at 16 years of age; the patient left 
school at 15 without taking any exams; no psychosis was observed. In total, 42 
hospital admissions were noted;
In the 3rd patient (6023-1), the duplications had arisen de novo and was not 
present in the proband’s father who also suffered from bipolar disorder. More 
information with regards to this family is provided in section 4.2.7.1.1 (page 115).
In addition, 16pl 1.2 locus will be discussed in more detail in the Discussion 
section, as the analysis from this PhD work has contributed to the evidence in favour 
of this locus in the susceptibility to bipolar disorder (McCarthy et al. 2009).
With respect to the 16pl3.1 duplication (Figure 31), two cases and five 
controls harboured the CNV. Phenotypic information was available for one of the 
cases. 5475-1 was diagnosed with bipolar I disorder. The age of onset was at 35 years 
of age. Psychotic symptoms were also observed (visual hallucinations and persecutory 
delusions).
Figure 31 Locus 16pl3.3
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With regard to 17pl2 locus, in the bipolar sample, one case had duplication. 
No duplications or deletions were observed in the controls (Figure 32).
Figure 32 Locus 17pl2
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No deletions were observed in the bipolar dataset at 22q ll.2  locus. However, 
eight people harbouring a reciprocal duplication in this region (six of them spanning 
the full region) were found in the control dataset. All were part of the National Blood 
Service sample set (Figure 33).
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Figure 33 Locus 22qll.2
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4.2.7.I.I. Follow up with Illumina arrays of lq21.1 and 16pll.2 in 
bipolar probands
For two of the individuals with CNVs that are reported in Table 25 (page 109), 
DNA from both parents was available. The probands and the parents were genotyped 
with an independent platform (Illumina HumanHap610 quad arrays) to validate the 
CNVs and to examine the transmission in the family.
Iu21.1 duplication 
Figure 34 Transmission of lq21.1 duplication in family 6014
BD
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The proband was affected with bipolar I disorder (Figure 34). The 1 q21.1 
duplication was confirmed in the proband (Figure 35) and was also found in the father 
(Figure 36), but not in the mother (Figure 37). Figure 35, Figure 36 and Figure 37 
demonstrate the findings from the Illumina arrays produced using Illumina 
GenomeStudio Genotyping Module (http://www.illumina.com/). It is of interest, that 
the father who transmitted the duplication also suffers with bipolar I disorder.
Figure 35 A proband with lq21.1 duplication
GT Sw nple« ■ 45«t7K 11_M 1C «2 | t |
.v . •
: . .y •. ■.** •
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142.895,380 143,539,820 144,184,260 144,828,700 145.473,140 146.117,580 146,762,020 147 .406,460 148,050,900
An output of the Illumina Genome Studio software is shown, which clearly demonstrates the 
presence of heterozygous SNPs of the type AAB, or ABB, i.e. two alleles from one parent 
and one from the other parent, for the duplicated interval
Figure 36 Father with identical lq21.1 duplication
GT S«m pte« , 4M 67K 8H  [«)
• • * ; . . s .
‘ * ' -
•
1
| ..........^
--------.--- * --- ----1—:--i--——*—■—
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Figure 37 Mother of the proband
GT S««npte» < 4 8 « « 7 tW ? J tt1 C 1  l»l
1 4 2 ,8 9 5 ,3 8 0  1 4 3 ,5 3 9 ,8 2 0  1 4 4 ,1 8 4 ,2 6 0  1 4 4 ,8 2 8 ,7 0 0  1 4 5 ,4 7 3 ,1 4 0  1 4 6 ,1 1 7 ,5 8 0  1 4 6 ,7 6 2 ,0 2 0  1 4 7 ,4 0 6 .4 6 0  1 4 8 ,0 5 0 ,9 0 0
16pll.2 duplication
Figure 38 Transmission of 16p 11.2.1 duplication in family 6023
In total, three bipolar cases were observed to harbour a duplication at the 
16pl 1.2 locus. For one of these probands, DNA for both parents was available. The 
proband was affected with bipolar I disorder, as well as the father (Figure 38). The 
duplication was confirmed in the proband, but was not found in either parent. 
Paternity was confirmed from the SNP data on the array. SNP analysis showed that 
the duplication arose from the maternal genome.
The daughter and the father had a very similar presentation of illness, with 
severe manic and depressive episodes, but no psychotic features. The traces from the
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Illumina arrays for the proband, father and mother are presented in Figure 39, Figure 
40 and Figure 41.
Figure 39 A proband with de novo 16pll.2 duplication
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Figure 40 The father of a proband with 16pll.2 duplication
GT Sam ple* 4644744417 R 1C 47 (1>)
28.400,880 29 .200,760 29 ,600,700
 ------------------------------- : ■ i i.» 1
30 ,000,640 30 ,400,580 30,800,520 31,200,460 31 ,600,400
P 4 M .C -H  | Q 4 m  . w - i i w p l l  1
118
Figure 41 The healthy mother of a proband with 16pll.2 duplication
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M
28 ,400,880 28 ,800,820 29,200.760 29 ,600,700 30.000,640 30,400,580 30 .800,520 31200,460  31 .600,400■
is g SB 3CS B B
4.2.7.2. CNV previously implicated in bipolar disorder
CNV regions previously implicated in susceptibility to bipolar disorder were 
investigated for their occurrence in the WTCCC bipolar case data.
The following loci: lp34.3,14q23.3 and 22ql2.3, affecting the GR1K3, 
AKAP5 and CACNG2 genes respectively, were examined (Wilson et al. 2006). No 
deletions or duplications were found in the bipolar dataset.
Locus 3ql3.3, reported to harbour a duplication in the GSK3J3 gene was also 
examined (Lachman et al. 2007). No CNVs were detected at this locus in the bipolar 
cases.
A study by Yang et al. examined the CNV structure in a large family with 
members affected with bipolar disorder (Yang et al. 2009). Certain regions have been 
found to harbour CNVs more often in the affected members o f the family (6q27,
9q21.11, 12pl3.31 and 15ql 1). No overrepresentation was observed in the WTCCC 
data in these loci.
4.2.8. Exploratory analysis of CNVs in bipolar subphenotypes
The bipolar disorder sample set consists o f cases with bipolar disorder I 
(n=1451), bipolar II disorder (n=121), bipolar disorder not otherwise specified 
(BPNOS) (n=38) and schizoaffective disorder (n=87). These diagnoses are based on 
DSM-IV criteria. To reduce the heterogeneity in the sample, these sample sets were
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compared separately to the controls. This analysis was not performed for BPNOS due 
to the limited number of cases.
In Table 26 are presented the results with regard to bipolar I disorder samples. 
The CNVs are split according to size.
Table 26 Global CNV burden in bipolar I cases
CNV type, 
size (kb)
Cases
(n=1451)
Controls
(n=2806)
CNV per 
case
CNV per 
control
case/control
ratio P
Del 270 632 0.186 0.225 0.83 0.01
Dup 444 901 0.306 0.321 0.95 0.45
Total 714 1533 0.492 0.546 0.90 0.03
Del<200 119 293 0.082 0.104 0.79 0.03
Dup<200 121 261 0.083 0.093 0.90 0.33
Total<200 240 554 0.165 0.197 0.84 0.02
Del 200-500 125 285 0.086 0.102 0.85 0.13
Dup 200-500 233 436 0.161 0.155 1.03 0.72
Total 200-500 358 721 0.247 0.257 0.96 0.55
Del 500-1000 20 34 0.014 0.012 1.14 0.67
Dup 500-1000 62 139 0.043 0.050 0.86 0.34
Total 500-1000 82 173 0.057 0.062 0.92 0.55
Del>1000 6 20 0.004 0.007 0.58 0.29
Dup>1000 28 65 0.019 0.023 0.83 0.44
Total>1000 34 85 0.023 0.030 0.77 0.21
Statistically significant results were observed with regard to the overall 
number of deletions and the total number of CNVs, when cases were compared with 
controls ( p  = 0.01 andp  = 0.03 respectively). When the CNVs were split according 
to their size, it became clear that these results were predominantly driven by deletions 
of size ss 200 ( p  = 0.03 ). The rest of the comparisons between the cases and controls 
were not statistically significant. It has to be noted that relatively more CNVs were 
observed in controls than in cases, and for all of the above-mentioned significant 
results, the controls had more CNVs than cases. None of the p -values were corrected
for multiple hypotheses testing.
Similar analyses were performed for the bipolar II disorder sample (Table 27). 
None of the comparisons between cases and controls were statistically significant.
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Table 27 Global CNV burden in bipolar II cases
CNV type, size 
(kb)
Cases
(n=121)
Controls
(n=2806)
CNV per 
case
CNV per 
control
case/cont 
rol ratio P
Del 23 632 0.190 0.225 0.84 0.44
Dup 41 901 0.339 0.321 1.06 0.75
Total 64 1533 0.529 0.546 0.97 0.81
Del<200 11 293 0.091 0.104 0.87 0.67
Dup<200 13 261 0.107 0.093 1.16 0.64
Total<200 24 554 0.198 0.197 1.00 1.00
Del 200-500 9 285 0.074 0.102 0.73 0.39
Dupl200-500 21 436 0.174 0.155 1.12 0.64
Total 200-500 30 721 0.248 0.257 0.96 0.86
Del 500-1000 2 34 0.017 0.012 1.36 0.66
Dupl500-1000 4 139 0.033 0.050 0.67 0.54
Total 500-1000 6 173 0.050 0.062 0.80 0.71
Del>1000 1 20 0.008 0.007 1.16 1.00
DupllOOO 3 65 0.025 0.023 1.07 1.00
Total>1000 4 85 0.033 0.030 1.09 1.00
The results with regard to the schizoaffective disorder, bipolar type sample set 
are presented in Table 28.
Table 28 Global CNV burden in schizoaffective disorder, bipolar type
CNV type, size 
(kb)
Cases
(n=87)
Controls
(n=2806)
CNV per 
case
CNV per 
control
case/control
ratio P
Del 23 632 0.264 0.225 1.17 0.49
Dup 33 901 0.379 0.321 1.18 0.41
Total 56 1533 0.644 0.546 1.18 0.25
Del<200 10 293 0.115 0.104 1.10 0.88
Dup<200 17 261 0.195 0.093 2.10 0.01
Total<200 27 554 0.310 0.197 1.57 0.02
Del 200-500 9 285 0.103 0.102 1.02 1.00
Dup 200-500 11 436 0.126 0.155 0.81 0.59
Total 200-500 20 721 0.230 0.257 0.89 0.67
Del 500-1000 4 34 0.046 0.012 3.79 0.03
Dup 500-1000 4 139 0.046 0.050 0.93 1.00
Total 500-1000 8 173 0.092 0.062 1.49 0.27
Del>1000 0 20 0.000 0.007 0.00 0.66
Dup>1000 1 65 0.011 0.023 0.50 0.72
Total>1000 1 85 0.011 0.030 0.38 0.38
Statistically significant differences are shown in red
In the schizoaffective disorder, bipolar type three of the performed 
comparisons were found to be statistically significant (duplications s  200 
kb, p  = 0.01; total CNVs s  200 kb, p  = 0.02 and deletions 200 -  500 kb, p  = 0.03 ). 
The p  -values are reported without a correction for multiple hypothesis testing.
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4.3. CNVs in schizophrenia sample
The schizophrenia sample set (n=440, DSM-IV criteria) was analysed for copy 
number variation. The number of schizophrenia cases analysed here and the number 
of schizophrenia cases, CNV analyses on which, we have previously published 
(n=471), differ (Kirov et al. 2009a). This is due to the fact, that for the analyses in the 
PhD, I excluded ~30 individuals due to diagnosis of schizoaffective disorder and then 
performed the analyses.
The schizophrenia sample set was compared with the control set with regard to 
the total number of CNVs and CNVs split according to size. The results from these 
comparisons are presented in Table 29. No statistically significant difference was 
observed with regard to the overall number of CNVs in cases as compared to controls. 
When the CNVs were split into different sizes, a statistically significant difference 
was observed with regard to CNVs of size ^ 1 Mb. Such large deletions and 
duplications were two times more frequent in cases than in controls ( p  = 0.005). This 
effect was most prominent in large deletions, observed three times more frequently in 
cases when compared with controls ( p  = 0.004). After correction for multiple 
hypotheses testing (eight independent test, i.e. four size intervals for each deletion and 
duplication), the association was still statistically significant- p  = 0.03. Although, 
large duplications did not exhibit a statistically significant difference between cases 
and controls, they were more frequently found in cases (~1.5 times more frequent 
than in controls).
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Table 29 Global CNV burden in schizophrenia cases
CNV type, size 
(kb)
Cases
(n=440)
Controls
(n=2806)
CNV per 
case
CNV per 
control
case/control
ratio P
Del 99 612 0.225 0.218 1.03 0.780
Dup 141 893 0.320 0.318 1.01 0.960
Total 240 1505 0.545 0.536 1.02 0.840
Del<200 33 273 0.075 0.097 0.77 0.170
Dup<200 35 253 0.080 0.090 0.88 0.500
Total<200 68 526 0.155 0.187 0.82 0.130
Del 200-500 51 285 0.116 0.102 1.14 0.420
Dup 200-500 65 436 0.148 0.155 0.95 0.750
Total 200-500 116 721 0.264 0.257 1.03 0.800
Del 500-1000 5 34 0.011 0.012 0.94 1.000
Dup 500-1000 25 139 0.057 0.050 1.15 0.570
Total 500-1000 30 173 0.068 0.062 1.11 0.680
Del>1000 10 20 0.023 0.007 3.19 0.004
Dup>1000 16 65 0.036 0.023 1.57 0.110
Total>1000 26 85 0.059 0.030 1.95 0.005
Statistically significant differences are shown in red
As the only group of CNVs that was significantly found more often in 
schizophrenia cases when compared with controls was the CNVs of size ^ 1 Mb. it is 
likely that a number of these CNVs could be pathogenic. These CNVs are presented 
in Table 30.
123
Table 30 CNVs of size 2:1 Mb observed in schizophrenia cases
Sample ID Chr Start [bp] End [bp] Size [kb]
Number 
observed in 
controls
Deletions
19336A5 2 139,150,475 140,198,728 1048 0
20577A5 3 17,179,123 20,586,352 3407 0
19338E3 6 48,110,720 49,298,238 1188 0
19328D4 7 157,744,094 158,798,338 1054 0
19338A2 10 12,673,372 14,643,305 1970 0
19325A4 17 14,048,304 15,357,533 1309 0
19338F6 17 14,048,304 15,357,533 1309 0
19338B6 22 17,275,227 19,791,017 2516 0
20579B3 X 323,881 2,726,346 2402 0
19339D3 X 6,505,282 8,051,350 1546 3
Duplications
19338A5 1 17,118,758 18,187,208 1068 0
20577F4 2 106,275,670 107,792,241 1517 0
20579B4 3 58,527,369 60,146,377 1619 2
19336D3 7 47,255,074 49,037,822 1783 0
19338B1 7 157,623,546 158,798,338 1175 0
19337A5 8 136,873,012 138,138,546 1266 0
19325E5 12 33,576,567 34,650,850 1074 4
19337F4 13 22,466,197 23,791,694 1325 2
19339B1 14 80,656,427 82,414,847 1758 0
19335E2 15 28,748,073 30,231,488 1483 0
19327C3 16 15,032,942 16,189,808 1157 6
19327F2 16 15,032,942 16,189,808 1157 6
20577B1 16 15,032,942 16,189,808 1157 6
19338A5 18 26,180,575 27,565,032 1384 0
19326C1 X 281,199 2,726,346 2445 4
19325H5 X 6,505,282 8,051,350 1546 6
O f the large deletions, presented in Table 30, the majority were observed only 
once. This makes drawing conclusions regarding their pathogenicity difficult.
One of these deletions was observed two times in the cases and was not 
observed in any of the controls, making it significantly associated with schizophrenia 
(Fisher’s Exact Test p  = 0.018). This deletion is affecting the 17pl2 locus. One of 
the probands with the 17pl2 deletion was part of a family with several members 
affected with neuropsychiatric conditions. One parent and three siblings (including 
the proband) had schizophrenia and another sibling had major depressive disorder. 
CNV analysis of all available family members, performed with Agilent arrays, 
showed that the affected parent, and three of the four siblings with a major psychiatric 
disorder, also carried the deletion. The absence o f the deletion in one schizophrenic
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member in this family is not compatible with the hypothesis that most of the risk in 
this family is attributable to a relatively highly penetrant CNV.
Of the large duplications, one was observed in more than one patient. Namely, 
a duplication at 16pl3.1 locus was found in three cases and six controls. The 
combined burden of duplications in this locus did not exhibit a statistically significant 
association (0.7% in cases and 0.25% in controls, Fisher’s exact test, p  = 0.11).
Even though the CNV involvement in schizophrenia is not a study aim in this 
PhD, the aforementioned analyses were presented as one of my main aims was to 
compare bipolar disorder and schizophrenia with respect to copy number variation 
(which follows in the next section).
4.4. Comparison between CNVs in bipolar disorder and 
schizophrenia
The bipolar disorder cases were compared with a set of schizophrenia cases 
that was examined using the same methodology and was presented above. CNVs were 
classified into size categories and results are presented in Table 31. Compared with 
bipolar disorder, the schizophrenia sample exhibited a significant excess of large 
deletions ( ^  1 Mb) ( p  = 0.0009 ), total number of large CNVs ( ^  1 Mb) ( p  = 0.0006 ), 
and a trend for an excess of large duplications ( p  = 0.053 ). The observed p  -values 
were not corrected for multiple testing. Those that would withstand a correction for 
multiple hypothesis testing were the excess of large (s: 1 Mb) deletions in 
schizophrenia compared with controls or bipolar cases.
125
Table 31 Comparisons of the rates of CNVs between controls, bipolar and 
schizophrenia cases
CNV type Size range (kb)
CNV per 
control
BD/control
ratio
( P )
SZ/control
ratio
( P )
BD/SZ 
ratio 
( P )
Deletions 100-200 0.104 0.801 (0.03) 0.771 1.045
200-500 0.102 0.864 1.141 0.758
500-1000 0.012 1.264 0.938 1.348
>1000 0.007 0.579 3.189 (0.004) 0.181 (0.0009)
Total deletions 0.225 0.85 (0.01) 1.032 0.825
Duplications 100-200 0.093 0.982 0.882 1.126
200-500 0.155 1.051 0.951 1.105
500-1000 0.050 0.868 1.147 0.757
>1000 0.023 0.839 1.570 0.53 (0.053)
Total duplications 0.321 0.990 1.007 0.984
Total (Del+Dup) 0.546 0.930 1.017 0.918
Statistically significant differences are shown in red; the non-statistically significant p  - 
values are not shown
4.5. Comparison between CNVs in bipolar disorder, schizophrenia 
and WTCCC non-psychiatric diseases
A cohort of 10,259 UK Caucasian individuals, affected with several non­
psychiatric diseases was studied. These are coronary artery disease (CAD), Crohn’s 
disease (CD), hypertension (HT), rheumatoid arthritis (RA), type 1 and type 2 
diabetes (T1D and T2D). All o f these sample sets have been examined in the WTCCC 
study (Wellcome Trust Case Control Consortium 2007) for associations of single 
nucleotide polymorphisms with these diseases. The bipolar cases and controls were 
part o f the WTCCC project and all three sample sets were genotyped in the same 
pipeline along with CAD, CD, RA, HT, T1D and T2D including the schizophrenia 
samples (ODonovan et al. 2008; Wellcome Trust Case Control Consortium 2007). 
This allowed comparing the CNV calling performed in this PhD work with 
independent calling performed by the WTCCC. Initially, I checked if the CNVs of 
size ^  1 Mb observed in the WTCCC study corresponded to those detected in this PhD 
work. These results were already presented in section 4.1.5 (page 101; 
correspondence rate between the two studies-93%). In addition, I checked the 
correspondence for loci implicated in other psychiatric disorders, in the bipolar
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disorder sample and controls. The correspondence rate between the calls for these 
large CNVs was 100% (36 relevant CNVs called by both teams). This permits a 
conclusion that these CNVs. even though called using different analytical methods, 
can be compared between the separate phenotypic groups.
4.5.1. Comparison with respect to loci, previously implicated in 
schizophrenia
Loci implicated to increase the susceptibility to schizophrenia were chosen for 
further examination, as these were already analysed in this PhD work. The reason for 
choosing these loci was that they had received replicated evidence from multiple large 
studies, or from reviews on these CNVs.
In Table 32 are presented the frequencies of the studied loci implicated 
previously in schizophrenia, in bipolar disorder, schizophrenia and WTCCC non­
psychiatric phenotypes. The corresponding significance levels derived from 
comparison between bipolar cases, schizophrenia, WTCCC controls (1958 cohort and 
NBS, analysed in this PhD work) with WTCCC non-psychiatric phenotypes are also 
presented. The WTCCC controls (2806 individuals, analysed in this PhD work) and 
the new dataset of 10,259 of non-psychiatric controls are not statistically different for 
any of the loci, while schizophrenia cases show a strong trend for an increased rate of 
these loci when compared with the new independent set of controls. There is no 
increased rate of these CNVs in the bipolar cases when compared with the new 
controls. There was a trend for overrepresentation only for one locus-16pl 1.2.
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Table 32 Loci implicated in schizophrenia and the corresponding rate in BD, SZ 
and WTCCC non-psychiatric phenotypes
CNV Rate
p  (based on comparison with the 
rate in WTCCC phenotypes) Review papers 
usedBD SZ WTCCCcontrols
WTCCC
phenotypes BD SZ
WTCCC
controls
lq21.1
del 0/1650(0%)
17/7918
(0.2%)
2/2806
(0.071%)
1/10259
(0.01%) 1 7.8X10-6 0.23
(International 
Schizophrenia 
Consortium 2008;
Kirov et al. 
2009a; Stefansson 
et al. 2008)
2pl6.3
del
NRXN1
0/1650
(0%)
14/8798
(0.16%)
2/2806
(0.071%)
7/10259
(0.068%) 0.6 0.08 0.96
(Kirov et al. 
2009b; Rujescu et 
al. 2009)
15qll.2
del 4/1650(0.242%)
47/7918
(0.59%)
14/2806
(0.499%)
40/10259
(0.39%) 0.51 0.05 0.53
(International 
Schizophrenia 
Consortium 2008;
Kirov et al. 
2009a; Stefansson 
et al. 2008)
15ql3.3
del 0/1650(0%)
15/7413
(0.2%)
0/2806
(0%)
4/10259
(0.039%) 1 0.002 0.66
(International 
Schizophrenia 
Consortium 2008;
Kirov et al. 
2009a; Stefansson 
et al. 2008)
16pll.2
dup 3/1650(0.181%)
26/8590
(0.3%)
1/2806
(0.036%)
4/10259
(0.039%) 0.06 4x1 O'6 0.94
(McCarthy et al. 
2009)
16pl3.1
dup 2/1650(0.121%)
23/6920
(0.33%)
5/2806
(0.178%)
25/10259
(0.24%) 0.57 0.3 0.67
(Ingason et al.
2009; 
International 
Schizophrenia 
Consortium 2008; 
Kirov et al. 
2009a)
17pl2
del 0/1650(0%)
8/5089
(0.16%)
0/2806
(0%)
7/10259
(0.068%) 0.6 0.11 0.35
(International 
Schizophrenia 
Consortium 2008;
Kirov et al. 
2009a; Stefansson 
et al. 2008)
22qll.2
del 0/1650(0%)
18/7038
(0.26%)
0/2806
(0%)
0/10259
(0%) NA 9.5xl0'8 N/A
(International 
Schizophrenia 
Consortium 2008;
Kirov et al. 
2009a; Stefansson 
et al. 2008)
Rate in SZ given for comparison purposes and based on the referenced articles, excluding the 
samples that overlap between the studies; Rate in BD cases, based on the WTCCC Sanger 
study; Rate in WTCCC controls (1958 cohort and NBS)-based on the PhD study for 
comparison purposes
The total number of implicated CNVs in schizophrenia in each of the 
phenotypes comprising the WTCCC study is presented in Table 33. For comparison,
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the corresponding numbers in the cases affected with schizophrenia, that were 
genotyped and analysed in the same pipeline as the WTCCC study (Kirov et al. 
2009a) and the schizophrenia cases and controls from the ISC study are also shown 
(International Schizophrenia Consortium 2008). When the total rate of previously 
implicated in schizophrenia loci was compared between bipolar cases and the 
WTCCC non-neuropsychiatric controls, no statistically significant difference was 
observed ( p  = 0.19). In contrast, when the combined sample of Cardiff and ISC
schizophrenia cases was compared with the WTCCC non-psychiatric controls (3862 
SZ cases with 94 CNVs vs. 10,259 non-psychiatric controls with 93 CNVs ), a highly 
statistically significant difference was observed- p -  5 x 10"11.
Table 33 Rate of all combined CNVs implicated in schizophrenia in the separate 
cohorts that comprise the WTCCC study
Phenotype Number individuals Number CNVs Frequency (%)
BD 1650 9 0.54
Cardiff: SZ cases 471 15 3.18
ISC: SZ cases 3391 79 2.33
ISC: controls 3181 22 0.69
NBS+1958 Cohort 2777 26 0.94
RA 1374 9 0.65
CD 1450 13 0.90
HT 1864 16 0.86
T1D 1903 18 0.95
T2D 1813 22 1.21
CAD 1855 15 0.81
Numbers in the International Schizophrenia Consortium study (ISC) are also given for 
comparison purposes
4.5.2. Comparison with respect to loci >1 Mb
In addition, this data set was also examined for CNVs ^ 1 Mb and found in 
< 1% of the sample. The results with respect to this analysis are presented in Table 34. 
It is of note that bipolar disorder and rheumatoid arthritis have lower rate of this type 
of CNVs compared to the controls. None of the rates in the other phenotypes are 
significantly different from those in the 2777 controls, using 2-tailed tests with 10,000
129
permutations (that is excluding schizophrenia). The rate in schizophrenia was derived 
from Kirov et al. (Kirov et al. 2009a).
Table 34 Rate of deletions and duplications >lM b in size in the WTCCC samples
Phenotype Nindividuals
Rate of del 
per person
Rate of dup 
per person
Rate of CNV 
per person
controls 2777 0.007 0.020 0.027
BD 1650 0.004 0.014 0.018
CAD 1855 0.009 0.025 0.033
CD 1450 0.01 0.021 0.032
HT 1864 0.011 0.018 0.029
RA 1374 0.005 0.012 0.017
T1D 1903 0.011 0.021 0.032
T2D 1813 0.009 0.028 0.037
SZ 471 0.028 0.040 0.068
When bipolar cases were compared with the 10,259 non-psychiatric controls 
with respect to the cumulative burden of CNVs ^ 1 Mb, statistically significant 
differences were observed with respect to deletions and total number of CNVs & 1 
Mb (Table 35). These differences were in the opposite direction than expected, i.e. the 
rate in the control sample was increased.
Table 35 Burden with respect to CNVs a: 1 Mb in bipolar disorder
Type CNV BDN=1650 Rate BD
WTCCC
phenotypes
N=10,259
Rate WTCCC 
phenotypes P
del 6 0.004 95 0.009 0.02*
dup 23 0.014 218 0.02 0.06
total 29 0.018 313 0.03 0.003*
p  -values derived using two-tailed Fisher’s exact test
*This significant result is for fewer CNVs in cases than controls
Schizophrenia cases were also compared with the 10,259 non-psychiatric 
controls. All types of CNVs ^  1 Mb were overrepresented in the schizophrenia cases 
(Table 36).
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Table 36 Burden with respect to CNVs ^ 1 Mb in schizophrenia
Type CNV SZN=471 Rate SZ
WTCCC
phenotypes
N=10,259
Rate WTCCC 
phenotypes P
del 13 0.03 95 0.009 0.001
dup 19 0.04 218 0.02 0.02
total 32 0.07 313 0.03 0.0001
p  -values derived using two-tailed Fisher’s exact test
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5. Discussion
In the final chapter of this PhD, I will discuss the methodological issues that I 
encountered whilst performing the analyses of the possible involvement of copy 
number variation in bipolar disorder. Then I will discuss the results and will put them 
in context of what is known with respect to copy number variation in neuropsychiatric 
disorders in general, and bipolar disorder in particular. In addition, I will consider 
what the results from studying the copy number variation in bipolar disorder tell us 
and finally will consider possible future strategies.
5.1. Main objectives
Recent studies have suggested that copy number variation in the human 
genome is extensive and may play an important role in susceptibility to disease. It has 
been shown that CNVs may confer susceptibility to infectious and complex diseases 
and play a role in adaptation to environment (Armengol et al. 2009; Flint et al. 1986; 
Gonzalez et al. 2005). Theoretically, relative to SNPs, large CNVs are more likely to 
induce phenotypic effects by altering genomic functionality (Cooper et al. 2007). In 
addition, it has been shown that CNVs could alter gene expression within and 
flanking the CNVs (Stranger et al. 2007; Yang et al. 2009). Furthermore, CNVs in 
general have been shown to have a possible causal role in severe neurodevelopmental 
syndromes and schizophrenia (Christian et al. 2008; Cook and Scherer 2008; Kirov 
2010; Marshall et al. 2008; Sebat et al. 2009; Sharp et al. 2008). In addition, some 
specific copy number variants have been implicated as susceptibility factors for 
schizophrenia (Ingason et al. 2010; Ingason et al. 2009; International Schizophrenia 
Consortium 2008; Kirov et al. 2009a; Kirov et al. 2009b; McCarthy et al. 2009; 
Rujescu et al. 2009; Stefansson et al. 2008; Walsh et al. 2008).
Based on studying the genetic factors predisposing to schizophrenia and 
bipolar disorder (e.g. SNPs), previously it has been shown that they might overlap, 
causing susceptibility to both of the disorders (Gottesman et al. 2010; Lichtenstein et 
al. 2009; Moskvina et al. 2009).
On the basis o f the possible overlap in the genetic factors between bipolar 
disorder and schizophrenia and evidence of the possible association between
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deletions/duplications and the propensity to schizophrenia, the primary hypothesis in 
this PhD work was that individuals with bipolar disorder could potentially exhibit a 
greater burden of CNVs and a greater burden with respect to specific CNVs that have 
been previously shown to increase risk for schizophrenia.
The potential involvement of CNVs in bipolar disorder has received little 
attention to date. Thus, the current PhD project is a formal attempt to try to shed some 
light on the relative involvement of CNVs in bipolar disorder. When this project was 
initiated (at the beginning of 2008), there were no genome-wide data published with 
respect to investigating the possible role of copy number variation in the susceptibility 
to bipolar disorder.
More specifically, the main objective of the PhD thesis was to determine if 
large f> 1 0 0  kb) and rare tfound in < 1% of the general population) copy number 
variants are associated with susceptibility to bipolar disorder. The possible 
involvement of some particular deletions and duplications as a factor for developing 
bipolar disorder was also examined.
A direct comparison between schizophrenia and bipolar disorder with respect 
to CNV structure was also attempted.
My role in the project was crucial as I saw the opportunity to infer CNVs 
using SNP intensity array data, outlined the project and suggested it to my PhD 
supervisors. Subsequently, I closely participated in every step of the project (DNA 
case sample preparation, genotyping quality control, CNV calling, CNV calling 
quality control, CNV validation, CNV analyses and interpretation).
5.2. Quality control of the data
For the CNV analysis, 1868 Caucasian bipolar disorder cases and 2938 
controls were used. Overall, 1697 cases (91% of the initial 1868) and 2806 controls 
(96%) passed the quality control filtering for the CNV analysis and were used for 
further CNV examination.
DNA from the case and control samples was genotyped with the Affymetrix 
500K Array set comprising two arrays: NspI and Styl. Using the intensity data from 
the SNP genotyping, deletions and duplications were inferred. A variety of quality 
control filtering steps was applied in an attempt to reduce the false-positive rate:
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• analysing copy number variants found in <; 1 % of the sample;
• analysing only deletions and duplications 1 0 0  kb;
• a deletion or duplication was called only if it spanned a: 1 0  consecutive 
SNPs on each of the two arrays;
• samples with an interquartile range ( I QR) ^ 0 . 4  were excluded;
• subjects with ^ 2 0  segments were omitted from any further analysis;
• CNVs with very low SNP density were also excluded (^  3 SNPs per 
1 0 0  kb);
• only CNVs observed on both of the arrays were analysed further.
Array-based experimental approach offers efficient and cost-effective method 
for whole-genome study of copy number variation in the human genome. McMullan 
et al. performed a study in which three European diagnostic centers assessed the use 
of Affymetrix 500K SNP arrays for molecular karyotyping in patients with mental 
retardation. The study was an attempt to examine if the array could be used for 
reliable detection of rare and large CNVs 100 kb). It was concluded that the 
platform provided robust results and could be used for a routine postnatal diagnostics 
in a clinical setting (McMullan et al. 2009). Other studies have also successfully 
interrogated SNP data to detect CNVs using the Affymetrix 500 K array (Friedman et 
al. 2009; Gardina et al. 2008). This provided evidence that Affymetrix 500K array can 
be confidently used for the purposes of the current study.
The Affymetrix 500K array set is one of the earliest whole-genome SNP 
genotyping platforms and has relatively lower resolution for CNVs as compared to 
later platforms. SNPs on the Affymetrix GeneChip 500K, have a median spacing of 
2.5 kb. However, due to the variable resolution across the genome, CNV detection has 
a lower limit of 10- 40 kb (Carter 2007). Platform comparisons between high-density 
bacterial artificial chromosomes, single-nucleotide and oligonucleotide microarrays 
have shown that the Affymetrix 500K array set has difficulties in detecting CNVs 
< 100 kb (Hehir-Kwa et al. 2007). Therefore, in a conservative approach, only copy 
number changes >100 kb were analysed. This relatively low resolution of the 
Affymetrix 500K array has much less impact on large CNVs (the focus of this study), 
but because of this limitation, the contribution of smaller CNVs (<100 kb) to disease 
susceptibility was not tested.
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It is of note that CNVs are associated with highly repetitive regions in the 
human genome, i.e. low copy repeats (Lupski and Stankiewicz 2005). Such regions in 
the early generation arrays were not interrogated as they created difficulties for the 
SNP genotyping and such SNP data failed to qualify for inclusion on earlier 
generation of the commercial arrays (Carter 2007; Cooper et al. 2008; McCarroll et al. 
2008). Because the probes on the Affymetrix 500K array were not uniformly 
distributed and were sparse in repetitive regions in the human genome, such arrays 
have poor abilities to call common CNVs. Thus, only CNVs observed in £ 1% of the 
data were examined. Nevertheless, it has been demonstrated that using early 
generation arrays, rare CNVs had little coverage bias and are captured relatively well 
fMcCarroll et al. 20081.
Additionally, common CNVs were not considered as the copv-numher 
detection is relative. That is, the CNV identification requires a comparison to a 
reference dataset (Scherer et al. 2007). In this PhD study, the case samples were 
compared to reference sets that comprised individuals in the range of 100 to 250. If a 
CNV is common and is found in both groups, then it will not be detected due to the 
smaller relative difference in the intensities between the two groups. This could 
potentially result in a decreased power to detect variants in highly polymorphic 
regions in the genome.
An important consideration that has to be taken into account when performing 
CNV analysis is that CNV studies are prone to batch effects, as they rely on 
differences in signal intensities between case and reference groups. Differences in the 
signal intensities could stem from DNA quality or from the actual processing of DNA 
in the laboratory. Batch effects could lead to spurious data and detecting false 
deletions or duplications. Initially, at the start of the project, I observed that when 
some individuals, always within one processing batch, were compared with a 
reference sample from another processing batch, the produced data comprised many 
CNVs (in the order of hundreds) per person. When the same batch was compared with 
a reference sample set from the same processing batch, the number of CNVs observed 
was much smaller ( < 20 segments per person). As CNV detection relies on intensity 
data, when samples from separate processing batches were compared against each 
other, a large number of falsely-detected CNVs were observed. In this PhD work, this 
problem was overcome by comparing samples with a reference set from the same 
processing batches. The importance of such batch effects and the means how to solve
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this problem are now well recognised in the scientific community, but these were 
largely unknown when this PhD was initiated. In this PhD study, I suggested a way of 
how to resolve this issue, although it has to be said that it is not always 
straightforward to get around the batch effect. For instance, Zhang et al. could not 
examine the specific regions previously found to be associated with schizophrenia in 
bipolar cases. This was due to a proximity of these loci to regions with plate batch 
effects (Zhang et al. 2008).
Part of the quality control methodology in the current PhD study included that 
a deletion or duplication was inferred only if it was observed on both of the arrays. 
This potentially introduced a tendency to underestimate the size of the CNVs as only 
the overlapping fragments between the NspI and Styl arrays were taken into account. 
However at the same time, in a way, this was a validation of the findings based on one 
of the array with the other. Additionally, a validation using separate platforms was 
also performed.
Generally, it is regarded that the quality of SNP genotyping exceeds the 
quality of the CNV calling methods. In a recent review, CNVs were referred to as “a 
headache to identify and classify” (Baker 2010). Therefore, validation is required to 
ensure that the CNV calling is reliable. For confirming some of the CNVs, inferred 
using the data from the Affymetrix arrays (25 CNVs in total), an Agilent CGH array 
was used. This array provided a genome-wide coverage with an average resolution of 
~30-35kb. It has been previously shown that using the Agilent array CGH platform, 
high quality data with respect to copy number changes could be obtained (De Witte et 
al. 2006). In addition, two CNVs in two bipolar disorder subjects (specifically 1 q21.1 
duplication and 16pl 1.2 duplication) were genotyped using Illumina Human Hap610 
quad arrays. All of the CNVs that were put through validation, were confirmed. This 
reflects the stringent OC criteria applied throughout this PhD work.
Further support that the applied methodology produces reproducible results 
was the comparison with data obtained from WTCCC. Wellcome Trust examined the 
same raw genotyping SNP data (1868 bipolar cases and 2938 control individuals), 
analysed in this thesis for CNVs, using different methods for CNV calling (Barnes et 
al. 2008; Olshen et al. 2004; Price et al. 2005). When 96 CNVs, * 1Mb, detected with 
the methods in this PhD study were compared with the data from Wellcome Trust, 
93% (90 out of 96), were concordant between the two studies. In addition, all of the 
specific loci which were examined in detail in this PhD were double-checked using
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the data from WTCCC. With respect to these loci, 100% concordance of the results 
between the two studies was observed.
In summary, the excellent validation rate corresponded to the stringent QC 
criteria, which were applied throughout this PhD work. This provided evidence that 
the produced CNV data were robust and trustworthy.
5.3. Global burden of CNVs in cases and controls
When bipolar disorder cases were compared with healthy controls, the main 
observation was that the rate of CNVs was not  increased in bipolar disorder as 
compared to controls ( p  -  0.1, Table 17, page 103), contrary to expectations. There 
was a statistically significant association in the opposite direction for deletions 
( p  = 0.01). It has to be noted that this statistical significance would not withstand a 
correction for multiple hypothesis testing. As such, this result is very likely to be false 
positive. Nevertheless, the effect was coming from controls having relatively more 
deletions than cases (0.23 CNVs per control as opposed to 0.19 CNVs per case).
The controls having more CNVs could be explained by different source of 
DNA, e. g. cell lines, which could potentially introduce differential bias in the number 
of CNVs between the cases and controls. The DNA for all of the cases was extracted 
from blood samples. The control sample used in this PhD work comprises two 
separate control datasets- National Blood Donor (NBS) and 1958 birth cohort. That is, 
blood for the NBS and EBV-transformed cell lines for the 1958 cohort. The general 
assumption is that DNA extracted from cell lines could exhibit an increased mutation 
rate (Mohyuddin et al. 2004). Therefore, to check this assumption, the difference 
between the two groups was examined with respect to the number of CNVs per 
person. When the two control groups were compared against each other, no 
statistically significant difference with respect to the total number of CNVs was 
observed ( p  = 0.7), although when the two groups were compared with respect to 
deletions only, the 1958 controls had relatively more deletions than NBS subjects 
( p  -  0.03 ). Furthermore, more duplications in the NBS sample were observed in
comparison to the 1958 cohort ( p  = 0.03 ). Nevertheless, the significant results with 
respect to deletions and duplications will not withstand a correction for multiple
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hypothesis testing. Therefore, it was concluded that the two control groups did not 
provide spurious results. In addition, WTCCC group has compared the two control 
datasets with respect to SNP data and the two groups were not differentially biased in 
terms of collection and sample preparation. Only a few significant differences were 
observed between the two control groups even though, they differed with respect to 
the sampled populations, DNA source, DNA processing and age. This finding 
justified the combining of the two control groups in the WTCCC SNP study 
(Wellcome Trust Case Control Consortium 2007). In a recent large study on common 
CNVs in 16,000 cases of eight common diseases and 3000 shared controls (the same 
control set used in this PhD work), a clear biological artefact was observed, i.e. 
systematic CNV differences between DNAs derived from blood and cell lines 
(Wellcome Trust Case Control Consortium et al. 2010). It was shown that these apply 
only to particular CNV loci in the human genome. These specific loci have been 
located in close proximity to the immunoglobulin genes, rearranged via the process of 
V(D)J recombination, which is inherent to the B cells (Rivera-Munoz et al. 2007).
The B cells are the cells used for producing cell lines, when DNA extracted from 
blood originates from a mixture of white blood cells (Wellcome Trust Case Control 
Consortium et al. 2010). In the current study, it can not be estimated whether this 
effect was observed or not.
Since the initial finding of controls having relatively more deletions than cases 
( p  = 0.01) was not highly significant in the context of multiple hypothesis testing, 
this could well be a chance finding. Therefore a conservative interpretation of no 
increase in burden of CNVs in bipolar cases rather than controls, may be more 
appropriate. In addition, the bipolar cases were compared with the 10,259 non­
psychiatric controls (described in 3.8, page 88) with respect to global burden of 
deletions, duplications and total number of CNVs. No statistically significant 
differences were observed with regard to global burden (irrespective of size) of 
deletions, duplications or total number of CNVs { p  = 0.09, p  = 0.84 and p  = 0.22 
respectively, not presented in the Results chapter). This indicated that 
abovementioned conclusion could be correct.
Other CNV studies in bipolar disorder have shown very similar findings. The 
overall genetic burden of CNVs was not increased when cases were compared with
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controls (Zhang et al. 2008). Furthermore, Yang et al. observed that the average 
number and size of CNVs that were found in affected individuals were not 
significantly different from CNVs in unaffected individuals in a large Amish pedigree 
{p  = 0.3 and p  = 0.24 respectively) (Yang et al. 2009).
Similar were the findings presented at the XVII World Congress of Psychiatric 
Genetics held in San Diego 2009. Dr. Shaun Purcell presented CNV analysis in a 
large bipolar disorder cohort (-1400 cases and 2000 controls). No increased CNV 
burden was observed in cases when compared with controls (Purcell 2009). A poster 
at the same congress presented analogous result with respect to an overall CNV 
burden, based on a CNV study of -900 cases and -900 controls (Priebe et al. 2009).
In a very recent analysis, studying deletions and duplications in the University 
College London bipolar disorder case-control sample (546 cases and 517 controls) no 
increase in the rate of copy number variants in cases was observed (McQuillin et al. 
2010). When cases were compared with controls with respect to total burden of 
deletions and duplications (> 100 kb), the observed 2-sided statistical significance was 
p  = 0.036 (not corrected for multiple comparisons), with cases having fewer CNV 
than controls. It is of great interest that in the University College London bipolar 
disorder case sample, similarly to the results presented in this PhD thesis, a lower rate 
of CNVs has been detected in the cases, in comparison to healthy controls (McQuillin 
et al. 2010). The finding of such lower rate in two independent studies suggests that 
this could indeed be a genuine finding. Further studies could provide evidence if this 
is the case.
Based on the data published/presented to date with respect to the global 
burden of large deletions and duplications in bipolar disorder, it could be concluded 
that the overall burden was not increased and it is not likely that it plavs a role in the 
susceptibility to developing bipolar disorder.
Since the main finding in this PhD work, from studying the genomic burden of 
rare (<\%) and large (MOOkbl variants in cases and controls, suggested that such 
CNVs were not involved in the susceptibility to bipolar disorder, one could pose the 
question whether relatively more common variants account for some of the 
susceptibility. Common CNVs have not been thus far associated with common 
diseases, such as schizophrenia. Generally, it is regarded that common CNVs are
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involved in the natural variation between individuals, where rare variants could cause 
the development of certain disorders (Kooy 2010). Common CNVs were not explored 
in this PhD study, but it has to be noted that almost the same bipolar cases and 
controls have taken part in a large genome-wide association study focused on 
common copy number variation performed by Wellcome Trust. This study has 
provided evidence that common CNVs were not likely to contribute to developing 
common diseases, such as bipolar disorder (Wellcome Trust Case Control Consortium 
et al. 2010). It was observed that CNVs at three loci affecting genes were associated 
with several diseases. Namely, these were: the IRGMgene in Crohn’s disease, the 
HLA for Crohn’s disease, rheumatoid arthritis and type 1 diabetes and the TSPAN8 
gene for type 2 diabetes. Interestingly, these loci were not novel. They had already 
been implicated in these disorders on the basis of evidence coming from genome-wide 
SNP studies. These data suggest that the majority of common CNVs were well tagged 
by SNPs and have already been indirectly studied. The main conclusion from this 
large genome-wide study was that common CNVs are unlikely to make a great 
contribution to the genetic basis of common human diseases (Wellcome Trust Case 
Control Consortium et al. 2010).
The finding of no increase in the CNV burden in cases when compared with 
controls observed in this PhD work and a similar observation in a number of other 
CNVs studies in bipolar disorder is in the opposite direction to findings in 
schizophrenia studies where an increased CNV load has been detected (International 
Schizophrenia Consortium 2008; Kirov et al. 2009a; Stefansson et al. 2008; Walsh et 
al. 2008). It has to be noted that CNV burden analysis alone could not identify 
specific risk factors (as the CNVs affect multiple genes), but only suggest a potential 
CNV involvement in disease susceptibility. Nevertheless, the approach used here has 
been proven pivotal in pointing to the involvement of CNVs in schizophrenia and 
other disorders (Abrahams and Geschwind 2008; International Schizophrenia 
Consortium 2008; Stefansson et al. 2008; Walsh et al. 2008). A possible explanation 
of the finding that schizophrenia and bipolar disorder differ with respect to the CNV 
involvement of the pathogenesis is discussed in section 5.11 (page 164).
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5.4. Global burden with respect to CNV size
When the observed CNVs were split into size categories and compared 
between cases and controls, apart from small deletions f<200 kb), statistically 
significant differences were not observed for any of the other size ranees. 
Significantly fewer CNVs in cases as compared to controls were observed with 
respect to deletions £ 200 kb ( p  -  0.03 ). If this result was to be corrected for the 
number of the tests performed, it would not withstand a correction for multiple 
hypotheses testing, thus suggesting that this was a potentially chance finding.
The finding that the controls had more deletions in total than cases (discussed 
in section 5.3, p  = 0.01) is likely to be driven by the number of small deletions. Even 
though the Affymetrix 500K array has been shown to have a lower limit for CNV 
detection of about 10-40 kb (Carter 2007), the small CNV (^  200 kb) category is the 
most difficult to call, hence, the most unreliable. Taking into account that this finding 
is not highly statistically significant and it would not withstand a correction for 
multiple hypotheses testing, it could be a chance finding. Thus, it could be 
conservatively interpreted as that cases showed no increase in the overall burden with 
respect to deletions £ 200 kb, as compared to controls.
These results are in agreement with a recent study in bipolar disorder, with 
respect to CNV size (McQuillin et al. 2010). In particular, no statistically significant 
observations were noted in the size ranges tested apart from for deletions with size 
range 200 -  500 kb which were observed more often in controls than cases 
( p  -  0.039, not corrected for multiple hypothesis testing) (McQuillin et al. 2010).
This observation in bipolar disorder is in the opposite direction to findings in 
schizophrenia where very large CNVs ( ^ 500 kb or ^ 1 Mb) have been observed to be 
enriched in people with schizophrenia (International Schizophrenia Consortium 2008; 
Kirov et al. 2009a). Discussion of the observed differences between bipolar disorder 
and schizophrenia is presented in section 5.11 (page 164).
5.5. Singleton observations
While the analysis for this PhD work was been performed, the first systematic 
genome-wide CNV analysis in bipolar disorder was published (Zhang et al. 2008).
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Similar to the main finding presented in this PhD, no increase in the total burden of 
CNVs in cases was observed when compared with controls.
The primary finding in Zhang et al. was an effect with respect to single 
deletions that were observed more often in cases when compared with controls 
(16.2% of the cases versus 12.3% in controls; p  = 0.007). However, the data from 
this PhD work did not replicate the finding of a significant increase in singleton CNV 
events in bipolar cases compared with controls (Table 37).
Table 37 Proportion of samples carrying at least one singleton CNV in this study 
compared with Zhang et al.
Single 
CNV type
cases with a CNV 
(this study) 1%1
controls with a CNV 
(this study) f%l
cases with a CNV 
(Zhang etal.) [%]
controls with a CNV 
(Zhang et al.) [%1
Del 6.0 6.2 16.2 12.3
Dup 7.1 8.3 19.7 19.1
Total 11.0 11.7 32.4 29.0
(Zhang et al. 2008); Del=deletions; dup=duplications
Zhang et al. used a higher resolution Affymetrix 6.0 array and had smaller 
sample size (1001 cases and 1034 controls) (Zhang et al. 2008). These factors could 
have led to the observation of a higher number of singleton CNVs, and could explain 
the differences with respect to the frequency of cases/controls with a singleton CNV 
(Table 37). It has to be acknowledged that the smaller the sample, the more likely is to 
observe an event only once in the data. In contrast, if the sample is very large, 
singleton events will be hardly ever observed unless there is an event that have a 
complete penetrance with bipolar disorder. It has to be noted that an overall reduction 
of singleton events has been observed in the current study when compared with Zhang 
et al. study.
In addition, the power of the current study at a  -  0.05 level to detect a 
statistically significant difference with the effect size observed by Zhang et al.
(<5 = 0.11), is very high (95%). For comparison, the power to detect a significant 
difference with the aforementioned effect size with the sample size in Zhang et al. is 
71% ( a  -  0.05). Power will be lower if there is a true, but smaller increase in 
singleton CNV burden (i.e. smaller effect size), or if the stringent QC criteria resulted 
in detecting a smaller proportion of the relevant loci in this PhD analysis. With 
respect to very weak effects, no single study will be powerful enough to provide 
definitive results. Therefore in this context, a type II error in the present bipolar versus
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control analysis could not be fully discounted. However, it should be noted that the 
findings of Zhang et al. were relatively weaker than those reported in a smaller-sized 
schizophrenia and autism studies (Guilmatre et al. 2009; Kirov et al. 2009a; Walsh et 
al. 2008; Zhang et al. 2008). It is possible that these results (in Zhang et al.) could 
represent type I error as they would not withstand a correction for multiple hypotheses 
testing concerning the CNV size, type and frequency.
Zhang et al. observed more pronounced effect with respect to single deletions 
in bipolar cases with early onset of mania 18 years of age, p  = 0.001) (Zhang et al. 
2008). At the XVII World Congress of Psychiatric Genetics held in San Diego (2009), 
a poster presented a CNV analysis of 882 patients with bipolar I disorder and 872 
healthy controls using genome-wide SNP data (Priebe et al. 2009). The analysis 
showed that singleton deletions in patients were larger (in terms of average size) than 
in controls (/? = 0.014). On average, single microduplications were also relatively 
larger in cases with an early onset when compared with controls (/? = 0.0048). None 
of the performed tests showed statistically significant differences in CNV load 
between cases with onset ^ 21 years of age when compared with controls. An effect 
with respect to singleton observations was observed, and similarly to the Zhang et al. 
study, this effect was more prominent in cases with an early age of onset. A 
statistically significant association was detected with respect to cases with early onset 
and duplications ( p  = 0.00022, after a Bonferroni correction for the performed 72 
tests,/? = 0.016) (Priebe et al. 2009). In addition, another CNV study in bipolar 
disorder, presented by Dr. Shaun Purcell at the same congress also showed evidence 
of possible involvement of CNVs in early onset bipolar disorder (Purcell 2009).
These three studies observed an effect of CNVs in early onset bipolar disorder. 
When the same criterion (age of onset of mania £ 18 years of age) was used in this 
PhD work, no statistically significant effect was detected. In the current bipolar study, 
there were only 65 cases with onset of mania ^ 18 years. This sample set was 
relatively small to draw any definitive conclusions.
McQuillin et al. tested the hypothesis if single CNV observations were 
involved in the predisposition to bipolar disorder. In contrast to Zhang et al. and in 
agreement with the results presented in this PhD work, no statistically significant 
enrichment was noted in bipolar cases (McQuillin et al. 2010). In addition, McQuillin 
et al. compared the rate of singleton events in cases with early onset (^  18 years of
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age) with the cases with a later first onset of mania. No statistically significant 
differences were observed between the two groups.
While additional studies are required to further explore the possible 
involvement of single CNVs in the susceptibility to bipolar disorder, the analysis 
presented in this PhD work and the findings of McQuillin et al.. provide evidence 
against the contribution of singleton CNVs in developing bipolar disorder in the size 
range tested (>100 kbf.
5.6. CNVs disrupting genes
Studies of schizophrenia have noted an elevated burden of CNVs that disrupt 
genes in cases as compared to controls (International Schizophrenia Consortium 2008; 
Walsh et al. 2008). Walsh et al. detected a raised load of CNVs that specifically 
disrupt genes in affected individuals as compared to controls ( p  = 0.012, OR -  2.79, 
95%C7:1.26 -  6.18 ) (Walsh et al. 2008). Furthermore, the International 
Schizophrenia Consortium detected an increased number of genes affected by CNVs 
in cases when compared with controls (1.41-fold increase, p  = 2 x 10-6) (International
Schizophrenia Consortium 2008). Similar analysis was carried out in this PhD with 
respect to CNVs disrupting genes. No statistically significant difference was observed 
between the number of CNVs disrupting genes in cases when compared with controls.
Although, there was no evidence of an increased burden of disrupted genes in 
cases when compared with controls, even a single occurrence of a CNV in a disorder 
could potentially make an important contribution to the understanding of the disease 
pathogenesis and could lead to possible mechanisms/pathways that underlie the 
disorder (Sudhof 2008). Such an example has been the observation of a rare deletion 
in the NRXN1 gene in probands with schizophrenia (Kirov et al. 2008; Kirov et al. 
2009b; Rujescu et al. 2009).
With respect to bipolar disorder, no statistically significant differences were 
observed when singleton CNVs affecting genes were analysed.
If a particular CNV has been observed only in cases and in no controls, this 
could potentially be an indication that such a variant is likely to be pathogenic. Thus, 
an analysis was performed for CNVs intersecting genes found exclusively in the 
bipolar cases. Several potentially intriguing genes were affected. Examples included
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neuroligin 1, neuregulin 3 and alpha-2 catenin. These genes have been previously 
associated with neuropsychiatric disorders (Chen et al. 2009; Chubykin et al. 2005; 
Dean and Dresbach 2006; Lesch et al. 2008), although no specific evidence was 
observed to support their contribution in the susceptibility to bipolar disorder. This 
comes from the fact, that it is not currently known how disruption in any of these 
genes could mechanistically translate into an illness. In addition, similar results were 
obtained when the number of genes disrupted in cases was analysed (i.e. no 
statistically significant differences at the 0.05 level).
The analysis with respect to overall genomic burden and analysis with respect 
to burden of CNVs disrupting genes did not point to possible genetic underpinnings of 
bipolar disorder. An approach which could potentially identify the involved genes and 
mechanisms in the disorder pathophysiology is pathway analysis.
5.7. Pathway analysis
It has been suggested that changes in many genes could lead to the expression 
of the bipolar disease phenotype. Such an effect can be explored by analysis that 
focuses on pathways rather than on single variants. This investigation could 
potentially reveal an insight into the genetic basis of the disease. The goal of such 
analysis is to determine if the susceptibility variants associated with bipolar disorder 
are clustered in particular biological pathways that are pertinent to the disease 
pathophysiology.
CNV data on its own do not provide answers to questions with respect to 
which biological processes are affected by the observed CNVs. The burden analysis 
that was performed in the PhD work does not help to identify genes that increase the 
susceptibility to the illness and overall does not provide resource for further research. 
How exactly a potential CNV burden translates into developing the disease is 
currently unknown. The main observation when the bipolar cases were compared with 
controls was that the CNV burden was not elevated in cases. Although, no increase 
was observed in the CNV load, it is possible that in cases, specific pathways are 
affected which are not disrupted in controls. Examining such pathways could indicate 
which biological processes are affected in cases. For instance, Walsh et al. analysed 
CNV data with respect to disrupted pathways and observed that CNVs in 
schizophrenia cases disproportionately disrupted genes belonging to pathways
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considered to be important for brain development. These pathways included 
neuregulin ( p  = 0.008) and glutamate signalling ( p  = 0.003 ), synaptic long-term 
potentiation ( p  = 0.0005), synaptic long-term depression ( p  = 0.017) and axonal 
guidance signalling ( p  = 0.015 ) (Walsh et al. 2008). For comparison, an 
overrepresentation of any pathway was not observed when control CNV data were 
analysed. Based on these data, it was speculated that CNV disrupting genes from 
neurodevelopmental pathways, can lead to developing neuropsychiatric 
psychopathology (Walsh et al. 2008). Similar results were detected in bipolar 
disorder. Pathway analysis showed that genes affected by CNVs were 
disproportionately disrupted in cases in pathways categories such as “psychological 
disorders” ( p  = 6.3x 10-6) and “learning behaviours” ( p  = 8.29x 10"3). When 
controls were studied, genes involved in such pathways were not found to be 
disrupted by CNVs (Zhang et al. 2008) .
To address the question if genes in certain pathways are disproportionately 
more likely to be disrupted in cases when compared with controls, pathway analysis 
was performed. The studied pathways were: brain-expressed genes, long-term 
potentiation, long-term depression, neurotrophin signalling, axon guidance and 
circadian rhythm pathways. Reasoning why these pathways were studied in bipolar 
disorder is provided below.
CNVs have been shown to account for some of the susceptibility to 
neuropsychiatric disorders. One hypothesis of how the specific CNVs are exerting 
their function is by affecting brain-expressed genes. If this is true, then the CNVs 
could affect brain-functioning genes more often than compared with controls. In 
addition, it has been shown that genes participating in synaptic plasticity could be 
involved in susceptibility to bipolar disorder (Schloesser et al. 2008). Long-term 
potentiation and long-term depression are forms of synaptic plasticity. With long-term 
potentiation is indicated the long-lasting stimulation of transmission of a signal 
between two neurons which have been induced at the same time, and long-term 
depression meaning the opposite process. A correlation has been observed between 
long-term potentiation/depression and learning and memory (Cooke and Bliss 2006). 
It is of note that in CNV bipolar data a statistically significant association has been 
observed with “learning behaviours” pathway (Zhang et al. 2008). With respect to the 
other studied nervous pathway (neurotrophin signalling), it has been previously
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observed that lithium, one of the drugs used to treat bipolar disorder, upregulates 
genes from the neurotrophin signalling pathway (i.e. brain-derived neurotrophic factor 
(BDNF), nerve growth factor, neurotrophin-3 (NT3), etc.). In addition, it has been 
shown that lithium exerts its function by acting upon receptors to these growth factors 
in animal brain (Young 2009). The reasoning for studying the axon-guidance pathway 
was that neuregulin (NRG1), a psychosis susceptibility gene, has been known to 
influence axon guidance and neuronal migration (McIntosh et al. 2008). In the case of 
circadian rhythm pathway, it has been shown that genes, known to influence 
regulation of circadian rhythms (i.e. TIMELESS, CLOCK) can be contributory 
variants to susceptibility to bipolar disorder (Harvey 2008; Mansour et al. 2005).
The results with respect to the performed pathway analysis showed an 
overrepresentation of brain-expressed genes and genes in the long-term potentiation 
pathway to be disrupted by CNVs more often in cases than controls (Table 23, page 
106). After correcting the observed significance levels for the number of the 
performed tests (i.e. 12), no statistically significant results were observed. Thus, it 
was concluded that the tested pathways were not enriched in the CNV bipolar data.
This observation does not support the findings of the Zhang et al. study, where 
a statistically significant observation was noted with respect to “psychological 
disorders” and “learning behaviours” pathways. However, Raychaudhuri et al. argued 
that in general some of the performed pathway analyses have the following 
shortcomings: a) do not meticulously compare the rate of CNV events in the cases 
with the rate in controls; b) as the studies compare rates of disrupted genes, not 
events, it is not taken into consideration that multiple genes could contribute to one 
event or that single genes could be disrupted by multiple CNVs. To take the above- 
mentioned considerations into account, a new method for pathway analysis, integrated 
in PLINK, was developed (Raychaudhuri et al. 2010). The method for comparison in 
this PhD work has made use of this PLINK test.
One possible explanation of why the results obtained in this PhD are different 
with the ones presented by Zhang et al., with respect to pathway analysis could stem 
from the fact that it has been observed that genes with common function can cluster 
together on the human genome and a CNV affecting this region could therefore show 
to affect an entire pathway (Raychaudhuri et al. 2010). It was noted that 11 of the 16 
deleted psychological disorder genes in the Zhang et al. data reside on 22ql 1.2 (CNV 
observed in two individuals). As this region has been previously implicated in
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schizophrenia, these genes could have been annotated as psychological disorder 
genes. It was shown that when the individuals with 22ql 1.2 deletion were removed 
from analysis, the psychological disorder pathway was no longer statistically 
significantly associated with bipolar disorder (Raychaudhuri et al. 2010). Thus, great 
care should be taken when interpreting results derived using pathway analyses.
In conclusion, although, the pathways analysis did not reveal significant 
findings and based on the fact that only a small number of key pathways were 
explored, further research is necessary to elucidate which pathways have biological 
relevance for developing bipolar disease.
5.8. Exploratory analysis of CNVs in bipolar subphenotypes
The WTCCC bipolar disorder sample set comprised bipolar I and II disorder, 
bipolar disorder not otherwise specified and schizoaffective disorder, bipolar type.
The issue of heterogeneity of large neuropsychiatric diagnostic categories has been 
previously addressed and it is logical to hypothesise that distinct phenotypic 
subgroups may have distinct genetic background (Craddock et al. 2010). In an attempt 
to reduce the heterogeneity in the sample, the different subphenotypes were analysed 
separately.
When bipolar I disorder cases were compared with controls with regard to 
CNV size, statistically significant associations were observed with respect to the 
overall number of deletions and the total number of CNVs (Table 26, page 120). This 
result was in the opposite direction than expected, i.e. controls had more CNVs than 
cases. These results were similar to the ones observed when the bipolar samples was 
analysed as a whole (Table 17, page 104). When the CNVs were split according to 
their size, it became clear that the significant findings in the bipolar I sample were 
mainly due to deletions of size £ 200 kb. This size range represented the smallest 
CNVs that the Affymetrix 500K array could detect. Even though the quality control 
metrics that were applied in this PhD were quite stringent, this CNV size category 
was the most likely to produce false-positive results.
All of the other comparisons in the separate size ranges were not significantly 
different. As the results were not corrected for multiple hypotheses testing, the 
observation that the controls exhibited more CNVs than the bipolar I disorder cases is 
likely to be a chance finding. The conservative interpretation of this finding should be
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that bipolar I cases are not very likely to be different than controls with respect to 
CNVs.
Similar analysis was performed for bipolar II disorder cases and none of the 
comparisons were statistically significant (Table 27, page 121).
When schizoaffective disorder bipolar type cases were compared with controls 
(Table 28, page 121), a statistically significant enrichment in the cases was found for 
duplications of size £ 200 kb ( p  -  0.01) and for deletions in the range of 200 -  500 
kb ( p  = 0.03). If multiple hypothesis correction is applied, these results will be no 
longer statistically significat. Therefore, the conservative interpretation of these 
results would be that it is likely to be a false-positive finding.
As the sample was split into categories according to the expressed phenotype, 
the sample size decreased. This poses the question if a sample size which for example 
comprises 87 individuals (this was the case with the schizoaffective disorder bipolar 
type cases), is large enough in terms of power to observe any CNVs that have 
inherently low frequencies. It is unlikely that such number of individuals is sufficient.
In summary, the data showed that large and rare CNVs did not play a 
particularly prominent role in one or more of the studied phenotypes. However, this 
does not rule out smaller CNVs or some specific variants that could increase the 
susceptibility to a particular type of bipolar disorder.
5.9. Specific CNVs in bipolar disorder
Although an overall increase of CNV burden in cases was not observed when 
compared with controls, some individual CNV were observed more frequently in 
cases than in controls. It has to be said that none of the comparisons showed 
statistically significant experiment-wise association (after multiple hypotheses 
correction!. Therefore, the data did not exhibit a statistically increased CNV burden in 
cases of some specific CNVs. From this analysis, no further evidence can be 
presented to show if these loci are true findings or not.
Genes disrupted by particular CNVs found more often in cases than controls 
could point to specific pathways involved in the susceptibility to bipolar disorder. The 
genes disrupted by the CNVs with an uncorrected nominal significance level a<0.05 
included tenascin R (TNR), ovostatin 2 (OVOS2), ankyrin repeat domain 30B
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(ANKRD30B) and zinc finger proteins (ZNF68, ZNF90, ZNF486 and ZNF254). The 
results with respect to this analysis can be found in Table 24 (page 107).
Tenascin R protein is exclusively expressed in the nervous system 
(Woodworth et al. 2004). Jager et al. performed serological analysis of different 
tumour types and observed that ANKRD30B mRNA in addition to breast and testes is 
also expressed in brain (Jager et al. 2001). The zinc finger proteins are 
uncharacterised proteins and typically function as DNA binding proteins and could 
have a possible role in gene expression. Interestingly, a zinc finger protein (ZNF804A) 
has been associated with schizophrenia in a large meta-study (O’Donovan et al. 2008).
In conclusion, the genes affected by CNVs found relatively more often in 
cases than in controls included some potentially interesting candidate genes based on 
their expression. However, in order to show if there is a genuine association between 
developing bipolar disorder and these CNVs, a replication in other studies is needed. 
Even though the support of these loci is weak, single observations of a CNV 
occurrence in a disorder could ultimately make an important contribution to the 
understanding of disease pathogenesis, as discussed already in section 5.6 (page 144). 
In order to facilitate this, the full list with rare CNVs found in the cases and controls 
has been uploaded on the following website, which has been made publicly available- 
http://x004.psycm.uwcm.ac.uk/~detelina/ (Grozeva et al. 2010).
5.10. Previously implicated CNVs in psychiatric disorders
5.10.1. Bipolar disorder
In contrast to schizophrenia, there were only a handful of studies exploring the 
potential involvement of CNVs in developing bipolar disorder. Following up on these 
studies, the putative CNVs were further investigated in the WTCCC bipolar data.
Wilson et al. studied on average ~ 35 brains from bipolar disorder cases, 
schizophrenia cases and controls using a BAC array comparative genome 
hybridisation (aCGH) with resolution of ~ 1.4 Mb and observed evidence suggesting 
that CNVs at lp34.3, 14q23.3 and 22ql2.3 loci were associated with bipolar disorder 
(Wilson et al. 2006). The inherent size-overestimation of CNVs inferred by BAC
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aCGH indicates the need for a more systematic approach to detect CNVs in bipolar 
disorder. In addition, Sutrala et al. did not identify the CNVs reported by Wilson et al. 
using different method in a large sample of schizophrenia patients, and most 
importantly, in two of the samples already analyzed by Wilson et al. and previously 
shown to exhibit the duplications and deletions in question. Sutrala et al. concluded 
that more reliable methods need to be used in order to validate the existence of CNVs 
prior to full scale association studies being carried out (Sutrala et al. 2007). Therefore, 
it was not surprising that the possible involvement of CNVs on chromosomes lp34.3, 
14q23.3 and 22ql2.3 affecting the GLUR7, AKAP5 and CACNG2 genes, in the 
WTCCC data, were not confirmed.
A study in bipolar disorder has reported a statistically significant increase in 
the frequency of gains affecting the GSK3J3 gene in bipolar patients as compared to 
controls (Lachman et al. 2007). GSK3/3 is a candidate gene for bipolar disorder as it 
encodes glycogen synthase kinase, which is a target for lithium salt. Lithium is well 
known as an effective treatment for bipolar disorder (Malhi et al. 2009). The sample 
size that Lachman et al. studied comprised ~80 individuals with bipolar disorder and 
~80 controls (Lachman et al. 2007). In order to refute or accept the hypothesis of the 
possible involvement of duplications disrupting the GSK3/3 gene, additional studies 
are required. Saus et al. studied CNVs overlapping the GSK3/3 gene and the possible 
association with mood disorders in a Spanish population, but failed to replicate the 
results observed by Lachman et al. (Saus 2009). Similarly to Saus et al., the data from 
WTCCC showed no association between CNV variants affecting GSK3f3 and bipolar 
disorder.
A recent whole-genome study presented an analysis of the CNV structure in a 
three-generation pedigree segregating affective disorder (Yang et al. 2009). Some 
CNVs were found to be enriched in subjects with affective disorder (located at 6q27, 
9q21.11, 12p 13.31 and 15ql 1 loci). These regions were examined in the WTCCC 
bipolar study, but no statistically significant associations were observed. The study by 
Yang et al. made use of a family-based design (i.e. one three generation Amish family 
consisting of 46 individuals). This could potentially explain the difference with the 
WTCCC results. Some of the CNV variants in the Amish family could be family- 
specific and therefore, not observed in a population-based bipolar case sample as the 
one used in this PhD work. Furthermore, the array used was Illumina HumanHap550 
BeadChip, which has a higher resolution than the one used in this PhD work. The
151
examined CNV of interest had size ranging from 19 kb to 207 kb. With the array 
applied in the current analysis, some of the CNVs could not be detected at all (e.g. 
with size of 19 kb) while others were with size, which was at the lowest end of the 
QC criteria 100 kb). Therefore, such CNVs could have been potentially missed in 
the current study.
Although deletions in the Velo-Cardio-Facial Syndrome (VCFS) region have 
been previously implicated in bipolar disorder, no deletions were observed in the 
current WTCCC analysis (Papolos et al. 1996). These data strongly suggested that 
deletions in this region were not involved in bipolar susceptibility. Murphy et al. 
could not also replicate the finding of high prevalence of bipolar spectrum disorder in 
VCFS (Murphy et al. 1999). In the bipolar cases no reciprocal duplications at this 
locus were observed. Interestingly, that was not the case with respect to controls.
Eight individuals exhibited duplications and six spanned the whole VCFS region. 
These eight controls were part of the National Blood Service controls. It has been 
previously suggested that the phenotype associated with duplication at the 22ql 1.2 
shares some characteristics with VCFS (Ensenauer et al. 2003; Ou et al. 2008; Portnoi 
et al. 2005). The duplication is considered to lead to a separate syndrome named 
microduplication 22ql 1.2 syndrome (MIM #608363). The clinical presentation is 
variable ranging from normal to mild behavioural abnormalities and to multiple 
defects. It has been previously argued that theoretically such reciprocal duplication 
should have similar frequencies to the deletion (Yobb et al. 2005). As such 
duplication was not observed in the 440 schizophrenia samples, there is little support 
that the duplication is a predisposing factor for schizophrenia. In addition, the 
WTCCC bipolar CNV data did not provide evidence to support the hypothesis that the 
duplication at the 22ql 1.2 locus predisposes to bipolar disorder.
Overall, previous studies investigating the possible involvement of CNVs in 
the susceptibility to bipolar disorder comprised relatively small sample sizes. 
Furthermore, some of them have only focused on specific candidate genes. Thus, 
extreme care is needed in determining if the observed associated variants do indeed 
play a role in the susceptibility to bipolar disorder. A more systematic approach is 
needed for the determination o f CNV structure in larger bipolar disorder sample sets. 
The first study satisfying these criteria was published in 2008 (Zhang et al. 2008). The 
results were already discussed individually in section 5.5 (page 141).
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5.10.2. CNVs implicated in autism and schizophrenia
There is a vast body of evidence for the potential association of CNVs and the 
development of autism and schizophrenia (Guilmatre et al. 2009; Hannes et al. 2009; 
Ingason et al. 2010; Ingason et al. 2009; International Schizophrenia Consortium 
2008; Kirov 2010; Kirov et al. 2009a; McCarthy et al. 2009; Rujescu et al. 2009; 
Stefansson et al. 2008). Some of the observed findings have been replicated in 
multiple studies. Replication of particular chromosomal abnormalities in independent 
reports is considered to be suggestive for the potential importance of the given 
variants and their association with the psychiatric illness.
In this section, I will present the main findings which have been reported in 
autism and schizophrenia and will discuss the possible involvement of these variants 
in bipolar disorder. Only variants which were reported in multiple studies or had 
reported a strong statistical support for the possible association with the diseases were 
considered. Examining the variants implicated in autism and schizophrenia with 
respect to bipolar disorder is justified as it has been postulated that these disorders 
could share some of the underlying genetic liability factors (Craddock and Owen 
2010; Lichtenstein et al. 2009; Moskvina et al. 2009; Rzhetsky et al. 2007). A table of 
the main findings with respect to these loci can be found in section 4.2.7.1 (Table 25, 
page 109).
The CNVs implicated in autism and schizophrenia have been examined 
together for involvement in the susceptibility to bipolar disorder. The reasoning 
behind this decision was that for most of these loci, the data show that the same CNVs 
are associated with both autism and schizophrenia. This gives support to the 
hypothesis that the two disorders share common pathogenetic mechanisms.
Iq21.1
Copy number variation at 1 q21.1 locus has been initially associated with 
schizophrenia in two large genome-wide CNV surveys (International Schizophrenia 
Consortium 2008; Stefansson et al. 2008). Overall, this deletion has a rare occurrence, 
but is a powerful risk factor for susceptibility to schizophrenia. In a study performed 
by the International Schizophrenia Consortium, the deletion at this locus was 
observed with a frequency of 0.29% in schizophrenia cases and in 0.03% of the 
controls (International Schizophrenia Consortium 2008). Similar results have been
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independently observed in a study performed by Stefansson et al. (Stefansson et al.
2008). The deletion was detected with frequency of 0.23% in cases, and 0.02% in the 
large control sample set respectively (Stefansson et al. 2008). When the individuals 
with the deletions were closely examined, three of the cases had learning disabilities 
and two controls had dyslexia.
Kirov et al. combined the data with respect to the deletion from these two 
large studies, excluding the overlapping individuals. The observed p  -value from the
combined data was p  -  9.6 x 1 0 ,OR = 10 (95%C7:2.9 -  34.2) (Kirov et al. 2009a).
Interestingly, chromosomal rearrangement (deletions and duplications) at 
1 q21.1 have been also implicated in phenotypes including autism spectrum disorders, 
developmental delay, dysmorphic features, congenital heart disease, mental 
retardation and learning disability (Brunetti-Pierri et al. 2008; Christiansen et al.
2004; de Vries et al. 2005; Mefford et al. 2008; Sharp et al. 2006b; Weiss et al. 2008).
No deletions at this locus were observed in the case bipolar data as compared 
with two deletions in 2806 controls. The rate of the deletions was very low in the non­
psychiatric phenotypes, analysed by WTCCC- 0.01%. Interestingly a duplication was 
observed in one bipolar case. The frequency of duplication at this locus was observed 
with similar frequencies in cases and controls (0.06% and 0.07% respectively). In the 
10,259 non-psychiatric controls, the duplication was found with similar rate-0.06%.
The general assumption is that a given rearrangement is more likely to be 
pathogenic if it has appeared de novo in an affected individual (Stefansson et al.
2008). To test if this duplication has arisen de novo or has been inherited from a 
parent, the proband and her parents were genotyped using an Illumina array. It was 
observed that the duplication was inherited from the father. Interestingly, the father 
also suffered from bipolar I disorder. Thus, it can be argued that the duplication in this 
particular family could play a role (potentially acting in concert with other factors) in 
developing the disorder. Of course, the hypothesis of the possible involvement of the 
1 q21.1 duplication as a susceptibility factor in some families with segregating bipolar 
disorder can only be accepted or refuted when there are more data from other whole- 
genome CNV studies in bipolar disorder.
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NRXN1, 2pl6.3
Deletions affecting the NRXN1 gene were found to be associated with 
schizophrenia by Kirov et al., who observed the deletion in two siblings with 
schizophrenia. When 372 controls were screened, the deletion was not detected 
(Kirov et al. 2008). Rujescu et al. analysed large sample comprising 2977 
schizophrenia cases and ~33,000 controls in order to determine the magnitude of the 
association, the prevalence and the odds ratio of the NRXN1 gene in schizophrenia 
cases. When all CNVs at this locus were taken into account, no statistically significant 
association with schizophrenia was observed. Nevertheless, the CNV in cases were 
found three times more often than control (0.47% in cases, 0.15% in controls). 
Furthermore, when CNVs disrupting exons were analysed, it was observed that such 
CNVs are statistically significantly enriched in schizophrenia cases (p  = 0.0027;
OR = 8.97, 95% C I : 1.8 -  51.9) (Rujescu et al. 2009). Other studies have also 
reported schizophrenia cases with CNVs affecting the NRXN1 gene (Ikeda et al. 2010; 
Need et al. 2009; Walsh et al. 2008). Interestingly, there are data that this deletion, 
disrupting the NRXN1 gene, appears to be also increased in autism (Glessner et al. 
2009; Kim et al. 2008; Kirov et al. 2009b; Szatmari et al. 2007; Weiss et al. 2008).
No deletions for duplications") were observed in the bipolar cases. This 
suggests that deletions affecting the NRXN1 gene could be a specific factor 
influencing the susceptibility to schizophrenia and autism, but not bipolar disorder.
15qll.2
Stefansson et al. observed an association between deletions at this locus and 
schizophrenia (frequency in cases and controls- 0.55% and 0.19% respectively) 
(Stefansson et al. 2008). Previously the same deletion has been observed in a case 
with mental retardation, developmental delay and speech impairment (Murthy et al.
2007). Kirov et al. combined data from Stefansson et al. study, data from the 
International Schizophrenia Consortium and results from their own study with respect 
to this region and observed the deletion with frequency of 0.6% in cases and 0.2% in 
controls (p  = 4.46x 10-8; OR = 2.8; 95% C /:2 .0 -3 .9 ) (Kirovetal. 2009a).
In the WTCCC bipolar cases the frequency of the deletion in this locus was 
0.18% compared with 0.49% in the controls. This result was in the opposite direction 
to previous findings in schizophrenia. A lower rate in cases when compared with
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controls has been also observed by Ikeda et al., in a Japanese whole-genome CNV 
study (0.2% in cases; 0.58% in controls) (Ikeda et al. 2010). The relatively high 
frequency of this deletion observed in the WTCCC controls and in the analysed 
controls by Ikeda et al. suggests that this CNV mav be less pathogenic than initially 
regarded.
However, this deletion has been observed in 0.8% of 1105 children with 
unexplained intellectual disability. When compared to publicly available control data, 
the deletions were found significantly enriched in such cases (p  = 0.003) (Mefford et 
al. 2009). Additionally, data presented by Doombos et al. have also suggested that the 
deletion is likely to be pathogenic. An increased rate of the deletion has been detected 
in patients with mental retardation and/or multiple congenital abnormalities (0.57%) 
(Doombos et al. 2009).
It is of interest that in the 10,259 non-psychiatric controls (Table 32, page 128) 
deletions at 15ql 1.2 locus were observed with higher frequency than the rate in 
previously analysed controls (0.39% vs. -0.2%). Furthermore, the new frequency 
estimations were in line with the ones observed in the 2806 controls analysed in this 
PhD (0.49%). Therefore, it could be argued that this CNV does not increase the 
susceptibility only to schizophrenia and other neurodevelopmental disorders, but also 
predisposes to other non-psychiatric disorders, such as the ones included in the 
WTCCC study.
15ql3.3
Associations between deletion at this locus and schizophrenia have been 
independently observed in two large studies (International Schizophrenia Consortium 
2008; Stefansson et al. 2008). The International Schizophrenia Consortium has 
observed the 1.3 Mb deletion in 0.27% of the cases and in 0% of the controls 
(p  = 0.046,OR -17 .9  ) (International Schizophrenia Consortium 2008). In Stefansson
et al. study the deletion was observed in 0.17% of cases and in 0.02% of controls 
p  = 5.3 x 10-4,OR -  11.54 ) (Stefansson et al. 2008).
Kirov et al. combined the data from these two studies with their own Cardiff 
data, excluding the overlapping individuals between the studies. The rate of the 
deletion in the three studies was 0.2% in the cases. In controls, the observed 
frequency was 10 times lower (0.02%). The association between the deletion and
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susceptibility to schizophrenia was statistically significant 
( p  = 2.81 x 1<T8; OR = 11.4,95%C7: 4.8 -  27 ) (Kirov et al. 2009a).
Similarly to the other loci previously discussed, the deletion has not been 
exclusively associated with schizophrenia. A recurrent microdeletion syndrome due to 
deletions at this locus was reported by Sharp et al. (Sharp et al. 2008). The syndrome 
is characterised with mental retardation, seizures and variable facial dysmorphic 
features. Notably, one of the genes in the critical region is CHRNA 7 (cholinergic 
receptor), encoding a synaptic ion channel protein that mediates neuronal signal 
transmission (http://www.ncbi.nlm.nih.gOv/gene/l 139). Linkage studies have 
implicated this gene in a susceptibility to juvenile epilepsy and schizophrenia (Elmslie 
et al. 1997; Freedman et al. 1997). CHRNA7 represents a plausible candidate gene as 
haploinsufficiency could cause the seizures observed in epilepsy cases with the 
deletion (Sharp et al. 2008). With respect to common epilepsy, it has been suggested 
that deletions at this locus constitute the most prevalent risk factor ( p  = 5.32 x 10-8) 
(Helbig et al. 2009). Subsequently, this finding has been replicated (Dibbens et al. 
2009).
The frequency of the deletion has been observed to be 0.17% in a large sample 
of cases with mental retardation/developmental delay and autism spectrum disorders 
(Miller et al. 2009).
Van Bon et al. characterised 18 probands with deletions at the 15ql3.3. In 
addition, four patients with a reciprocal duplication have also been assessed in an 
attempt to ascertain the clinical significance of the duplication. The deletion has been 
characterised by a broad intra- and inter-familial variability ranging from cardiac 
defects, mild developmental delay to a complete lack of learning problems (i.e. some 
of the carriers have been functioning at normal cognitive level). The observation that 
the deletion was detected in some healthy individuals suggests that it does not lead to 
mental retardation per se as the only causative factor. Therefore, it was concluded that 
the deletion plays a significant role in the pathogenesis of different conditions 
affecting the brain (including schizophrenia), but the broad phenotypic variability 
have also suggested that the outcome is likely to be determined in combination with 
other factors, such as other genetic, epigenetic or environmental factors. It was also 
argued that there was a possibility that some individuals were able to compensate this 
impairment, originally caused by the CNV. Evidence comes from the observation that
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some individuals have shown learning problems during childhood which have been 
overcome in adulthood and they have exhibited normal functioning at the time of 
ascertainment (van Bon et al. 2009).
In contrast to the deletion, no distinct phenotype was observed in people with 
a reciprocal duplication (van Bon et al. 2009). It is of note that one of the cases with 
duplication, suffered from bipolar II disorder, pervasive developmental disorder not 
otherwise specified and has shown autistic features. He had positive family history of 
psychiatric disorders: the mother had personality disorder and recurrent depression, 
when the father was known to have schizophrenia. Notably, CHRNA7, one of the 
affected genes by the duplication has been previously shown to be associated with 
bipolar disorder (Hong et al. 2004; Turecki et al. 2001). Patients with the duplications 
were not found to share recognisable phenotype, but it is of note that psychiatric 
disease was noted in two out of the four studied individuals (van Bon et al. 2009).
In the WTCCC bipolar dataset no deletions were observed. Duplications were 
found with a frequency of 0.12% (two of 1697 cases). In the controls neither deletions 
nor duplications were detected. Even although this rate was not significantly different 
between the cases and controls, this CNV deserves further attention as it was observed 
in a case diagnosed with bipolar disorder, as shown by van Bon et al. (van Bon et al.
2009). In addition, in the 10,259 non-psychiatric control group, four duplications were 
observed (frequency-0.04%), which makes the duplication observed three times more 
often in cases than in controls.
The deletion at 15ql3.3 has exhibited an association with neuropsychiatric 
conditions in multiple studies, which lends support to the theory that this CNV could 
potentially be pathogenic. There is not such strong evidence with respect to the 
reciprocal duplication. Nevertheless, the duplication has been found with increased 
frequencies in cases with schizophrenia as compared to the frequency in controls 
(International Schizophrenia Consortium 2008; Stefansson et al. 2008). Furthermore, 
duplications have been observed in cases with autism, language delay, anxiety 
spectrum disorder or obsessive compulsive disorder (Miller et al. 2009).
The potential association between developing bipolar disorder and duplication 
at 15ql3.3 awaits investigation in independent studies.
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16pll.2
Recurrent deletions and duplications at the 16p 11.2 locus have been 
implicated in the susceptibility to autism spectrum disorders (Fernandez et al. 2009; 
Kumar et al. 2008; Marshall et al. 2008; Weiss et al. 2008). Weiss et al. investigated 
families with a proband affected with autism and observed a recurrent deletion (along 
with a reciprocal duplication), statistically associated with autism (p  = l.lxlO"4) 
(Weiss et al. 2008). In the same study, a replication was performed using large 
number of cases and controls. The deletion was found to be present in one of 648 
cases with schizophrenia, 1 out of 420 cases with bipolar disorder, in 1 of 203 
attention-deficit hyperactivity disorder cases and in 1 of 3000 patients with panic 
disorder, anxiety or addiction. Overall, the frequency of autism deletion carriers was 
1%, 0.1% among patients with a psychiatric or language disorder and 0.01% in the 
general population. The reciprocal duplication was observed in two subjects with 
bipolar disorder (0.48%) and five unscreened controls in the Icelandic control 
population (total number controls-18,834). The overall frequency was as follows: 0.5 
% in subjects with psychiatric or language disorder and in 0.03 % of the general 
population (Weiss et al. 2008).
A deletion at 16pl 1.2 is thought to be one of the most frequent CNV 
associated with autism (the other one is a duplication of the Prader-Willie/Angelman 
region) found in ~ 1% of the cases (Glessner et al. 2009; Kumar et al. 2008; Weiss et 
al. 2008).
To add to the evidence of the possible involvement of this locus in developing 
neuropsychiatric disorders, two individuals with childhood onset schizophrenia have 
also been found to carry the duplication (Walsh et al. 2008). Furthermore, a 
duplication at this locus has been significantly associated with a substantial risk for 
developing schizophrenia ( p  = 4.8 x 10"7; OR = 8 .4 ,95%C7:2.8 -  25.4 ) (McCarthy 
et al. 2009). The same duplication has also been associated with bipolar disorder 
{p  = 0.017) and autism (p  -  1 .9x l0-7). Conversely, the reciprocal deletion has only
been associated with autism and developmental disorders (p  = 2.3 xlO-13). McCarthy 
et al. examined these findings further. The head circumference has been found to be 
increased in patients with the deletion when compared with duplication carriers 
(p  = 0.0007). The finding that autism features an increased head circumference is not
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new. Several studies have reported an increased head circumference in patients with 
autism (Fidler et al. 2000; Lainhart et al. 2006).
These findings have suggested that mutations at this locus confer risk not only 
to schizophrenia, but also to other neuropsychiatric conditions (Kumar et al. 2008; 
Marshall et al. 2008; McCarthy et al. 2009). McCarthy et al. studied the duplication in 
families, where the proband was a carrier and observed the duplication in some 
relatives exhibiting a range of neuropsychiatric conditions including schizophrenia, 
bipolar disorder, depression and psychosis signs not otherwise specified. Healthy 
carriers were also observed. Such observations are consistent with the theory that 
variants at this locus are associated with incomplete penetrance and variable 
expression. The findings of the possible involvement of rare CNVs in schizophrenia 
have shown marked genetic heterogeneity. Although 16pl 1.2 locus accounts for only 
a small fraction of the schizophrenia cases, people who harbour the duplication are at 
a substantial risk of developing schizophrenia ( OR = 8.4, 95% C I: 2.8 -  25.4 ) 
(McCarthy et al. 2009).
With respect to variants at 16pl 1.2, three duplications were observed in the 
WTCCC bipolar cases (0.2% frequency) as compared to one in the controls (0.04% 
frequency). This locus, showed a trend for an overrepresentation in bipolar cases. The 
rate in the cases was increased 5-fold when compared with the baseline rate (i.e. the 
rate in the control population), although it did not reach a statistical significance. 
Nevertheless, a statistical significance has been noted when a meta-analysis was 
performed as part of the McCarthy et al. study. The meta-analysis comprised 4822 
bipolar cases and 25,225 controls (including the results from the current PhD 
analysis). A significant difference between the cases and controls was detected 
(p  -  0.017) (McCarthy et al. 2009). Interestingly, in schizophrenia the statistical
association with the duplication is much stronger- p  = 4.8 x  10-7. Furthermore, the 
effect size is much more pronounced in schizophrenia than bipolar suggesting that the 
effect of this duplication is weaker in bipolar disorder. The finding that duplications at 
16pl 1.2 locus may be involved in bipolar disorder was further supported by the 
analysis of the 10,259 non-psychiatric controls. The duplication in the bipolar cases 
had a frequency of 0.18% whereas the frequency in the controls was 0.04%
(/? = 0.06).
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Parent DNA was available for one of the three probands found to be a 
duplication carrier. The trio was genotyped in order to examine the transmission and it 
was found that the duplication had arisen de novo. Notably, the father also suffered 
from bipolar I disorder. Thus, it can be argued that in this family, there are more 
factors that could potentially play a role in developing the disease, such as other 
genetic factors shared in the family, shared environmental factors, epigenetic factors, 
etc.
16pl3.1
Initially CNVs at this locus were implicated in autism (Sharp et al. 2006b; 
Ullmann et al. 2007) and mental retardation (Freitag 2007; Hannes et al. 2009; 
Mefford et al. 2009). A 1.5 Mb duplication at 16p 13.1 locus has been found 
associated with autism while the reciprocal deletion- with mental retardation and 
other clinical abnormalities. Nevertheless, the duplications and the reciprocal 
deletions have been found to be present in mildly affected and in completely healthy 
individuals suggesting that the CNVs at this locus predispose to autism/mental 
retardation, but developing the disease could be dependent on other factors as well 
(Ullmann et al. 2007).
CNVs at 16p 13.1 have also been implicated in schizophrenia (Ikeda et al. 
2010; Kirov et al. 2009a). Kirov et al. observed the duplication with frequency in 
cases of 0.6% and in controls-0.2%. Furthermore, Ingason et al. examined a large 
sample set of schizophrenia cases and controls (4345 and 35,079 respectively) for 
duplications or deletions at this locus (Ingason et al. 2009). A 3-fold excess of 
duplications and deletions was observed in the schizophrenia cases when compared 
with controls. The duplications were present in 0.30% of cases vs. 0.09% in controls 
(p  = 0.007) and deletions in 0.12% of cases vs. 0.04% in controls ( p  > 0.05).
In the WTCCC bipolar study, two duplications (0.12% frequency) were 
observed in cases compared to five duplications in the controls (0.18% frequency). In 
the 10,259 controls the rate of the duplication was even higher-0.24%. Therefore, it 
could be concluded that there was no trend for overrepresentation of the duplication in 
the bipolar cases at this locus. Similar were the results with respect to the reciprocal 
deletion, which was not observed in any cases and was detected in one control.
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17pl2
Kirov et al. observed a 1.4 Mb deletion at 17pl2 locus that was not detected in 
any of the studied controls. When these data were combined with data from two large 
genome-wide surveys on schizophrenia, the combined statistical significance level 
was p  -  5 x 10-5. The deletion was found to be 10 times more common in
schizophrenia cases than in controls ( 0.15% in cases vs. 0.015% in controls) (Kirov 
et al. 2009a).
It is of note that deletions at this locus cause hereditary neuropathy with 
pressure palsies (HNPP, MEM #162500) (Chance et al. 1993). The reciprocal 
duplication has been found to cause Charcot-Marie-Tooth disease Type 1A (CMT1 A, 
MIM #118220) (Lupski et al. 1991). These neurological phenotypes are known to be 
caused by the deletion/duplication of peripheral myelin protein 22 (PMP22) (Chance 
et al. 1993; Lupski et al. 1991). Nevertheless, there has been a previous report of a 
patient with schizophrenia having the deletion, without manifestation of neurological 
symptoms (Ozeki et al. 2008).
In the WTCCC bipolar data, one duplication at 17pl2 was detected 
(ffequency-0.06%). In the controls neither deletions nor duplications were observed. 
In the analysed 10,259 non-psychiatric controls the frequency of the duplication was 
0.03%. At present, the suggestion of a possible involvement of the duplication at this 
locus in bipolar disorder and especially the duplication of the PMP22 gene, is 
premature as the prevalence rate of Charcot-Marie-Tooth disease type 1A is 1 in 2500 
individuals (Lupski et al. 1991). Therefore, it is difficult to determine whether the 
duplication is a genuine rare variant predisposing to bipolar disorder or a chance 
occurrence.
22qll.2
This locus was discussed already in section 5.10.1 (page 150), where loci 
previously associated with bipolar disorder were described. In summary, in the 
WTCCC bipolar cases no deletions were observed. The presented herein data did not 
provide evidence to support the hypothesis that deletions at the 22ql 1.2 locus 
predispose to bipolar disorder.
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Summary from follow up of the autism/schizophrenia loci in WTCCC 
bipolar data
Several specific deletions and duplications have been implicated in 
schizophrenia in more than one study (e.g. Iq21.1, NRXN1, 15ql 1.2,15ql3.3,
16pl 1 .2 ,16pl3.3 and 22ql 1.2). Furthermore, for most of these loci a plethora of 
evidence for the possible involvement in autism or mental retardation has been 
observed.
Analysing these loci in the bipolar cases has provided some suggestive 
evidence for their potential involvement in the pathogenesis of the disorder, namely:
1 q21.1, 15ql3.3 and 16pl 1.2. It should be noted, however, that none of these were 
found to be significantly overrepresented in bipolar cases when compared with 
controls. This suggests that these findings should be treated with caution and should 
await further replication in other whole-genome CNV studies in large bipolar sample 
sets. Interestingly, for three of the loci implicated in schizophrenia (1 q21.1,15ql3.3 
and 17pl2) the duplication was observed in bipolar cases, opposed to the deletion in 
schizophrenia cases.
There has been previous evidence that duplications as compared to deletions 
are not as pathogenic. The clinical presentation associated with deletions is likely to 
be more uniform, severe and commonly includes dysmorphology which facilitates 
diagnosis (Miller and Therman 2001).
Interestingly, Need et al. observed an excess of deletions in schizophrenia 
patients (Need et al. 2009). For duplications, on the other hand, evidence is emerging 
for more subtle presentations, creating the potential for duplication carriers to go 
undetected (Cook and Scherer 2008). If deletions are indeed more likely to be 
pathogenic than duplications, it could be speculated that deletions could contribute to 
the chronic course of schizophrenia. In contrast, bipolar disorder is characterised with 
an episodic nature of the illness and duplications could confer to the more cyclic 
nature of the phenotype.
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5.11. CNVs in bipolar disorder and schizophrenia
5.11.1. Direct comparison between bipolar disorder and 
schizophrenia with respect to CNVs
There is a plethora of prior data that bipolar disorder and schizophrenia share 
underlying genetic components that predispose to developing the disorders 
(Gottesman et al. 2010; Lichtenstein et al. 2009; Rzhetsky et al. 2007). Therefore, it 
was sought to determine if the similarities in the genetic overlap stretch to CNVs as 
well.
As the same methodology as in the analysis of the bipolar cases was applied 
for the analysis of the schizophrenia cases, a direct comparison between the two was 
possible. Genotyping in the same pipeline of the two cohorts in the WTCCC context, 
and analysing them at the same time using identical methods ruled out any batch 
effects. Thus. I was able to test the hypothesis if bipolar disorder resembles 
schizophrenia with respect to CNV structure. In the previous section, it was shown 
that there are differences with respect to the involvement in the susceptibility of 
specific CNV loci. Herein, results from comparison between bipolar disorder and 
schizophrenia with respect to CNV burden will be presented.
When bipolar and schizophrenia cases were compared directly against each 
other with respect to CNVs ^ 1 Mb, a statistically significant excess of deletions was 
observed in the schizophrenia cases ( p  = 0.0009 ) and total number of CNVs 
(p  = 0.0006). These p  -values were not corrected for multiple hypotheses testing, but
nevertheless they would survive a Bonferroni correction for the number of the 
performed tests. There was also a trend towards an excess of large duplications 0 1 
Mb) (p  -  0.053 ) in schizophrenia cases compared with bipolar cases. The full results 
with respect to this comparison were presented in section 4.4 (page 125). The data 
exhibited a statistically significant difference between bipolar disorder and 
schizophrenia with respect to global burden of rare and large CNVs 1 Mb).
The bipolar disorder sample set was nearly four times larger than the studied 
schizophrenia cohort (1697 bipolar cases versus 440 schizophrenia cases). This 
suggests that if there were an effect similar to the one detected in the schizophrenia 
sample- it should have also been detected in the bipolar dataset. In conclusion, the
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comparison between the bipolar and schizophrenia cohorts suggests that the disorders 
differ with respect to the CNV burden.
5.11.2. Comparison between CNVs in bipolar disorder, schizophrenia 
and WTCCC non-psychiatric diseases
Recently, data from one of the largest genetic studies became publicly 
available (Wellcome Trust Case Control Consortium 2007). All the phenotypes that 
took part in Wellcome Trust Case Control Consortium (WTCCC) study were 
analysed with respect to CNVs. This analysis was done by WTCCC based on the SNP 
genotyping data of the Affymetrix 500K array. This provided an opportunity to 
compare the copy number variation structure in bipolar disorder and schizophrenia 
with a very large sample set of >10.000 people from the general population in the UK. 
who are not affected with neuropsvchiatric disorders.
As the analysed bipolar cases and controls in this PhD were part of the 
WTCCC study, the first question was how the two studies relate to each other. This 
presented an opportunity to examine the correspondence rate between the two studies, 
as the analysed samples and initial raw genotyping data used for inferring of the 
CNVs were the same.
When the calls for the large CNVs implicated in schizophrenia (that is, 
lq21.1, 15ql 1.2, 16pl 1.2, etc.) were examined in the WTCCC data and in the bipolar 
cases and controls (analysed in this PhD work), 100% correspondence between the 
two studies was observed. This provided confidence that results, even though based 
on different calling algorithms, were comparable without introducing bias.
The frequency of the schizophrenia-associated loci in over 10,000 people from 
the general population affected with non-psychiatric diseases was examined and 
compared with the frequency in the bipolar cases (section 4.5, Table 32, page 128). 
Only one region showed marginal trend for an overrepresentation in cases- 
duplications at 16pl 1.2 ( p  = 0.06). This finding was not surprising, as this locus has 
been tested in a large meta-analysis in bipolar disorder as discussed previously 5.10.2 
(page 153).
To evaluate if there is a correspondence between the rates in the original 2806 
controls analysed in this PhD and the rates in the new large sample set of non­
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Ipsychiatric controls, a comparison between the two was performed. The rate was 
almost the same, which was indicated by the non-significant association between the 
two groups. This observation has shown that there was no differential bias between 
the two studies. In addition, it was shown that the previously inferred rate of CNVs in 
the 2806 controls could be relied upon.
The rate of the CNVs previously implicated in schizophrenia was compared 
between the bipolar cases and the large set of non-psychiatric controls. As observed 
previously, no statistically significant overrepresentation was observed in bipolar 
cases for any o f the loci. Therefore, a replication of the main finding in this PhD was 
noted, using previously not analysed large control sample set. Furthermore, the 
bipolar cases were analysed independently by the Wellcome Trust and the results, 
confirmed the findings already presented in the PhD work.
When the rate of the CNVs previously associated with schizophrenia was 
compared between a large set of schizophrenia cases and the 10,259 non-psychiatric 
controls, most of the CNVs were statistically significantly overrepresented in the 
schizophrenia cases. The loci which were confirmed to be associated with 
schizophrenia were the following: 1 q21.1, 15ql 1.2 (confirmed with p  = 0.05, 
therefore the results should be treated with caution), 15ql3.3, 16pl 1.2 and 22ql 1.2. 
Surprisingly, the evidence was not that convincing for CNVs at the NRXN1 gene,
16p 13.1 and 17pl2. The CNVs at these loci were detected at rates that are closer to 
the frequencies among schizophrenia patients, and higher than in previous controls. 
Therefore, further large samples will be required to establish the exact prevalence of 
these CNVs and their role in psychiatric and non-psychiatric phenotypes. It could be 
speculated that some of these CNVs do not increase the risk specifically to develop 
schizophrenia and other neurodevelopmental disorders, but also predispose to other 
disorders, such as diabetes and heart disease (included in the WTCCC study), or to 
non-specific changes in the brain that lead to increased help-seeking behaviour and 
increase the probability of being sampled in a disease study. This can explain their 
relatively high rate in unscreened members of the general population who suffer with 
non-psychiatric medical disorders. It is also possible that the current frequency results 
in controls could be more representative of the true population prevalence, and the 
odds ratios reported for some of these loci might have to be scaled down. It should be 
a c k n o w le d g e d  th a t the frequencies of all of these loci were still higher in the
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fschizophrenia cases when compared with the 10.259 controls. In addition, when the 
cumulative rate of the CNVs, previously implicated in schizophrenia was compared 
between schizophrenia cases and non-psychiatric controls, a highly statistically 
significant difference was noted- p  = 5 x l0 -11. Bipolar cases were also compared 
with the large set of controls and no difference was observed (p  = 0.19). This further 
replicates the findings already presented in this PhD and provides further support to 
the observation that bipolar disorder and schizophrenia are different with respect to 
involvement of CNVs in the susceptibility.
When the burden of very large CNVs ( ^ 1 Mb) was compared between the 
diseases, bipolar and rheumatoid arthritis cases had the lowest rate. These differences 
were statistically significant when bipolar cases were compared with the large set of 
controls with respect to deletions and total number of CNVs ^ 1 Mb (p  = 0.02 and 
p  -  0.003 respectively). The differences originate from the fact that the cases have 
lower rate of such CNVs than controls. When the schizophrenia cases were compared 
with the controls, statistically significant differences were also observed with respect 
to all tested CNVs ^ 1 Mb (deletions- p  = 0.001, duplications- p  = 0.02 and total 
number CNVs- p  = 0.0001). In contrast to bipolar disorder, the statistical significance 
indicates that the schizophrenia cases had an increased rate of these CNVs than the 
controls.
It is of interest that the cumulative burden of all the tested CNVs, previously 
implicated in schizophrenia and all the CNVs ^  1 Mb in bipolar disorder was in fact 
the lowest compared to any other cohort in the WTCCC study (Figure 42 and Figure 
43). This was already noted by the comparison with the 1958 cohort and NBS 
controls from the WTCCC and was in line with the aforementioned results in this 
PhD.
Based on the fact that the rate of CNVs ^  1 Mb is the lowest in bipolar 
disorder it could be speculated that this trend is a genuine finding. As the rate of such 
very large CNVs (^  1 Mb) is the highest in schizophrenia, it could be also suggested 
that the presence of such CNVs makes somebody who is already susceptible to 
psychotic disorder develop schizophrenia rather than bipolar disorder.
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Figure 42 Rate of deletions, duplications and total number of CNVs >i Mb in the 
cohorts from the WTCCC study
o 0.03
deletions duplications total CNVs
■  NBS+1958 
Cohort
■  BD
□  CAD
■  CD
■ HT
□  RA
■  T1D
□  T2D
■  Cardiff SZ
Figure 43 Rate of cumulative burden of CNVs, previously implicated in 
schizophrenia in the cohorts from the WTCCC study
burden based on loci lq21.1 ,NRXN1 gene, 15qll.2, 15ql3.3, 16pll.2, 16p 13.1, 17pl2and 
22ql 1.2; ISC SZ cases- schizophrenia cases that participated in the International 
Schizophrenia Consortium study
The evaluation o f the data, independently analysed by WTCCC and the 
inclusion o f additional > 10,000 controls in the analysis, provides further support to 
the observation, already presented in the PhD, that in bipolar disorder, unlike 
schizophrenia, the large and rare CNVs do not influence the liability to the condition.
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I5.11.3. Are bipolar disorder and schizophrenia different with respect 
to CNV burden?
Bipolar disorder and schizophrenia were compared with respect to the possible 
involvement of CNVs in the pathophysiology of the illnesses as previous evidence has 
shown an existence of some shared genetic susceptibility factors between the two 
disorders (e.g. ZNF804A, DISCI, CACNA1C genes) (Blackwood et al. 2001; Green 
et al. 2009; Moskvina et al. 2009; O'Donovan et al. 2008).
Further evidence for the possible common underlying genetic variants 
between schizophrenia and bipolar disorder comes from a large Swedish population- 
based study ( > 2 million families). A key finding has been an increased risk for both 
schizophrenia and bipolar disorder in first-degree relatives of probands with either of 
the disorders. Furthermore, the comorbidity between the two disorders has been 
estimated to be mainly due to genetic effects common to both disorders (63%) 
(Lichtenstein et al. 2009). Another large population study (based on 1.5 million 
patient records) has observed genetic overlap between not only bipolar disorder and 
schizophrenia, but also between bipolar disorder, schizophrenia and autism (Rzhetsky 
et al. 2007).
Until now the hypothesis of a possible overlap with respect to copy number 
variants in bipolar disorder and schizophrenia has not been tested. Having performed 
studies of CNVs in both disorders using samples collected from the same population, 
which were genotyped and analysed for CNVs in the same pipeline, allowed such a 
direct comparison to be performed.
Overall, the main finding from the comparison was that bipolar disorder and 
schizophrenia differed with respect to the involvement of CNVs in the susceptibility 
of development of the disorders fthe differences are mainly in respect to CNVs >1 
Mb. and for CNVs previously implicated in schizophrenia"). In contrast to the 
observations of the possible involvement of some common SNPs and genes, the CNV 
findings suggest that copy number variation could have a relatively specific influence 
on the susceptibility to schizophrenia, but not bipolar disorder. Evidence for this 
comes not only from the comparison between bipolar disorder and schizophrenia with 
respect to the overall CNV burden (in section 4.4, Table 31, page 126), but also from
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the investigation of the specific CNVs implicated in schizophrenia that were not 
observed in bipolar cases (section 108, Table 25, page 109).
Similar to these findings, the CNV studies performed in bipolar disorder to 
date have observed that CNVs appear to contribute to a lesser extent to the 
susceptibility to bipolar disorder than to schizophrenia (McOuillin et al. 2010: Priebe 
et al. 2009: Purcell 2009: Zhang et al. 2008T
The current PhD study has also shown that the variants influencing bipolar 
disorder are less likely to be deletions (specifically. Iq21.1.15ql3.3 and 17pl2t and 
have a smaller effect as compared to schizophrenia (e.g. 1 6 p 1 1 .2 ) .
If the assumption that larger CNVs especially deletions, are more likely to 
affect brain development is true, then the findings presented herein are consistent with 
schizophrenia having a stronger neurodevelopmental component than bipolar disorder 
(Craddock and Owen 2010; Murray et al. 2004). Based on this evidence, Craddock 
and Owen suggested that there is a gradient of decreasing neurodevelopmental 
impairment between syndromes such as autism and mental retardation on one hand, 
and bipolar disorder on the other (Craddock and Owen 2010). The gradient is 
presented at Figure 44. Evidence for this continuum does not solely come from 
genetic studies. Overlapping symptoms like depressive symptoms or psychoses, the 
“intermediate” phenotype of schizoaffective disorder and the co-occurrence of bipolar 
disorder and schizophrenia in families, lends support to the theory of a clinical 
continuum (Alaerts and Del-Favero 2009).
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Figure 44 Suggested model of the potential gradient in the neurodevelopmental 
impairment between mental retardation and bipolar disorder and the potential 
gradient of involvement of CNVs
MR Autism SZ SA BD
neurodevelopmental pathology
affective pathology
CNVs
adapted from (Craddock and Owen 2010); MR-mental retardation, SZ-schizophrenia, SA- 
schizoaffective disorder
It is possible that CNVs predispose to brain dysfunction that affect intellectual 
functioning and personality development and therefore could modify expression of 
the phenotype in those who have a tendency to develop psychosis (Craddock et al.
2009). It is o f note, that most o f the CNVs robustly associated with schizophrenia, 
have also been implicated in neurodevelopmental disorders with childhood onset in 
which cognitive impairment is common (that is, mental retardation and autism 
spectrum disorders). Guilmatre et al. estimated the collective frequency of a set of 
recurrent CNVs in patients suffering from schizophrenia, autism and mental 
retardation (Guilmatre et al. 2009). 28 loci previously associated with schizophrenia, 
autism and mental retardation were investigated. It was observed that recurrent CNVs 
were found in 39.3% o f the selected loci and that the collective frequency of CNVs is 
significantly associated with schizophrenia, autism and mental retardation ( p  = 0.01, 
p  < 0.001 and p  = 0.001 respectively). The main finding from the study suggested 
that most o f the studied CNVs were present in the three examined illnesses, which 
supports the existence o f shared biological pathways for the susceptibility to the three
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Iconditions. Guilmatre et al. concluded that none of the recurrent rearrangements were 
limited to one disease (Guilmatre et al. 2009).
The observation that most of the specific CNVs, found in schizophrenia, are 
also detected in mental retardation and autism spectrum disorders lends support to the 
hypothesis that schizophrenia and these disorders share overlapping biological 
pathways. Why one CNV leads to developing schizophrenia in one patient and autism 
in other, could be explained by the fact that expressivity could be influenced by 
additional genetic events, epigenetic effects, environmental influence, etc.
In contrast, in bipolar disorder the relative paucity of these variants, lends 
support to the hypothesis that large and rare CNVs have less prominent role in the 
development of the disorder (Tigure 44. page 171t. Studies of CNVs have found an 
overlap between autism and schizophrenia, whereas common single nucleotide 
variants have demonstrated overlap between schizophrenia and bipolar disorder. It 
could also be speculated that a subset of schizophrenia cases share common biological 
underpinnings with childhood neurodevelopmental disorder whereas other subset is 
more closely related to bipolar disorder. Nevertheless, this finding further supports the 
view that schizophrenia has a more prominent neurodevelopmental component than 
bipolar disorder.
It has been shown that cognitive impairment among schizophrenia patients is 
present from early childhood, before the disease onset which supports the hypothesis 
of a stronger neurodevelopmental component that could play part in developing 
schizophrenia. Schizophrenia and bipolar disorder differ for the fact that 
schizophrenia has been characterised with earlier onset, poor response to medication, 
frequent relapse and chronic course of illness (Williams et al. 2009). Furthermore, 
minor physical anomalies are more prevalent in schizophrenia patients than in healthy 
controls and are considered as markers of an aberrant neurodevelopment (John et al.
2008). Andreasen has also shown that schizophrenia is associated with cognitive and 
social impairment (Andreasen 1995). Patients with schizophrenia perform one or two 
standard deviations below when compared with healthy controls on cognitive tasks 
involving memory, attention, problem solving and social cognition. Interestingly, 
these deficits have been present prior to the start of treatment with antipsychotic drug, 
suggesting that the cognitive impairment is not caused by the treatment (Keefe and 
Eesley 2009). It has been noted that to some extent first-degree relatives have also 
exhibited cognitive impairment.
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!In contrast to the diminished cognitive functioning in schizophrenia, cognitive 
impairment is less typical for bipolar disorder patients and it has been observed after 
the disease onset. Unlike schizophrenia, bipolar disorder is generally not considered 
to have a neurodevelopmental component (Murray et al. 2004; Walker et al. 2002). 
This theory has been supported by a number of longitudinal studies which have 
described no differences in the intelligence of children who will later develop bipolar 
disorder as compared to children who will not develop the disorder (reviewed in 
(Barnett et al. 2006)). In bipolar disorder, like schizophrenia, cognitive impairment 
has also been noted, but it is found after the onset of the illness and limited to acute 
episodes (reviewed in (Burdick et al. 2009)). Nevertheless, there are studies that 
report some evidence for neurodevelopmental basis of bipolar disorder, but the 
evidence is far from conclusive as it is in schizophrenia.
In summary, the analysis from this PhD showed that large rare CNVs were not 
involved in bipolar disorder as compared to the extent they were involved in 
schizophrenia. Therefore. CNVs could have a specific effect on schizophrenia, but not 
in bipolar disorder. The genetic liability factors for developing bipolar illness could be 
smaller deletion/duplications. SNPs. point mutations, environmental factors and pure 
random factors that could work together to influence the expression of bipolar 
disorder.
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6. Future directions
Studying psychiatric disorders in general and bipolar disorder in particular are 
challenging due to their inherent genetic heterogeneity, incomplete penetrance of 
psychiatric traits and non-Mendlian inheritance of complex traits.
Nevertheless, there is unequivocal evidence that genetic factors play an 
important role in developing bipolar disorder. The research that I present herein 
focused on investigating a particular type of genetic factors. As we are still in the 
discovery phase of investigation, in order to study the full variety of genomic 
variation, sequencing approaches will be the most powerful methods. They would be 
particularly potent at identifying small changes along with inversions and 
translocations, which to date have received little attention. As technology is 
constantly improving, it seems plausible that the cost of sequencing will decrease up 
to a point when processing of many samples (in the range of thousands) would be 
feasible. The high-throughput DNA sequencing promises to improve power to 
identify new mutations associated with susceptibility to developing disease.
In addition, increasing the sample size of investigated bipolar individuals will 
help to tease out genetic variants with low-penetrance effect. Furthermore, if well 
phenotypically characterised samples are readily available, this could potentially help 
to unravel genetic variants that could influence specific phenotypes.
My belief is that in the next couple of years much more will become known 
with respect to possible causal genomic factors that engender risk for developing 
common and complex disorders. The results are awaited with great anticipation as the 
findings will bring enormous benefit to the people who suffer from such disorders.
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7. Conclusions
The CNV structure was successfully inferred in a large cohort of bipolar cases 
and healthy controls using SNP genotyping data from Affymetrix 500K arrays. It was 
observed that considerable care is needed in analysing copy number data based on 
SNP genotyping data, as CNV analyses are susceptible to a range of artefacts which 
could potentially lead to false-positive results. Despite the important technical 
challenges and potential artefacts, it was demonstrated that high-confidence and 
robust CNV calls are possible to be inferred.
Furthermore, it was determined that large and rare copy number variants were 
not associated with developing bipolar disorder. Some specific CNVs were found 
more often in cases than in controls, but this observation did not withstand correction 
for multiple hypotheses testing.
Analysing schizophrenia and bipolar cases using identical methods and 
processing the data in the same pipeline, allowed direct comparisons between the 
disorders. The main observation was that in bipolar illness, very large CNVs were not 
involved to the extent that they have been shown to be involved in schizophrenia. 
Furthermore, some specific duplications (at loci already implicated in schizophrenia, 
e.g. 1 q21.1, 1 6 p ll.2 ,16p 13.1, 17pl2and 15ql3.3) were observed in cases with 
bipolar illness, but the evidence for their involvement was suggestive and needs 
replication in other bipolar studies. The relative paucity of large CNVs in bipolar 
disorder suggests a lesser neurodevelopmental component than schizophrenia, given 
that large aberrations have been associated with severe neurodevelopmental 
phenotypes, such as mental retardation and autism, and are often accompanied by a 
variety of more pronounced physical anomalies, where bipolar disorder is 
characterised by relapse and remit.
The strengths of this PhD work comprise a large sample size, rigorous quality 
control and the ability to directly compare bipolar disorder with schizophrenia. Some 
important limitations are inherent in all CNV studies. The first is with respect to the 
power to detect very small increases in CNV burden. Second, the Affymetrix 500K 
array has less resolution for CNV detection than later platforms. This has much less 
impact on large CNVs (the focus of this PhD work), but due to this limitation, smaller 
CNVs (^  100 kb) were not examined. It has been previously shown that the number
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of CNVs exponentially increases with decrease of CNV size (McCarroll et al. 2008). 
In future studies, it will be important to use platforms with much higher resolution. 
This will potentially allow CNVs to be called at similar levels of accuracy as SNPs in 
order to provide further information about a wider spectrum of CNV sizes.
While additional studies are required to further explore the hypothesis of the 
potential involvement of CNVs in the susceptibility to bipolar disorder, the analysis 
presented in this PhD thesis, provides one of the first attempts to shed some light on 
the potential involvement (or lack of involvement) of large deletions and duplications 
in the aetiology of bipolar disorder.
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Appendix
Table 38 Genes in CNVs in cases only
Chr Start bp End bp CNV NCBI genes Number of observations
1 45592076 45881891 dup TESK2,LOC 126661,MMACHC,PRDX 1 ,AKR1 A 1 ,N ASP,CCD C17,GPBP1L1 1
1 46131935 46268021 dup MAST2 1
1 65071676 65413912 dup JAK1,MIRN101-1,AK3L1,AK3L2 1
1 86324452 86589985 del COL24 A1 ,ODF2L 1
1 88847985 89032679 dup PKN2 1
1 107551303 107823281 dup NTNG1 1
1 143576984 143916898 del PDE4DIP,FL J21272, SEC22B 1
1 152936201 153149168 del KCNN3 1
1 166729757 167024066 del XCL2,XCL 1 ,DPT 1
1 173980586 174202365 dup LOC100128153,RFWD2 1
1 217365162 217613673 del LOC643723,LYPLALl 1
1 221702789 222127692 dup LOC644151,LOC653428,CAPN8,CAPN2,TP53BP2 1
1 231361905 231514154 del PCNXL2 1
1 244896239 245307486 dup C1 orf7 l,SCCPDH,LOC 100130097,LOC 149134,AHCTF 1 ,ZNF 695,ZNF670 1
2 155674 306842 dup LOC727818,SH3 YL 1,ACP 1,FAM150B 1
2 9950762 10157626 dup TAF 1B,GRHL1 ,UNQ5830,KLF 11 ,LOC 100131506,CYS1 1
2 46875500 47239348 dup LOC388948,MCFD2,TTC7A,LOC 100129286,C2orf61 1
2 49008203 49120697 del FSHR 1
2 49149900 49602914 del FSHR 1
2 53738562 53909774 dup ASB3,CHAC2,C2orf30 1
2 67026445 67574931 del LOC644838,ETAA 1 1
2 80501388 81016718 del CTNNA2 1
2 105308220 105583762 del TGFBRAP1 ,C2orf49,FHL2,LOC728966 1
2 108755278 109814503 del RANBP2,CCDC 13 8,EDAR,SH3MD4,LOC 100132457,LOC72 9164,SEPT10,ANKRD57,LOC100131577 1
2 137213276 137516286 del THSD7B 1
2 175063486 175545089 del LOC100130325,WIPF1,LOC100133109,CHRNA1,CHN1 1
2 211762892 212453633 dup ERBB4 1
2 230634380 230823051 del SLC16A14,SP110,SP140 1
3 96226 577858 del LOC642891,CHL 1 1
3 6731867 7502372 dup GRM7
3 56538380 56738659 dup CCDC66,C3orf63,ARHGEF3 1
3 65782031 66651118 dup MAGI 1 ,SLC25 A26,LRIG1 1
3 108045770 108523998 del LOC344595 1
3 109343496 109735186 dup IFT57,HHLA2,MYH15 1
3 126612179 126918638 dup SNX4,0SBPL11 1
3 159972476 160172525 del MFSD1 1
3 169645563 170273620 dup LOC389174,MIRN551B,LOC253820,C3orf50 1
3 175127179 175441056 dup NLGN1 1
3 191379157 191640477 del CLDN1 ,CLDN 16,UNQ846 1
4 5108518 5215976 del STK32B 1
4 74735392 74864580 dup IL8 1
4 78951173 79103165 dup CNOT 6L,MRPL 1 1
4 95781900 96255099 dup PDLIM5,L0C728442,BMPR1B 1
4 100189816 100342799 del METAP1,ADH5,ADH4 1
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4 113529096 113893894 dup ALPK1 ,NEUROG2,LOC91431 ,C4orf21 ,L ARP7,MIRN367,MI RN302D,MIRN302A,MIRN302C,MIRN302B 1
4 114884938 115470791 dup CAMK2D,ARSJ 1
4 120432331 120685299 dup USP53 ,LOC401152,FABP2,LOC729249,FLJ14186,LOC64551 3,PDE5A 1
4 144067928 144176340 del LOC729675 1
4 154588412 155163845 dup KIAA0922,TLR2,RNF 175, SFRP2 1
4 162419238 162568359 del FSTL5 1
4 177932828 178065111 dup VEGFC 1
4 178467820 178584108 dup NEEL3 1
4 184350807 184681169 dup WW C2,CLDN22,LOC 100132463,LOC 100131811 ,CDKN2 AIP ,ING2 1
5 1695155 1883374 dup MRPL36,NDUFS6 1
5 2409789 2732511 dup LOC100133292 1
5 19203456 19757247 dup CDH18 1
5 20009671 20700523 dup CDH18 1
5 22346817 23379949 dup CDH12 1
5 37541744 37660208 dup WDR70 1
5 58867115 59095265 del PDE4D,MIRN 5 82 1
5 60152290 60767215 dup ELOVL7,ERCC8,NDUFA12L,DKFZP686E2158,ZSWIM6,LOC728153 1
5 95457099 95693430 del LOC441097 1
5 99678948 100293602 dup LOC100133050,LOC 100132020,TMEM157,ST8SIA4 1
5 110682996 110894149 del CAMK4,STARD4 1
5 126925062 127404930 del CTXN3,LOC728586 1
5 130387114 130720739 dup HINT 1 ,L YRM7,CDC42 SE2 1
5 180460061 180624927 dup
TRNAL-AAG,TRNA V 9,OR2 V2,TRNA V-AAC,TRNA V - 
CAC,TRNAP-UGG,TRNAT1,TRIM7,TRNAA-UGC,TRNAK- 
CUU,TRIM41 ,GNB2L 1 ,SNORD96A,SNORD95,TRIM52
1
6 119769 496352 dup FLJ43763,DUSP22,IRF4,EXOC2,LOC727827,LOC642335 1
6 63009959 63255396 dup KHDRBS2 1
6 68334871 68703877 del LOC100128757 1
6 74168491 74593230 dup DDX43, C6orfl 5 0,MTO 1 ,EEF 1A 1, SLC17A5, CD 109 1
6 91481484 94497325 dup EPHA7 1
6 106604408 106937568 dup PRDM1,ATG5
6 125557330 125906207 dup TPD52L1 ,HDDC2 1
6 127357460 127691043 del RSP03 ,RNF 146.ECHDC 1 1
7 12695794 13112747 dup ARL4A 1
7 16058262 16586160 dup LOC729920, SO STDC1 ,LOC 100129771,LOC100129335 1
7 49540495 49894866 dup VWC2,LOC100128734 1
7 63200647 63487624 del LOC730291 ,ZNF679,LOC728927 1
7 141274408 141407299 del CLEC5A,TAS2R38,MGAM 1
7 145582575 145743361 del CNTNAP2 1
7 157369323 157513462 del PTPRN2 1
8 1987919 2374301 del MYOM2 1
8 18566441 19801599 dup
PSD3,LOC 100131275,LOC 100128993,SH2D4A,ChGn,LOC 10 
0130604,INTS10
8 82552799 82735204 dup FABP4,LOC646486,LOC 100129523,IMPA 1 1
8 86461282 86722738 dup C A 1 ,C A3 ,LOC 100132709,CA2 1
8 87220440 87426294 dup ATP6 V OD2,LOC 100128962, SLC7A13, WWP1 1
8 124096689 126212968 del
DERL1,WDR67,TRNAM- 
C AU,FAM83 A,LOC 100131726,C8orf76,ZHX 1, ATAD2,MIRN 
548D l,C8orf32,FBX032,C80RFK3 6,ANXA 13 ,FAM91A 1 ,FE 
R1L6,TMEM65,TRMT12,RNF139,TATDN1,NDUFB9,MTSS 
1 ,ZNF572, SQLE,KIAA0196,N SMCE2
1
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[8 138893819 139296115 dup FLJ45872,FAM135B 1
8 145891814 146125907 dup ZNF251,ZNF34,RPL8, ZNF517, LOC 100130027, LOC 10012959 6,ZNF7,COMMD5,ZNF250 1
9 9423671 9550338 del PTPRD 1
9 18416823 18776181 del ADAMTSL1 1
9 70797218 71143539 dup PIP5K 1B,PRKACG,FXN,L0C 100131414,TJP2,C9orf61 2
9 71528430 72053813 dup PTARl,C9orfl35,MAMDC2 1
9 104723219 104885068 del CYLC2 1
9 118549097 118655895 del ASTN2 1
9 131966512 132099642 dup FREQ 1
10 1412160 6132099 dup
AD ARB2,LOC642384,C1 Oorfl 09,LOC 100129465,LOC72820 
9,LOC727878,PFKP,LOC 100133296,PITRM 1 ,KLF 6,LOC 100 
130652,LOC727894,LOC728544,LOC 100128356,LOC338588, 
AKR1 CL2,tAKR, AKR1C1 ,AKR1 C2, AKR1C3, AKR1 CL 1, AK 
R1 C4,UCN3 ,TUB AL3 ,NET 1 ,C ALML5 ,C ALML3, ASB13 ,C 10 
orfl 8,GDI2,TRN AV - 
UAC^ANKRD 16,FBXO 18,IL 15RA,IL2RA
1
10 29684578 29911570 dup SVIL,MIRN604 1
10 41956473 43152050 dup
LOC 100131936, LOC653097, LOC 100132349, CCNYL2,MGC 1 
6291,ZNF37B,LOC 100128934,ZNF33B,LOC 100129622,LOC 
283028,BMS 1,RET,GALNACT-2,RASGEF 1A
1
10 47063957 51229942 dup
LOC728684,ANXA8L2,LOC728449,FAM21B,ASAH2C,LOC 
727950,LOC 100132209,CT GLF 6,LOC 100133093, ANXA8,LO 
C653110,ZNF488,RBP3,GDF2,GDF10,PTPN20B,FRMPD2L1 
,LOC644021,LOC644054, LOC 100133265, FRMPD2,MAPK8, 
ARHGAP22,C 1 Oorf64,LOC642343,WDFY4,LRRC 18,C 10orf7 
2,C 10orf73,LOC728883,C 10orfl28,LOC 100132730,C 10orf71, 
LOC 100130757,DRGX,LOC 100128032,ERCC6,PGBD3,CHA 
T,SLC18A3,C10orf53,OGDHL,LOC727726,FAM21D,LOC72 
8955,CTGLF5,TIMM23B,LOC100133089,CTGLF4,MSMB
1
10 51462803 51815423 dup FAM21 A,ASAH2,SGMS 1 1
10 57761600 58753290 del ZWINT 2
10 65228767 68139445 dup CTNNA3 2
10 81567623 81966905 dup LOC642361 ,FAM22E,SFTPD,LOC642521 ,LOC64253 8,C lOor f57,PLAC9,ANXAl 1 1
10 83980248 84561902 del NRG3 1
10 93824133 94106871 del CPEB3,LOC 100130772,MARCH5 1
10 98850750 99028923 dup SLIT1,ARHGAP19 1
10 112373593 112648954 dup RBM20,LOC282997,LOC100132573,PDCD4,LOC92482 1
11 201447 373554 del RIC8A,SIRT3,PSMD 13,NLRP6,ATHL 1 ,IFITM5,IFITM2,IFIT M1,IFITM3,B4GALNT4 1
11 201447 430343 dup
RIC8A,SIRT3,PSMD 13,NLRP6,ATHL 1,IFITM5,IFITM2,IFIT 
M1 ,IFITM3 ,B4GALNT 4,PKP3, SIGIRR,TMEM 16 J 1
11 4120756 4232709 dup LOC196120,LOC390031 1
11 54596906 55739642 dup
TRIM48,OR4A 16,OR4A 15,OR4C 15,OR4C 16,OR4C 11 ,OR4P 
4,OR4S2,OR4C6,OR5D 13,OR5D 14,OR5L l,OR5D 18,OR5L2, 
OR5D16,SPRYD5,OR5 W2,OR511 ,ORl 0AG1 ,OR5F 1 ,OR5 AS 
l,OR8I2,OR8H2,OR8H3,OR8J3,OR8K5,OR5J2
2
11 54937013 55112298 del OR4C15,OR4C 16 1
11 68304836 68542057 dup CPT1 A,MRPL21 ,IGHMBP2,MRGPRD,MRGPRF 1
11 69837338 70074717 dup PPFIA1 ,CTTN,SHANK2 1
11 121963463 122151248 dup UBASH3B 1
11 128156738 128275086 dup FLI1,KCNJ1,KCNJ5,C1 lorf45 1
12 971525 1119511 dup LOC 100130219,ERC 1 1
12 2022432 2541278 dup CACNA1C 1
12 5094169 5260067 del LOC387826 1
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k
12 24357971 24519700 dup SOX5 1
12 38872898 39028521 del LRRK2 1
12 52503589 52628593 del HOXC13 1
12 71297905 71840265 dup TRHDE 1
12 77701054 77869712 del LOC 100129021 1
12 86803928 87584968 del C12orf50,C 12orf29,CEP290,TMTC3,KITLG 1
12 95329061 95526343 del C12orf55 1
12 97551176 97756322 dup ik ip ,a p a f i ,a n k s ib 1
12 100749452 101055184 del DRAM,CCDC53 ,NUP3 7,C 12orf48 1
12 121217208 121868133 dup
LRRC43,IL31,B3GNT4,DIABLO,VPS33A,CLIP1,TRNAD- 
GUC,ZCCHC8,RSRC2,KNTC 1,GPR109A,GPR109B,GPR81, 
DENR.CCDC62
1
12 127358570 127647495 dup TMEM132C 1
13 30803641 30977080 dup B3GALTL 1
13 31177504 31439521 dup RXFP2 1
13 48259408 48519957 del LOC647131 ,FNDC3 A 1
13 82905273 83506735 dup SLITRK1 1
14 21604337 21840943 dup
TRA@,TRA V 22,TRA V 23D V 6,TRD V 1 ,TRA V 24,TRA V25,TR 
AV26-1 ,TRAV8-7,TRAV27,TRAV29DV5,TRAV30,TRAV26- 
2,TRAV34,TRAV35,TRAV36DV7,TRAV38-1,TRAV38- 
2DV8
4
14 33465639 33586331 dup EGLN3 1
14 50241969 50382223 del NIN 1
14 52385742 52525010 dup FERMT2 1
15 58226926 58465642 dup ANXA2 1
15 74654705 74895929 del SCAPER 1
15 82306210 82555245 dup ADAMTSL3 1
15 99212626 100060877 del LOC 145757,ALDH 1 A3 ,LRRK 1 ,CHS Y1 ,SELS,SNRP A 1 ,PCS K6,TM2D3,TARSL2 1
16 5059873 5217562 del ALG1,FAM86A 1
16 6490401 6854359 dup A2BP1,LOC100131413 1
16 7134152 7356599 dup A2BP1 1
16 8760561 8866827 del ABAT,TMEM186,PMM2,LOC100132944,LOC100130283,CA RHSP1 ,LOC 100129895 1
16 25870606 26088563 dup HS3ST4 1
16 26422573 27239475 dup C 16orf82,JMJD5,NSMCE 1 ,IL4R 1
16 45086927 45948101 dup FLJ43980,LOC 100128802,SHCBP1,VPS3 5,ORC6L,MLCK,L OC3 88272,GPT2,DNAJA2,NET02,LOC 100127930,ITFG 1 1
16 76340176 76766570 del KIAA1576,CLEC3 A, WWOX 1
16 76901619 77102849 del WWOX,LOC645947 1
16 87678937 87804936 del ACSF3 ,C 16orf81 ,LOC400558,CDH 15,LOC 146429 1
17 9975140 10275516 dup GAS7,LOC 100129677,MYH13,LOC 100128560,MYH8 1
17 14093529 15357533 dup
HS3 ST3B1 ,LOC 100131109,LOC388339,FLJ45831,PMP22,TE 
KT3,CDRT 4,FAM 18B2 1
17 16659493 17062349 dup
LOC 100129981,LOC96597,LOC 100129535,TNFRSF 13B,LO 
C100128283,M-RIP,LOC201164,FLCN
1
17 31923810 33308219 dup
ZNHIT3 ,MY 0 19,PIGW,GGNBP2,MGC4172,MRM 1 ,LOC727 
862,LHX1 ,AATF,ACACA,C 17orf78,TAD A2L,DU SP14, AP1G 
BP 1 ,LOC 100131822,DDX52,HNF 1 B,LOC284100
1
17 78476537 78599918 dup TBCD,B3GNTL1 1
18 12246238 12506082 dup CIDEA,TUBB6,AFG3L2,SLMO 1,SPIRE 1 1
18 14597916 15092421 dup ANKRD3 OB,LOC647983,LOC 100131500
18 28682047 29322188 dup C18orf34 1
18 45714083 45940515 del MY05B 1
180
19 7035307 7181438 del ZNF557,LOC 100131165,INSR,LOC 100128567 1
19 19969224 20657868 dup ZNF682,ZNF90,LOC729903,ZNF486,FLJ44894,ZNF626 5
19 23605608 24295825 dup ZNF675,ZNF681,LOC730087,ZNF254 3
19 44819692 45042569 del LOC 148003,LOC400696,LGALS 14,CLC,D YRK 1B,FBL 1
19 59886999 60014905 del KIR3DL3 ,KIR2DL3 ,KIR2DL 1 ,KIR2DL4 1
20 116466 352407 del DEFB128,DEFB129,DEFB32,C20orf96,ZCCHC3,SOX12,NRSN2,TRIB3,RBCK1 1
20 25794494 26236535 dup C20orf91 ,LOC284801 ,MIRN663 1
22 24873287 25340497 dup SEZ6L,FL J38343, ASPHD2, LOC100128401,HPS4,SRRD,TFIP 11 ,TPST2,LOC 100130561 ,CRYBB 1 1
23 142664 2770060 del
PLCXDl,GTPBP6,PPP2R3B,SHOX,LOC442442,CRLF2,CSF 
2RA,IL3RA,SLC25A6,LOC729629,CXYorf2,ASMTL,P2RY8, 
SFRS17A,ASMT,DHRSX,ZBED l,LOC 100130595,LOC40157 
7,CD99,XG,GY G2
5
23 22008574 22149641 dup PHEX 1
23 35570709 35917535 dup MAGEB 16,CXorf22 1
23 37739464 37857804 dup SYTL5 1
23 56824308 57065815 dup SPIN3 1
23 86509912 86714253 dup KLHL4 1
23 139671186 139903522 dup CDR1 1
23 143459775 146067963 del
SPANXN1 ,SLITRK2,LOC 100129095,CXorfl ,MIRN890,MIR 
N888,MIRN892A,MIRN892B,MIRN891B,MIRN891 A,LOC 10 
0128265,LOC100133053,LOC100129239,LOC100132556
1
23 144046112 144430381 dup SPANXN 1 1
23 151732760 151922021 dup CETN2,NSDHL,ZNF 185,PNMA5 1
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